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1. INTRODUCTION 
1.1 The architecture of chromatin 
When chromatin components compact and organize genomic DNA, almost all DNA-related 
metabolic processes including transcription, recombination, DNA repair, replication, 
kinetochore and centromere formation are affected. The major structural components of 
chromatin are nucleosomes, composed of histone octamers, but insulators, chromatin domains 
and enhancer-promoter contacts determine the three-dimensional architecture of chromatin. 
1.1.1 Nucleosomes are histone octamers 
1.1.1.1 Nucleosome components 
The condensation of two meters of DNA into a nucleus of a human cell is mediated by the 
packaging function of nucleosomes (Fig. 1.1). Typically, nucleosomes consist of two copies 
of the four canonical histone proteins (H2A, H2B, H3 and H4), the so-called histone octamer 
(Kornberg, 1977). 147 base pairs (bps) of DNA are wrapped 1.65 turns around the histone 
octamer. Every 10.4 bps histones and the phosphate backbone make connections, which are 
mediated by the charged residues of the histone proteins. This nucleosomal structure provides 
14 histone-DNA contacts and establishes positional stability (Luger et al., 1997). In higher 
eukaryotes, a linker histone (most commonly an H1 or H5 subtype) packages often regions of 
chromosomes in a dense manner forming the chromatosome (Kornberg, 1974). Depending on 
the organism and cell type, the typical distance between nucleosomes varies between seven 
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and 100 bps. Within one cell the linker region can vary up to 40 bps compassing active and 
repressed genes (Grigoryev, 2012). 
                        
Fig. 1.1 The crystal structure of the nucleosome in two different orientations demonstrates the compaction 
of DNA wrapped around the histone octamer (adopted from Luger, 2001) 
The α-helices of the histone proteins are shown as spirals. H3 is colored blue, H4 green, H2A yellow and H2B 
red. The DNA is shown in grey. 
(A) The nucleosome core particle viewed down the superhelical axis. 
(B) The same structure is rotated 90° around the y-axis to emphasize the disc-like shape of the particle. 
The nucleosome is not a simple static but a highly dynamic entity regulated by additional 
proteins complexes. Nucleosomes vary also in the composition of their histone protein 
components. Nucleosome specialization is based on the incorporation of posttranslational 
modifications of histone amino acid side chains and histone variants (see chapter 1.1.1.2). 
Nucleosomes often occupy important regulatory regions in the DNA, and their occupancy 
competes with other transcription factors. Architectural chromatin proteins, nucleosome-
binding proteins, histone chaperones, and ATP-dependent chromatin remodelers play 
important roles in the regulation of the chromatin structure and gene expression at all levels. 
1.1.1.2 Histone modifications and histone variants 
Modifications of nucleosomes are frequent and highly dynamic. Their impact on 
transcriptional regulation is well established. More than 60 different amino acid residues of 
both histone tails and globular domains can carry posttranslational modifications (Kouzarides, 
2007). The modifications include the addition of a small chemical residue or the incorporation 
of large and bulky peptides: methylation (me) of arginine (R) residues, methylation, 
acetylation (ac), ubiquitination, ADP-ribosylation, and sumolation of lysines (K), and 
  INTRODUCTION  9 
 
phosphorylation of serines (S) and threonines (T). The amino acids in the histone tail can be 
singly, doubly, or triply modified depending on the amino acid. With four core histone 
proteins, at least eight modes of modifications and the possibility of different modifications of 
single residues, the diversity of combinations is very high reflecting a plethora of possible 
chromatin states. Modifications like acetylation of histone 3 (H3) or histone 4 (H4) and di- or 
trimethylation (me2 or me3) of H3K4 are associated with active transcription (euchromatin). 
In contrast, modifications like H3K9me and H3K27me are associated with transcriptional 
repression (heterochromatin). An overview of histone modifications is listed below (Tab.1.1). 
Tab. 1.1 A selection of possible histone modifications and their putative functions 
Histone 
modification Putative functions 
H3K4me1 Mark of regulatory elements associated with enhancers and other distal elements, but also 
enriched downstream of transcription start sites (TSS) 
H3K4me2 Mark of regulatory elements associated with promoters and enhancers 
H3K4me3 Mark of regulatory elements primarily associated with promoters/TSS 
H3K9ac Mark of active regulatory elements with preference for promoters 
H3K9me1 Preference for the 5′ end of genes 
H3K9me3 Repressive mark associated with constitutive heterochromatin and repetitive elements 
H3K27ac Mark of active regulatory elements; may distinguish active enhancers and promoters from their 
inactive counterparts 
H3K27me3 Repressive mark established by polycomb complex activity associated with repressive domains 
and silent developmental genes 
H3K36me3 Elongation mark associated with transcribed portions of genes, with preference for 3′ regions 
after intron 1 
H3K79me2 Transcription-associated mark, with preference for 5′ end of genes 
H4K20me1 Preference for 5′ end of genes 
(table modified from Consortium TEP, 2012) 
Histone-modifying enzymes add and remove posttranslational modifications. The enzymes 
are recruited through diverse mechanisms including site-specific DNA-binding factors 
(Eissenberg and Shilatifard, 2010), co-activators and repressors (Brownell et al., 1996), RNA 
polymerase II (Krogan et al., 2003), or preceding histone modifications (Zippo et al., 2009). 
A variety of histone acetyltransferase complexes (HATs) carry out histone acetylation at 
multiple lysine residues (Brown et al. 2000). Histone acetylation of numerous lysine residues 
might have a cumulative effect. In contrast, histone methylation, phosphorylation, 
ubiquitination, etc. are often carried out by a specific enzyme at a specific amino acid residue 
resulting in unique functions. Histone modifications can lead to (i) the disruption of DNA-
histone contacts due to the change in the net charge of nucleosomes, which can provoke 
loosening of inter- or intranucleosomal interactions. Histone modifications can (ii) encourage 
or discourage other chromatin modifying proteins to bind. Specific domains mediate the 
recruitment of proteins to specific histone modifications. Chromatin organization modifier 
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(chromo)-like domains of the Royal family (chromo, tudor, MBT) and nonrelated plant 
homeodomain (PHD) domains, bromodomains, and a domain within 14-3-3 proteins 
recognize methylation, acetlylation and phosphorylation, respectively (Bannister and 
Kouzarides, 2011). Certain histone modifications (iii) affect contacts between different 
histones in adjacent nucleosomes or the interactions of histones with the DNA. For instance, 
H4K16ac can directly influence higher-order chromatin structure by inhibiting the 
compaction into 30 nm fibers (Shogren-Knaak et al., 2006). 
In addition to the four canonical histone proteins, all eukaryotes contain histone variant 
proteins, which are able to positively or negatively regulate gene transcription (Kamakaka and 
Biggins, 2005; Bernstein and Hake, 2006).  Histone variants are expressed independently of 
the cell cycle and its S phase. They can be incorporated into nucleosomes independent of 
DNA replication and assembly of canonical histones. Most histone variants have been 
identified for histone H2A and H3. They are highly conserved between different species and 
fulfill important functions that cannot be accomplished by their canonical counterparts. At 
active genes, histones H3 and H2A are replaced by the histone variants H3.3 and H2A.Z, 
respectively (Kamakaka and Biggins, 2005; Sarma and Reinberg, 2005). Certain histone H3 
variants localize to the centromeres, where their unique N-terminal tails likely play roles in 
establishing the kinetochore. H2A variants like H2A.Z differ from canonical H2A at several 
specific residues near the C-terminus and are integral components of nucleosomes, which 
flank the TSS (Clapier and Cairns, 2009). The incorporation of H2A.Z into a nucleosome can 
be mediated by the SWR1 chromatin remodeler family (Mizuguchi et al., 2004) or by the 
histone chaperone Nap1 (Park et al., 2005). The INO80 (inositol requiring 80) chromatin 
remodeler family catalyses the reversal exchange of H2A.Z/H2B dimers with free H2A/H2B 
(Papamichos-Chronakis et al., 2011). 
1.1.1.3 Nucleosome positioning 
The mapping of nucleosome position over entire genomes to near base pair precision is 
possible with high-resolution sequencing techniques (Jiang and Pugh, 2009). Across all 
eukaryotic species, promoters and other regulatory sequences tend to be more nucleosome-
depleted, whereas transcribed regions are generally occupied with well-positioned, high-
density nucleosomal arrays (Bai and Morozov, 2010). Several factors are known to control 
nucleosome positions: DNA sequence preferences, DNA methylation, histone variants and 
posttranslational modifications, higher order chromatin structure, and the actions of 
transcription factors, chromatin remodelers and other DNA-binding proteins. 
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DNA sequence preferences: 
DNA sequence preferences are not caused by the few base-specific contacts between histone 
and DNA but by the characteristics of the DNA flexibility (Widom, 2001; Morozov et al., 
2009). The DNA sequence contains particular dinucleotides (AA, TT and TA), which occur at 
ten bp intervals (Ioshikhes et al., 2006; Segal et al., 2006). This arrangement provides a 
rotational setting of the DNA on the histone surface because AA or TT dinucleotides tend to 
expand the major groove of DNA. When the particular dinucleotides are placed in phase with 
the helical twist of DNA, they facilitate the sharp bending of DNA around the histone 
octamer. In contrast, GC dinucleotides tend to contract the major groove stiffening the DNA 
strand so that DNA-wrapping around the histone octamer is avoided (Jiang and Pugh, 2009). 
Also, many pentamers in the linker regions are disfavored by nucleosomes, for example 
AAAAA, pentamers composed exclusively of A/T nucleotides, and CGCGC (Field et al., 
2008). 
DNA methylation: 
In higher eukaryotes, cytosine methylation at CpG dinucleotides might decrease the ability of 
DNA to bend into the major groove and can thereby directly influence nucleosome 
positioning (Nathan and Crothers, 2002; Pennings et al., 2005). The regulation mechanism, 
which is so far poorly understood, needs further investigation. 
Histone variants and posttranslational modifications: 
Histone variants and posttranslational modifications influence the binding of DNA-binding 
proteins and govern nucleosome positioning. Hyperacetylation and the presence of the core 
histone tails increase the accessibility and stability of nucleosomal DNA (Polach et al., 2000; 
Widlund et al., 2000; Anderson et al., 2001). The core histone tails can also contribute to 
sequence-dependent nucleosome positioning (Yang et al., 2007). Nucleosomes containing 
histone variants show also a different nucleosome position pattern because of altered histone-
DNA interactions. Additionally, the nucleosomes with altered histone compositions show 
DNA sequence preferences, which differ from nucleosomes with canonical histones. The 
presence or absence of the linker histone H1 or its variants can also influence the DNA 
sequence preferences of the nucleosome (McArthur and Thomas, 1996). 
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Higher order chromatin structure: 
Nucleosomes are present in long and dense one-dimensional arrays (10 nm fibre) resulting in 
a five-fold compaction of DNA. The next level of compaction is the three-dimensional 
organization of the nucleosome arrays in a 30 nm fibre. Higher order chromatin structure can 
influence nucleosome positioning in four ways. First, the density of nucleosomes along the 
DNA imposes a trade-off between occupancy and sequence specificity in nucleosome 
positioning (Kornberg and Stryer, 1988). The positioning of loosely scattered nucleosomes 
depends more on sequence specificity, whereas dense nucleosomes will be positioned often 
despite contradictory sequence specificity. Second, neighboring nucleosomes influence each 
other through repulsive and attractive interactions dictating the tolerated linker lengths 
(Widom, 1992). Third, there is emerging evidence that a periodicity of strong nucleosome 
positioning sites may encode regularly spaced chromatin (Davey et al., 1995). Forth, 
nucleosome positioning might also depend on the role of the linker histone H1 in DNA 
packing of nucleosomes, because H1 facilitates the folding of chromatin into 30 nm fibres 
(Thoma et al., 1979; Yao et al., 1991). 
Transcription factors, chromatin remodelers and other DNA-binding proteins: 
Transcription factors, chromatin remodelers and other DNA-binding proteins (e.g. pioneer 
factors) can directly or indirectly influence nucleosome positioning by competing with 
nucleosomes for access to DNA (see chapter 1.2). The outcome of this competition depends 
on the relative affinities of the nucleosomes and the above-mentioned factors to the 
underlying DNA and on their concentrations (Segal and Widom, 2009). 
1.1.2 Enhancer-promoter contacts 
Nuclear organization is not only maintained by nucleosomal structures, but also by enhancer-
promoter contacts. Studies of long-range interactions revealed that gene regulation is often 
decoupled from the promoter-proximal region and distributed among distal sequence 
elements, termed enhancers. Enhancers can be located far from the TSS and their activity is 
associated with activation of transcription regardless of the location or orientation relative to 
the promoter. Promoters and enhancers show distinct characteristic chromatin signatures that 
distinguish them. Promoters and enhancers share certain features such as nucleosome 
depletion and enrichment of histone acetylation, but they also show characteristic chromatin 
signatures that can be used to identify and locate both regulatory elements in the human 
genome. The H3K4 methylation signature is the most studied one. Promoters are located at 
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the 5`ends of genes in close vicinity of the TSS. Promoters are the point of assembly of the 
transcriptional machinery and initiation of transcription (Smale and Kadonaga, 2003). 
Conserved across species, active promoters are marked by acetylation of various residues of 
histones H3 and H4 and methylation of H3K4. They show high level of H3K4me3 and low 
level of H3K4me1 at TSS. Nucleosome depletion in active promoters is also a general 
characteristic in yeast and flies, but is still an open issue in mammalian systems. Enhancers 
contribute to the activation of their target genes from positions upstream, downstream or 
within the introns of the genes they regulate or even within the introns of neighboring genes 
(Blackwood and Kadonaga, 1998; Bulger and Groudine, 1999). Enhancers show no 
H3K4me3 signature but are marked by H3K4me1 (Barski et al., 2007; Birney et al., 2007; 
Heintzman et al., 2007; Koch et al., 2007; Wang et al., 2008). Often HATs e.g. p300, which 
acetylates H3K27, are present at enhancers (Blow et al., 2010; Ghisletti et al., 2010). 
H3K27ac in combination with H3K4me1 correlates with enhancers near active genes. In the 
absence of H3K27ac, the H3K4me1 marked enhancer is considered to be inactive or “poised” 
(Creyghton et al., 2010; Rada-Iglesias et al., 2010). Hypersensitive sites have been also 
correlated with enhancer elements carrying the H3K4 methylation signature (Xi et al., 2007). 
The broadly accepted mechanism of linking enhancers and promoters is termed looping. 
Looping out the intervening DNA permits the direct interaction of promoter and enhancer 
(Blackwood and Kadonaga, 1998; Bulger and Groudine, 1999; de Laat et al., 2008). Special 
transcription factors can bring distal gene loci into proximity with each other regulating gene 
expression. The CCCTC-binding factor (CTCF) is able to bind to insulator elements and 
forms chromatin loops (Phillips and Corces, 2009; Hou et al., 2010). CTCF co-operates with 
cohesins (protein complexes that physically connect sister chromatids during mitosis and 
meiosis) to partition the genome in looped chromatin domains. Depending on the location of 
the anchor points of these looped domains, enhancers are either separated from the 
corresponding promoter or brought in close proximity to the corresponding promoter resulting 
in transcriptional repression and activation, respectively (Rubio et al., 2008; Wendt et al., 
2008). 
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1.2 Chromatin regulators and their way of functions 
Transcription factors sequence-specifically bind regulatory regions (so-called DNA binding 
sites) in the context of free DNA and target the assembly of the transcriptional machinery, 
which controls gene expression (Hahn, 2004). In eukaryotic cells, the majority of potential 
DNA-binding sites is not accessible because they are compacted by nucleosomes 
(nucleosomal DNA) and occupied by higher-order chromatin structures and repressor 
complexes. The recruitment of transcription factors to their cognate binding sites depends on 
the chromatin landscape i.e. the nucleosomal distribution, epigenetic modifications, and the 
three-dimensional structure of the chromatin (Magnani et al., 2011). How transcription factors 
can bind to their motifs to activate gene expression is enigmatic because the majority of the 
DNA-binding sites is inaccessible. Most of the studied transcription factors are not capable of 
binding nucleosomal DNA, only their cooperative and simultaneous binding supports the 
successful interaction with nucleosomes (Adams and Workman, 1995; Zaret and Carroll, 
2011). Two classes of chromatin regulators find directly access to nucleosomal DNA using 
two distinct strategies: chromatin remodelers and pioneer factors. 
1.2.1 Chromatin remodelers 
Chromatin remodeling complexes (remodelers) play an important role in chromatin 
regulation. They carry out various functions and alter the accessibility of DNA to 
transcription factors by packaging or unpackaging the genome (Clapier and Cairns, 2009). All 
remodelers show high affinity for nucleosomes. Chromatin remodelers utilize the energy of 
ATP hydrolysis to alter histone-DNA contacts by moving, destabilizing, ejecting, or 
restructuring nucleosomes. The presence of 53 different chromatin remodelers in the human 
cell suggests specialized functions of these enzymes and the associated complexes (Manelyte 
and Längst, 2013). 
The catalytic subunit of chromatin remodelers consists of a conserved ATPase domain and 
unique flanking regions (Fig. 1.2). The ATPase domain consists of two tandem RecA-like 
folds (DExx and HELICc), containing seven conserved helicase-related sequence motifs that 
classify the enzymes as part of the Superfamily 2 group of helicase-like proteins (Eisen et al., 
1995; Flaus et al., 2006). Chromatin remodelers do not separate nucleic acid strands like 
typical helicases, but they use the energy of ATP hydrolysis to reposition nucleosomes like 
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DNA translocases. The association of the catalytic subunit with unique subunits ensures the 
specialization of a given remodeler complex. It can recognize covalent histone modifications, 
regulate the catalytic subunit, and interact with other chromatin or transcription factors 
(Clapier and Cairns, 2009).  
Individual families are conserved from yeast to human, although there is a certain variation in 
their species-specific complex composition. The division of chromatin remodelers into classes 
is based on different protein compositions and functions. There are four major remodeler 
families: SWI/SNF, ISWI, INO80 and CHD (Clapier and Cairns, 2009). In the following I 
will concentrate on discussing chromatin remodelers in human cells. 
 
Fig. 1.2 Classical organization of remodeler families defined by their catalytic domain (modified from 
Manelyte and Längst, 2013). 
All remodeling enzymes consist of a shared ATPase domain and unique flanking domains. DExx and HELICc 
are responsible for nucleic acid binding and ATP hydrolysis. Bromo recognizes acetylated lysines in histone 
tails. Chromo binds methylated lysines in histone tails. HAND, SANT and SLIDE recognize nucleosomes and 
internucleosomal DNA. HSA binds actin-related proteins. 
SWI/SNF family remodelers: 
The SWI/SNF (switching defective/sucrose nonfermenting) family remodelers are composed 
of large, multi-subunit complexes containing eight to 14 proteins. They are conserved in 
eukaryotes and all contain a DNA-dependent ATPase as their catalytic subunit. The catalytic 
ATPase (Fig. 1.2) includes a N-terminal helicase-SANT (HSA) domain and a C-terminal 
bromodomain, which recruit actin/actin-related proteins and bind to acetylated lysines of 
histones, respectively (Clapier and Cairns, 2009). Each organism builds a slightly different set 
of SWI/SNF-related complexes, using both conserved proteins and also unique attendant 
subunits to help specialize each complex. Members of this family have many activities. They 
slide and eject nucleosomes at many loci and participate in diverse processes of chromatin 
remodeling but lack roles in chromatin assembly (Clapier and Cairns, 2009). Remodelers like 
SWI/SNF are targeted to particular nucleosomes either through histone modifications or 
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through a “pioneering” DNA-binding protein. The human SWI/SNF remodeler complexes 
BAF and PBAF utilize BRM or BRG1 as catalytic subunits, share nine identical subunits 
(BAF45, BAF57, BAF53, BAF57, BAF60, BAF155, BAF170, SNF5 and β-actin), but differ 
with respect to several unique subunits (BAF250 for BAF and BAF180, BAF200 and BRD7 
for PBAF) (Wilson and Roberts, 2011). Variant subunits contribute to targeting, assembly and 
regulation of lineage-specific functions of the remodeler complexes. An overview of all 
subunits of selected SWI/SNF family remodelers is listed below (Tab.1.2). 
Tab. 1.2 Selected SWI/SNF family remodelers and their composition 
Complex Catalytic subunit Attendant subunits 
BAF BRM or BRG1 BAF250, BAF155, BAF170, BAF60 (A, B or C), SNF5, BAF57, BAF53 (A or B), β-actin, BAF45 (A, B, C or D) 
PBAF BRG1 BAF180, BAF200, BRD7, BAF155, BAF45 (A, B, C or D), BAF170, BAF60 (A, B or C), SNF5, BAF57, BAF53 (A or B), β-actin 
(table modified from Manelyte and Längst, 2013) 
ISWI family remodelers: 
The ISWI (imitation switch) family compromises highly conserved protein complexes that 
utilize the energy of ATP hydrolysis to slide nucleosomes along DNA and/or replace histones 
within nucleosomes. The ISWI family remodelers contain two to four subunits. Most 
eukaryotes form multiple ISWI family complexes using one or two different catalytic subunits 
with specialized attendant proteins. The most intensively studied members of this group are 
ACF (ATP utilizing chromatin assembly and remodeling factor), NURF (nucleosome 
remodeling factor), and CHRAC (chromatin accessibility complex). All these complexes 
contain a nucleosome-dependent ATPase (SNF2L or SNF2H), which is homologous with the 
ATPase of the SWI/SNF remodeler family (Vignali et al., 2000). The ISWI family ATPase 
contains the conserved catalytic ATPase domain and a helicase domain (Fig. 1.2), but the C-
terminus additionally harbors a characteristic set of domains, known as HAND, SANT, and 
SLIDE (Clapier and Cairns, 2009). The SANT domain binds unmodified histone tails, the 
SLIDE domain binds nucleosomal DNA near the dyad axis, and the HAND domain is 
implicated in both histone and DNA binding/recognition. The mammalian homologues 
SNF2L and SNF2H can act on their own or in presence of one or more attendant subunits 
forming different remodeling complexes with different properties (Manelyte and Längst, 
2013). SNF2L interacts with CECR2 and BPTF to form CERF and NURF complexes, 
respectively (Manelyte and Längst, 2013). SNF2H interacts with ACF1, Tip5, Rsf1, Wstf, and 
WCRF180 proteins to form ACF1 or CHRAC, NoRC, RSF, WICH, and WCRF complexes, 
respectively. Specialized attendant proteins contain many chromatin binding domains, 
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including histone fold motifs (in CHRAC), PHDs (in Tip5), bromodomains (in BPTF, ACF1, 
Tip5), and additional DNA-binding motifs (HMGI(Y) in NURF; AT hooks in Tip5). ACF, 
CHRAC, and NoRC complexes have established roles in chromatin assembly and in the 
formation of nucleosome arrays with well-ordered, optimized spacing, which might help to 
promote repression (Cairns, 2005). Instead, NURF randomizes spacing, which can assist 
RNA polymerase II activation (Clapier and Cairns, 2009). An overview of all subunits of 
selected ISWI family remodelers is listed below (Tab. 1.3). 
Tab. 1.3 Selected ISWI family remodelers and their composition 
Complex Catalytic subunit Attendant subunits 
CERF CECR2 
NURF 
SNF2L 
BPTF, RbAp46 or RbAp48 
ACF ACF1 
CHRAC ACF1, CHRAC17, CHRAC15 
NoRC Tip5 
RSF Rsf1 
WICH Wstf 
CRF 
SNF2H 
WCRF180 
(table modified from Manelyte and Längst, 2013) 
INO80 family remodelers: 
The INO80 (inositol requiring 80) family remodelers are complexes composed of more than 
ten subunits (Clapier and Cairns, 2009). They are part of ATP-dependent chromatin-
remodeling complexes, which interact with nucleosomes and remodel chromatin by either 
sliding nucleosomes along the DNA or exchanging histones within nucleosomes. INO80 
catalyzes the exchange of H2A.Z/H2B dimers with free H2A/H2B (Papamichos-Chronakis et 
al., 2011). In yeast, the reverse reaction, the incorporation of H2A.Z is catalyzed by the 
related SWR1 complex (Mizuguchi et al., 2004), and both complexes regulate the global 
distribution of H2A.Z with emerging implications in genomic stability, cancer development, 
and embryonic stem cell differentiation (Billon and Cote, 2012; Li et al., 2012). Both INO80 
and SWR1 remodeling complexes can slide nucleosomes and evict histones from DNA (Shen 
et al., 2003; Tsukuda et al., 2005; van Attikum et al., 2007). INO80 family remodelers have 
been reported to alter the chromatin structure during transcription (Shen et al., 2000), in 
recombination and DNA replication (Papamichos-Chronakis and Peterson, 2008; Bao and 
Shen, 2011), cell devision, and DNA repair (Downs et al., 2004; Morrison et al., 2004; van 
Attikum et al., 2004). Unique is the core ATPase with a split ATPase domain (Fig. 1.2), as 
well as Rvb proteins, which share limited homology to bacterial RuvB, the Holliday junction 
DNA helicases (West, 1997). Unlike remodelers of other families, the INO80 remodelers 
exhibit DNA helicase activity and binds to specialized DNA structures resembling Holliday 
  INTRODUCTION  18 
 
junctions and replication forks consistent with the function of the complex in homologous 
recombination and DNA replication (Shen et al., 2000; Wu et al., 2007). The interactions 
between the remodeling complexes and nucleosomes likely involve actin and the Arp 
subunits, which associate with the conserved HSA domain of the core ATPase in each 
complex. Examples for human orthologs are the core ATPases hINO80 and Domino/p400, 
which contains also HAT activity. An overview of all subunits of two selected INO80 family 
remodelers is listed below (Tab. 1.4). 
Tab. 1.4 Selected INO80 family remodelers and their composition 
Complex Catalytic subunit Attendant subunits 
INO80 hIno80 INO80D, INO80E, Amida, Uch37, NFRKB, MCRS1, Arp4, Arp8, YY1, Arp5, Ies2, Ies6, Tip49a, Tip49b 
TIP60 Domino/p400 TRRAP, Rvb1 (RuVB-like), Rvb2, Bdf6, Act1 (actin), Baf53, Gas41, Dmap1, Mrg1, Mrgbp, Epc1, Ing3, Tip60 
(table modified from van Attikum and Gasser, 2005 and Chen et al., 2013) 
CHD family remodelers: 
The CHD (chromodomain helicase DNA-binding) remodeler family is defined by the 
presence of two tandem chromodomains, which are N-terminally located of the ATPase 
domain (Fig. 1.2). Additional structural motifs are used to further divide the CHD family into 
the subfamilies CHD1, Mi-2 and CHD7 (Flaus et al., 2006; Sims and Wade, 2011). Members 
of the CHD1 subfamily (CHD1 and CHD2 proteins in higher eukaryotes) contain a C-
terminal DNA-binding domain with a SANT-SLIDE like fold that preferentially binds to AT-
rich DNA (Delmas et al., 1993; Stokes and Perry, 1995). The Mi-2 subfamily members 
(CHD3 and CHD4 proteins in humans) contain a pair of PHD domains in their N-terminal 
part and have been implicated in nucleosome binding (Watson et al., 2012). The CHD7 
subfamily members have additional C-terminal domains, like the SANT or BRK domains. An 
overview of the CHD family remodelers is listed below (Tab. 1.5). 
Tab. 1.5 Selected CHD family remodelers and their composition 
Complex Catalytic subunit Attendant subunits 
CHD1 CHD1  
CHD2 CHD2  
Mi-2/NuRD CHD3/CHD4 MBD2/3, MTA1/2/3, HDAC1/2, RbAp46/48, p66a/b, DOC-1 
 CHD5 Unknown 
 CHD7 PARP1, PBAF complex 
(table modified from Manelyte and Längst, 2013) 
The Mi-2/NuRD remodelers couple a chromatin remodeling ATPase and the histone 
deacetylases 1 and 2 (HDAC1/HDAC2) (Tong et al., 1998; Wade et al., 1998; Xue et al., 
1998; Zhang et al., 1999). This complex is unique because it links two independent, 
  INTRODUCTION  19 
 
chromatin-directed enzymatic functions for gene regulation. This family is broadly distributed 
in cells and tissues. The subunit composition of the enzyme appears to vary with cell type and 
in response to physiologic signals within a tissue (Denslow and Wade, 2007). The catalytic 
helicase-like ATPase subunits are the two Mi-2 a and b proteins, also known as CHD3 and 
CHD4, respectively (Eisen et al., 1995), which are widely conserved throughout the animal 
and plant kingdoms, but absent in yeast (Denslow and Wade, 2007). The ATPases contain 
conserved PHD fingers, implicated in nucleosome binding, N-terminally tandem 
chromodomains, and a putative C-terminally DNA-binding domain (Woodage et al., 1997). 
The catalytic deacetylase subunits HDAC1 and HDAC2 of Mi-2/NuRD are highly conserved 
and present in all eukaryotes. Additionally, the Mi-2/NuRD complex contains several 
additional proteins of importance. The smallest subunit is a member of the methyl CpG-
binding domain (MBD) family of proteins, MBD2 or MBD3 (Wade et al., 1999; Zhang et al., 
1999) selectively recognizing methylated DNA. The retinoblastoma associated proteins 46 
and 48 (RbAp46 and RbAp48), termed RBBP7 and RBBP4, respectively, are additional 
subunits of the Mi-2/NURD complex. Presumably, these two proteins are structural subunits 
because they contain a number of WD repeats, a sequence motif that forms a propeller 
structure providing a protein interaction surface (Marhold et al., 2004). Interestingly, RBBP4 
and RBBP7 have been shown to be components of several other multi-protein chromatin 
modification complexes in which they interact directly with core histones (Loyola and 
Almouzni, 2004). Certain versions of the Mi-2/NURD complex contain additional structural 
and/or regulatory subunits. The proteins p66a or p66b, also known as GATAD2A and 
GATAD2B (Wade et al., 1999; Brackertz et al., 2002; Feng et al., 2002), have the capacity to 
interact directly with core histones (Brackertz et al., 2006). Another characterized subunit of 
the Mi-2/NuRD complex consists of the metastasis associated (MTA) protein family (Bowen 
et al., 2004; Manavathi and Kumar, 2007), but the functional role of MTA1, MTA2, and 
MTA3 proteins in the Mi-2/NuRD complex remains unknown. The Mi-2/NuRD complex 
catalyses the conversion of an active, hyperacetylated promoter to that of an inactive, 
hypoacetylated promoter with densely packed nucleosomes. The Mi-2 ATPase facilitates 
nucleosome mobility through a sliding mechanism (Brehm et al., 2000; Guschin et al., 2000) 
and the enzymes HDAC1/2 perform histone deacetylation. 
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1.2.2 Pioneer factors 
Pioneer factors are considered as a specific class of transcription factors that autonomously 
can establish competence for gene expression (Zaret and Carroll, 2011). They find access to 
their DNA binding sites in condensed chromatin prior to other factors binding and prior to the 
time of transcriptional activation. They often play crucial roles in development and 
differentiation by promoting cell type-specific transcriptional programs (Magnani et al., 
2011). Pioneer factors are defined as nucleosome-binding proteins that precede and enable the 
subsequent binding of other transcription factors, chromatin modifiers, and nucleosome 
remodelers involved in chromatin remodeling. Alternatively, certain pioneer factors can 
actively open local chromatin themselves (Zaret and Carroll, 2011). Conversely, there is also 
emerging evidence that pioneer factors might establish stably silenced chromatin domains by 
recruiting corepressor complexes (Sekiya and Zaret, 2007). Epigenetic modifications provide 
signals for pioneer factors indicating that they can read and interprete epigenetic 
modifications. Also, the insulator protein CTCF can influence the binding of pioneer factors 
to the chromatin (Magnani et al., 2011). The regulation of pioneer factors and their impact on 
the chromatin structure still remain to be further investigated. There are several known 
pioneer factors with various peculiar characteristics. 
FoxA: 
In liver cells, the fork head-like transcription factor FoxA binds the albumin enhancer region, 
which harbors an array of precisely positioned nucleosomes. FoxA binding results in the 
expression of the albumin gene. In non-liver tissues nucleosomes are randomly positioned 
over the enhancer in the absence of FoxA promoting a silent state of the albumin gene 
(McPherson et al., 1996; Cirillo et al., 2002). The pioneer factor binds to nucleosomal DNA 
as well as or even better than to naked DNA (Cirillo et al., 1998). The co-occupancy of FoxA 
with nucleosomes can serve as a structural recruiting signal for gene regulatory complexes 
(Chaya et al., 2001). The C-terminus of FoxA contains a core histone motif and binds the 
histones H3, H4, and weakly H2B (Cirillo et al., 2002). The N-terminus and DNA-binding 
domain (DBD) do not bind core histones, but the DBD is important for targeting the C-
terminus to specific genomic regions. FoxA has a winged helix DBD with a helix-turn-helix 
(HTH) motif, which makes base-specific DNA contacts, and two flanking loops (wings) of a 
polypeptide chain that contact the phosphodiester backbone of DNA. FoxA’s HTH motif is 
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highly homologous with that of histone H1 (Cirillo et al., 1998). In that way the DBD of 
FoxA structurally resembles the linker Histone H1 and disrupts internucleosomal interactions 
(Cirillo et al., 2002; Sekiya et al., 2009). The recruitment of FoxA to enhancers is dependent 
on epigenetic changes of enhancer hallmarks (Serandour et al., 2011). The histone binding is 
facilitated by H3K4me2 (Cirillo and Zaret, 1999; Lupien et al., 2008). 
PBX1: 
The pre-B cell leukemia homeobox 1 (PBX1) is a member of the three amino acid loop 
extension (TALE)-class homeodomain family and is required for hematopoiesis, skeleton 
patterning, pancreas and urogenital systems organogenesis (Magnani et al., 2011). PBX1 is 
essential for the estrogen receptor alpha (ERα) mediated transcriptional response driving 
aggressive tumors in breast cancer (Holmes et al., 2011). PBX1 occupies chromatin prior to 
transcription factor recruitment, mediates nucleosome depletion, and recruits other factors 
involved in transcriptional regulation. The pioneer factor has the capacity to read specific 
epigenetic signatures like H3K4me2 and can open chromatin at specific chromatin locations 
(Magnani et al., 2011). 
PU.1: 
The transcription factor PU.1 plays an important role at early stages of B cell differentiation 
and development by binding the enhancer of the paired box protein Pax-5 gene in multipotent 
hematopoietic progenitors prior to the time of Pax5 activation (Zaret and Carroll, 2011). As a 
pioneer factor, it expands the linker region between nucleosomes and promotes local histone 
modifications. PU.1 binding initiates nucleosome repositioning and chromatin opening 
followed by H3K4me1 deposition at enhancers in the course of macrophage and B cell 
differentiation (Ghisletti et al., 2010; Heinz et al., 2010). H3K4me1 deposition is followed by 
the recruitment of transcription factors guiding the cell-type specific transcriptional program 
that promotes B cell or macrophage differentiation (Magnani et al., 2011). 
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1.3 Epigenetic regulation in EBV 
1.3.1 EBV and its life cycle 
EBV is characterized by three phases of its life cycle: the pre-latent phase, the latent phase, 
and the lytic phase (Fig 1.3). 
 
Fig. 1.3 EBV’s life cycle in human B cells 
Upon infection of human B lymphocytes, the main target cells of EBV, the pre-latent phase is 
initiated. The linear viral DNA genome reaches the host cell nucleus and forms a circular 
plasmid. The viral DNA is first completely naïve, i.e. it is free of histones and devoid of 
methylated CpG dinucleotides (Kintner and Sugden, 1981; Fernandez et al., 2009; Kalla et 
al., 2010). Subsequently, proteins of the host cell machinery compact the viral DNA into 
nucleosomal arrays, modify the N-terminal histone tails and extensively methylate the 
majority of the many viral CpG sites (Kalla et al., 2010). Two distinct sets of viral genes are 
expressed during the pre-latent phase: the classical latent set of genes and a restricted number 
of genes, which are characteristic of the set of lytic genes. The expression of latent genes 
(Epstein-Barr nuclear antigens (EBNAs), latent membrane proteins (LMPs)), and viral non-
coding RNAs and microRNAs activates the quiescent B lymphocytes, which become 
lymphoblasts and begin to proliferate. Activated B lymphocytes have to be protected from 
endogenous stress, immediate activation-induced apoptosis (Altmann and Hammerschmidt, 
2005) and the consequences of DNA damage response signals (Nikitin et al., 2010). Latent as 
well as a restricted number of lytic genes encompassing transcription factors and cytokines 
ensure the survival of the infected primary B lymphocytes. The pre-latent phase lasts about 
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one to two weeks and progeny virus is not synthesized in this period (Kalla and 
Hammerschmidt, 2011). 
In the consecutive strictly latent phase, characterized by a stable virus-host relationship, the 
viral DNA is maintained in the nucleus of the proliferating B cells. Only EBNAs and LMPs, 
the viral latent genes, as well as non-coding RNAs are expressed and support cellular 
proliferation of lymphoblastoid cell lines (LCLs). The expression of EBNA genes is governed 
by different promoters, indicating a change in viral gene regulation from the pre-latent to the 
latent phase (Woisetschlaeger et al., 1990; Altmann and Hammerschmidt, 2005). This 
promoter switch is caused by the gradual epigenetic modifications of viral DNA, which 
results in a global transcriptional repression and a high degree of CpG methylation of the viral 
genome (Kalla et al., 2010). In the latent phase, all lytic genes are efficiently repressed but 
latent viral genes are spared from epigenetic silencing. Latent gene products mimic central 
cellular functions and contribute to B cell activation, survival and proliferation.  
Exogenous signals such as antigen-encounter or artificial cross-linking of the B cell receptor 
(Tovey et al., 1978; Takada, 1984) initiate a cellular signaling cascade in the latently EBV-
infected cells resulting in the transcriptional activation of the viral immediate-early gene 
BZLF1. It encodes the transcription factor BZLF1, which is responsible for the molecular 
switch from the latent to the lytic phase (Countryman and Miller, 1985; Chevallier-Greco et 
al., 1986; Takada et al., 1986; Countryman et al., 1987). Upon lytic induction, viral de novo 
synthesis starts and infected cells release viral progeny within 48 hours (Countryman and 
Miller, 1985; Takada et al., 1986). BZLF1 binds viral and cellular promoters sequence-
specifically and induces their gene expression. Upon BZLF1’s induced expression, a cascade 
of three classes of viral lytic genes starts: the immediate-early, early, and late viral genes. The 
immediate-early gene products encompass the two transcription factors BZLF1 and BRLF1. 
Early and late lytic genes encode viral proteins important for lytic viral DNA replication and 
viral structural components, respectively. The released viral progeny contains again a 
completely naïve viral genome free of histones and unmethylated CpG sites (Kalla et al., 
2010). 
During the latent phase, EBV genomes persist as multicopy DNA episomes in the nucleus of 
human B lymphocytes (Lieberman, 2006; Lindner and Sugden, 2007). The establishment of a 
latent EBV infection efficiently transforms these cells into LCLs in vitro, and is implicated in 
the etiology of infectious mononucleosis, Burkitt’s lymphoma, Hodgkin’s disease, 
nasopharyngeal carcinoma and lymphoproliferative diseases in immunocompromised 
individuals (Young and Rickinson, 2004). In healthy individuals, resting memory B cells are 
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the reservoir of EBV’s latent infection (Babcock et al., 1998). During latency, the EBV 
genome can adopt one of four different gene expression patterns that are generally referred to 
as latency programs (termed latency 0, I, II and III) and are classified on the basis of EBNA 
and LMP protein expression. Type 0 latency is defined as latency with no viral gene 
expression and is found in non-dividing B cells (Miyashita et al., 1995, Thorley-Lawson et 
al., 1996; Miyashita et al., 1997;). In cells of Burkitt’s lymphoma, only EBNA1 is expressed 
(latency I) (Thorley-Lawson et al., 1996). In Hodgkin’s disease, nasopharyngeal carcinoma 
and T cell lymphomas, EBNA1 and variable combinations of the three members of the LMP 
family (LMP1, LMP2A and LMP2B) are expressed (latency II) (Thorley-Lawson et al., 
1996). During acute infectious mononucleosis, in lymphoproliferative syndromes in 
immunocompromised individuals and in LCLs, all six nuclear antigens (EBNA1-6) required 
for B cell proliferation and survival, and all three LMPs are expressed (latency III) (Hudson et 
al., 1985; Bodescot et al., 1987). 
1.3.2 EBV and its lytic switch transactivator BZLF1 
The viral transcription factor BZLF1 is an immediate-early gene product that triggers the 
switch from the latent to the lytic phase (Countryman and Miller, 1985; Chevallier-Greco et 
al., 1986; Takada et al., 1986; Countryman et al., 1987). EBV encodes BZLF1 from the 
BZLF1 gene (Baer et al., 1984). BZLF1 binds to target sites termed BZLF1 Responsive 
Elements (ZREs) in the promoter regions of early lytic genes and induces their expression 
(Miller, 1989; Speck et al., 1997; Schwarzmann et al., 1998). BZLF1 binds sequence-
specifically to two different classes of ZREs. Class I ZREs includes classical AP1-like 
recognition elements, while class II ZREs harbor a CpG motif. BZLF1 binds preferentially to 
class II ZRE sites, only, if they contain 5’-methylated cytosine residues (meZREs) (Bhende et 
al., 2004; Karlsson et al., 2008; Dickerson et al., 2009; Kalla et al., 2010). meZREs 
predominate in the early lytic promoters (Bergbauer et al., 2010) and their CpG methylation is 
essential for the expression of lytic genes (Kalla et al., 2012) and in turn indispensable for 
viral progeny synthesis (Bergbauer et al., 2010; Kalla et al., 2010). Therefore, DNA 
methylation is no hindrance but a must for lytic reactivation mediated by BZLF1 (Woellmer 
et al., 2012). Due to its essential role in the viral life cycle, the structure and function of 
BZLF1 (Fig 1.4) has been extensively reviewed (Miller, 1989; Sinclair and Farrell, 1992; 
Speck et al., 1997; Schwarzmann et al., 1998; Petosa et al., 2006). 
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Fig. 1.4 Crystal structure of the BZLF1-DNA complex (modified from Petosa et al., 2006) 
The α-helices of the BZLF1 homodimer are shown as spirals in green and yellow. The DNA double helix is 
shown in light and dark blue. N- and C-terminus are indicated. 
(A) The BZLF1-DNA bound structure. 
(B) The same structure is rotated by 90° around the x-axis. 
BZLF1 is a 245 residue long protein that belongs to the basic leucine-zipper (bZIP) family of 
transcription factors (Farrell et al., 1989; Chang et al., 1990; Lieberman and Berk, 1990). The 
bZIP transcription factors, including c-Jun, c-Fos, ATF/CREB, and the C/EBP family of 
proteins, form homo- and heterodimers through a coiled-coil domain, also called a leucine 
zipper and bind DNA through a 60 residues long region rich in basic amino acids located 
adjacent to the dimerization domain. BZLF1 is modular in structure and consists of a N-
terminal transactivation domain (TAD) (aa1-174), a bZIP domain (aa175-220), and a C-
terminal domain (aa221-245). BZLF1’s bZIP domain lacks the otherwise usual heptad repeat 
of leucine residues, which normally mediates dimerization (Farrell et al., 1989; Chang et al., 
1990; Flemington and Speck, 1990; Kouzarides et al., 1991). Like other bZIP proteins, the 
BZLF1 homodimer binds the DNA via its two long bZIP helices (Morand et al., 2006; Petosa 
et al., 2006). The basic region of each helix contacts the major groove and the zipper region 
forms a coiled-coil. The C-terminal tail forms an additional structured motif, which stabilizes 
the coiled-coil through numerous interactions and greatly enlarges the dimer interface 
explaining the dimer’s stability despite the missing heptad repeat of leucine residues. 
BZLF1 fails to heterodimerize with the cellular bZIP proteins c-Fos, c-Jun, C/EBPα, and 
CREB (Chang et al., 1990; Kouzarides et al., 1991; Wu et al., 2004). Four amino acids, 
R183, A185, C189, and R190 in the basic domain of BZLF1 have been described to 
specifically contact DNA with BZLF1 recognition elements, since alanine or valine 
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substitutions at these positions drastically weakened or abbrogated DNA binding (Heston et 
al., 2006). 
In order to maintain infected cells in the latent phase and prevent unwanted activation of the 
lytic phase, the expression of BZLF1 is tightly regulated at different levels. The transcription 
of BZLF1 is regulated by epigenetic modifications of its promoter. Repressive histone marks 
like H3K27me3, H3K9me2/me3, and H4K20me3 negatively regulate BZLF1 and prevent 
transcriptional activation maintaining the latent phase (Murata et al., 2012). In addition, 
heterochromatin protein 1 (HP1) and H2A ubiquitination are associated with the latent phase 
(Murata and Tsurumi, 2013). The induction of active histone marks such as histone 
acetylation and H3K4me3 results in transcriptional activation of the BZLF1 gene and 
reactivation from latency (Jenkins et al., 2000; Miller et al., 2007; Countryman et al., 2008; 
Murata et al., 2012). The cellular zinc finger E-box binding factor 1 and 2 (ZEB1 and ZEB2) 
can repress the BZLF1 gene expression by directly binding its promoter (Yu et al., 2007; Ellis 
et al., 2010; Zhao et al., 2011). A silencing element in the BZLF1 promoter region, termed 
ZIIR, plays a key role in establishment and maintenance of EBV latency by inhibiting BZLF1 
promoter activation through the proteinase kinase C (PKC) signal transduction pathway (Yu 
et al., 2011). BZLF1’s silencing element is associated with the Jun dimerization protein 2 
(JDP2), which suppresses also the promoter activity of BZLF1. Additionally, a correlation 
with HDAC3 association and reduced levels of histone acetylation has been reported (Murata 
et al., 2011). The promoter region of BZLF1 contains weak ZREs but no meZREs indicating 
that its regulation is independent of the methylation status of DNA. The regulation of BZLF1 
itself relies on positive feedback loops (Speck et al., 1997; Binne et al., 2002). Further, 
reversible posttranslational modifications are in play, which dynamically regulate BZLF1’s 
protein activity. The conjugation of BZLF1 with the small ubiquitin-related modifier (SUMO) 
negatively modulates its transcriptional activity (Murata et al., 2010). This transcriptional 
repression by SUMO correlates with the association of repressor complexes, including 
HDAC3. Additional protein-protein interactions between BZLF1 and cellular proteins have 
been described to have an impact on the regulation of EBV’s life cycle (see chapter 1.3.3). 
1.3.3 Epigenetic regulation mechanisms upon lytic reactivation 
Mechanisms of epigenetic regulation control the different phases of EBV’s life cycle. CpG 
methylation, nucleosome occupancy, histone modifications, and cellular regulatory proteins 
contribute to the transcriptional regulation of viral latent and lytic promoters. 
The repression of early lytic promoters in the latent phase correlates with extensive DNA 
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methylation, high nucleosome occupancy, and Polycomb silencing with characteristic 
H3K27me3 histone marks (Woellmer et al., 2012). The repressive histone mark H3K9me3 
seems to be important to maintain the compaction of the viral chromatin in certain cell lines 
(Ramasubramanyan et al., 2011; Woellmer et al., 2012). 
Upon lytic reactivation the silenced state of early lytic promoters is reverted. Initially, 
nucleosomal occupancy drastically diminishes followed by the removal of the repressive 
histone mark H3K27me3 and the establishment of the active histone marks like H3K4me3. 
As a consequence the promoters open locally and the transcription machinery is recruited. 
Since BZLF1 binds its meZRE motifs only if methylated, DNA methylation is the 
prerequisite for the activation of early lytic promoters (Bergbauer et al., 2010; Kalla et al., 
2010; Woellmer et al., 2012). Therefore, the transition to the lytic phase does not alter the 
level of CpG methylation of viral DNA. The modification of the histone variant H2AX by 
phosphorylation has been associated with lytic regulatory regions during lytic phase 
(Ramasubramanyan et al., 2011). Phosphorylation of H2AX is associated with the DNA 
damage response pathway (Lukas et al., 2006). 
The expression and action of the transcription factor BZLF1 correlates with the loss of 
nucleosomes upon lytic phase induction (Woellmer et al., 2012). The TAD of BZLF1 is 
required only for the nucleosomal eviction of a subset of early lytic promoters (BMLF1p, 
BRLF1p and BMRF1p). A truncated BZLF1 version without TAD is capable of evicting 
histones at many more BZLF1-regulated promoters, suggesting that either the bZIP domain or 
the C-terminus of BZLF1 play a role for the nucleosomal removal. It has been hypothesized 
that BZLF1 has pioneering functions because it can reactivate silenced, inactive chromatin 
and might recruit chromatin remodelers (Adamson and Kenney, 1999; Zerby et al., 1999; 
Schelcher et al., 2007; McDonald et al., 2009; Woellmer et al., 2012). 
The chromatin regulatory factors CTCF and cohesin have been implicated in controlling 
EBV’s latent phase. CTCF binding has been detected at several key regulatory regions and 
many of these CTCF-binding sites are co-occupied by cohesin (Day et al., 2007; Holdorf et 
al., 2011; Arvey et al., 2012). A single CTCF binding site controls LMP2A and LMP1 
promoter selection, chromatin boundary function, DNA loop formation, and episome copy 
number control during EBV latency (Chen et al., 2014). The CTCF binding site is required 
for cohesin binding and for DNA loop formation between LMP1/LMP2A and OriP (Arvey et 
al., 2012). The loss of CTCF results in the switch from euchromatic to heterochromatic 
epigenetic marks at the LMP2A and LMP1 promoter regions. Strong binding of CTCF have 
been also detected immediately upstream of the latent promoters Cp and Qp, and the EBER 
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TSS (Day et al., 2007; Takacs et al., 2010). CTCF binding at these regions could provide 
several functions, including insulating neighboring viral lytic promoters from activation 
during latent infection, and the regulation of enhancer-promoter interactions. 
1.3.4 Interactions of BZLF1 with viral and host cell proteins 
The viral transcription factor BZLF1 has been reported to interact with a large number of viral 
and cellular host cell proteins influencing both latency and lytic reactivation of the virus. 
Viral interactors: 
BZLF1 protein is not only essential as a transactivating factor for early lytic gene expression, 
but also for lytic viral DNA replication. BZLF1 interrupts viral latency by interacting with the 
components of EBV’s replication machinery. It binds to the helicase-primase complex 
consisting of BBLF4 (helicase; Gao et al., 1998; Liao et al., 2001), BSLF1 (primase; Gao et 
al., 1998), and BBLF2/3 (primase-associated factor; Gao et al., 1998). Also BALF5 (DNA 
polymerase; Baumann et al., 1999) and BMRF1 (polymerase processivity factor; Zhang et al., 
1996; Baumann et al., 1999) interact with BZLF1. BZLF1 also binds to a number of classical 
ZRE motifs in the lytic origin of viral DNA replication and tethers the replication machinery 
to the origin for its initial activation. In addition, BZLF1 protein binding was shown with 
BFRF3, a component of the viral capsid antigen complex (Katz et al., 1992; Serio et al., 
1996) and BGLF4, the viral kinase and virion tegument protein regulating BZLF1’s TAD 
(Asai et al., 2006; Asai et al., 2009). 
Cellular interactors: 
The many reported interactions and regulatory loops of the viral transcription factor BZLF1 
with cellular proteins is of great complexity and might have an important influence on the 
control of EBV’s life cycle. 
Various interactions of BZLF1 and cellular proteins have been described to inhibit the lytic 
reactivation process in latently infected cells. BZLF1 may influence cellular regulatory 
pathways by protein-protein interactions between the basic domain of BZLF1 and key cell 
cycle control proteins involved in cell cycle arrest. BZLF1’s interaction with the tumor 
suppressor protein p53 may inhibit the transcriptional function of p53 and the ability of 
BZLF1 to disrupt viral latency (Mauser et al., 2002; Zhang et al., 1994). Interestingly, 
opposing effects of BZLF1 on p53 function have also been observed, where BZLF1 
expression activates p53-dependent transcription (Dreyfus et al., 2000), and BZLF1 induces a 
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cell cycle arrest and enhances the expression of p53 (Cayrol and Flemington, 1996). BZLF1 
causes also cell cycle arrest through induction of the cyclin-dependent kinase inhibitors p21 
and p27 (Cayrol and Flemington, 1996; Rodriguez et al., 1999). BZLF1 has also been 
described to interact with the cellular CCAAT/enhancer binding protein α (C/EBPα), which 
is essential for the induction of p21 and BZLF1-induced G1 arrest during EBV lytic cycle 
(Wu et al., 2003). The interaction with the p65 component of NF-κB inhibits transactivation 
of several EBV promoters (Gutsch et al., 1994). Also, the retinoic acid receptors RAR and 
RXR have been shown to interact with BZLF1 and negatively regulate its transactivation of 
early lytic promoters (Pfitzner et al., 1995; Sista et al., 1993; Sista et al., 1995). Furthermore, 
the B cell transcription factor Oct-2 interacts with BZLF1 inhibiting its function as an 
immediate early protein and preventing lytic viral reactivation (Robinson et al., 2012). 
Ubinuclein, an ubiquitously expressed nuclear protein, binds to the basic domain of BZLF1, 
might prevent its DNA binding, and acts as a chaperone for bZIP factors (Aho et al., 2000). 
Other cellular interactions with BZLF1 have been described that support reactivation of the 
productive cycle in latently infected cells. BZLF1 is involved in the activation of transcription 
by stabilizing the TFIIA-TFIID complex (Lieberman and Berk, 1991; Chi and Carey, 1993; 
Lieberman and Berk, 1994; Chi et al., 1995; Chi and Carey, 1996; Lieberman et al., 1997; 
Deng et al., 2001) and interacts also with the TATA-binding protein (TBP) (Mikaelian et al., 
1993). BZLF1 also recruits the CREB-binding protein (CBP), which stimulates transcription 
through histone acetylation (Adamson and Kenney, 1999; Zerby et al., 1999; Chen et al., 
2001). The receptor of activated C-kinase, RACK1, was identified as an interaction partner of 
BZLF1 via its transactivation domain (Baumann et al., 2000). RACK1 is involved in targeting 
activated PKCs (protein kinase C) that phosphorylate BZLF1 and increase its activity. BZLF1 
has been also reported to form a complex with the transducer of regulated CREB activity 2 
(TORC2) (Murata et al., 2009). The recruitment of this complex to BZLF1’s own promoter 
induces lytic reactivation of viral latency. Further, the viral latent phase in EBV-infected B 
cells is negatively influenced by the interaction of BZLF1 and the B cell specific transcription 
factor Pax5. The interaction may promote lytic replication in B cells by inhibiting Pax5 
function (Adamson et al., 2005). The interaction of BZLF1 with the cellular promyelocytic 
leukemia protein (PML) alters its localization from nuclear dots to a diffuse nuclear pattern 
(Bowling and Adamson, 2006). Since PML is part of the cell’s response to viral invasion, the 
re-localization of PML by BZLF1 may enhance EBV lytic replication. 
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1.4 Scope of my thesis work 
Genome-wide studies during the last years have revealed that the vast majority of 
transcription factor binding sites in the genome are inaccessible in vivo because repressive 
chromatin structures occlude their binding to DNA. Only cooperative binding of several 
factors or the concomitant recruitment of chromatin remodelers allow a single transcription 
factor to access its target sequence and induce transcription. In contrast to the majority of 
transcription factors, pioneer factors of transcription do bind to repressed and compacted 
target sequences without the help of chromatin remodeler or the use of ATP. Only very few 
examples of this type of factors have been identified so far, among them FoxA, PBX1, and 
PU.1. They are the first proteins engaged at specific sites to open up chromatin and facilitate 
transcriptional activation at previously repressed loci. Pioneer factors are therefore defined as 
a specific subclass of transcription factors that are required and sufficient to trigger 
competency of transcriptional regulatory sites (Magnani et al., 2011; Zaret and Carroll, 2011). 
 
The central hypothesis whether the viral transcription factor BZLF1 might have 
characteristics of a pioneer factor that acts during the process of lytic gene activation was the 
starting point of my PhD work. The previous findings of Woellmer et al. (2012) let us 
speculate that BZLF1 might overcome the silenced, repressed state of viral chromatin by 
binding and positioning nucleosomes that occupy the promoter regions of early lytic genes. In 
order to provide a better understanding of the epigenetic alterations that occur during the 
switch from the latent to the lytic phase in EBV, I sought to discover whether BZLF1 is not 
only required but also sufficient to remodel the chromatin landscape at the proximity of 
EBV’s lytic genes or if cellular chromatin regulatory factors are needed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. MATERIAL 
2.1 Oligonucleotides 
The synthesis of all oligonucleotides used in my PhD work was performed by the company 
Metabion (Munich). The sequences of the oligonucleotides are listed in the appendix. 
2.2 Plasmids 
All plasmids listed below were generated (unless noted otherwise) and used in the context of 
this work. They are part of the plasmid collection of the Research Unit Gene Vectors.
Plasmid Description 
p0509 CMV promoter driven BZLF1 expression vector (Hammerschmidt and Sugden, 1988) 
p1925 eGFP-C1 lacking MCS to express GFP (Dagmar Pich) 
p3925 FLAG- and tandem Strep-tag II expression plasmid pN-SF-TAP for N-terminal fusion proteins 
(Marius Ueffing and Johannes Glöckner) 
p3928 FLAG- and tandem Strep-tag II expression plasmid pN-SF-TAP with BZLF1 (aa 149 to 245) 
(Wolfgang Hammerschmidt and Martin Bergbauer) 
p4816 pRTR, oriP expression vector with EBNA1, reverse tetracycline controlled transactivator rtTA2(S)-
M2 and Tet repressor tTS (PLDLS-135-L) as a silencer, puromycin resistance, luciferase reporter 
gene of vector was substituted by BZLF1 as gene of interest (SfiI sites), NGF-R-IRES-GFP for 
monitoring inserted with AscI/SwaI (Martin Bergbauer and Marisa Schäffner) 
p5406 FLAG- and tandem Strep-tag II expression plasmid pN-SF-TAP with BZLF1 (aa 1 to 245) 
p5594 pUC18 plasmid containing Asp718I-flanked BRLF1 ZRE 0 multimers 
p5595 pUC18 plasmid containing Asp718I-flanked BBLF4 ZRE 3 multimers 
p5596 pUC18 plasmid containing Asp718I-flanked BBLF4 ZRE 3+4 multimers 
p5597 pUC18 plasmid containing Asp718I-flanked BBLF4 ZRE 4 multimers 
p5686 FLAG- and tandem Strep-tag II expression plasmid pN-SF-TAP with BZLF1 (aa 175 to 236) 
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p5693 pRTR, oriP expression vector with EBNA1, reverse tetracycline controlled transactivator rtTA2(S)-
M2 and Tet repressor tTS (PLDLS-135-L) as a silencer, puromycin resistance, luciferase reporter 
gene of vector was substituted by Flag-tandem Strep-BZLF1 (aa1 to 245) as gene of interest (SfiI 
sites), NGF-R-IRES-GFP for monitoring inserted with AscI/SwaI 
p5694 RTR, oriP expression vector with EBNA1, reverse tetracycline controlled transactivator rtTA2(S)-
M2 and Tet repressor tTS (PLDLS-135-L) as a silencer, puromycin resistance, luciferase reporter 
gene of vector was substituted by Flag-tandem Strep-BZLF1 (aa175 to 236) as gene of interest (SfiI 
sites), NGF-R-IRES-GFP for monitoring inserted with AscI/SwaI 
p5748 pUC18 plasmid containing Asp718I-flanked BBLF4 ZRE 0+4 multimers 
p5749 pUC18 plasmid containing Asp718I-flanked BBLF4 ZRE 3+0 multimers 
p5836 pUC18 plasmid containing Asp718I-flanked BBLF4 ZRE 3+0 -5nt multimers 
p5837 pUC18 plasmid containing Asp718I-flanked BBLF4 ZRE 3+0 +5nt multimers 
p5838 pUC18 plasmid containing Asp718I-flanked BBLF4 ZRE 3+0 +10nt multimers 
p5839 pUC18 plasmid containing Asp718I-flanked BBLF4 ZRE 3+0 +15nt multimers 
p5840 pUC18 plasmid containing Asp718I-flanked BBLF4 ZRE 3+0 +30nt multimers 
p5906 pEGFP-N3 + SNF2H 
p5916 pmCherryC1 + LacI-BZLF1 (aa 1-245) 
p5985 pEGFP-C1 + hIno80 
p6013 FLAG- and tandem Strep-tag II expression plasmid pN-SF-TAP with BZLF1 (aa 175-245)  
p6014 FLAG- and tandem Strep-tag II expression plasmid pN-SF-TAP with BZLF1 (aa 1-236) 
2.3 Antibodies 
All antibodies used in this work are listed below.  
Specificity Species Distributor Application Amount 
Anti-acetyl-Histone H3 Rabbit Millipore (#06-599) ChIP 3 µg 
Anti-BZLF1 Mouse E. Kremmer (HMGU) Western 1:50 
Anti-Flag Mouse Stratagene (#200474-21) Western/EMSA 1:5000/1 µg 
Anti-GFP Rat Chromotek (#3H9) Western 1:1000 
Anti-Histone H3 mono methyl Lys4 Mouse Abcam (#ab8895) ChIP 3 µg 
Anti-INO80 Rabbit Abcam (#ab118787) Western 1:2000 
Anti-mouse IgG, HRP Goat Cell Signaling (#7076S) Western 1:5000 
Anti-rabbit IgG Rabbit Millipore (#PP64B) ChIP 3 µg 
Anti-rabbit IgG, HRP Rabbit Cell Signaling (#7074S) Western 1:5000 
Anti-rat IgG, HRP Goat Cell Signaling (#7077) Western 1:5000 
Anti-RNA polymerase II (N20) Mouse Santa Cruz (#sc-39097) ChIP 10 µl 
Anti-SNF2h Mouse Active Motif (#39543) Western 1:2000 
Anti-tubulin Mouse Santa Cruz (#sc-23948) Western 1:5000 
Anti-ZEBRA Goat Santa Cruz (#sc-17503) ChIP/ReChIP 3 µg/15 µg 
2.4 Bacterial strains 
For all cloning purposes and the preparation of plasmid DNA, the strain DH5-α (F-, lacl-, 
recA1, endA1, hsdR17, ∆(lacZYA-argF), U169, F80d lacZ∆M15, supE44, thi-1, gyrA96, 
relA1; Hanahan, 1985) was used. 
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2.5 Eukaryotic cell lines 
All used cell lines stem from the collection of the Research Unit Gene Vectors or were 
established (*) in the course of my work and are recorded below. In case of established cell 
lines the stably transfected plasmid is noted.  
Name Description 
HEK293 Human embryonic kidney cells transformed after transfection with DNA from human Adenovirus 
Type 5 (Graham et al., 1977) 
Raji Human EBV-positive Burkitt-lymphoma cell line (Pulvertaft, 1964) 
Raji/4816* Raji cells carrying a tet-inducible plasmid for BZLF1 (aa 1-245) 
Raji/5693* Raji cells carrying a tet-inducible plasmid for flag- and tandem strep-tagged BZLF1 (aa 1-245) 
Raji/5694* Raji cells carrying a tet-inducible plasmid for flag- and tandem strep-tagged BZLF1 (aa 175-236) 
2.6 Cell culture media and additives 
2.6.1 Media for the cultivation of bacteria 
Bacteria were either cultivated with LB-medium in liquid culture for large-scale production or 
on solid agar plates if single clones were cultured. 
Appellation Ingredients Distributor 
LB-medium 1 % (w/v) tryptone, 1 % (w/v) NaCl, 0.5 % (w/v) yeast extract Invitrogen, Karlsruhe 
Select agar LB-medium with 1.5 % (w/v) select agar  Invitrogen, Karlsruhe 
2.6.2 Media for the cultivation of eukaryotic cells 
Media and additives for eukaryotic cell culture used in this work are listed below.  
Appellation Application Distributor 
RPMI-1640 Cell culture medium for cultivation of HEK293 and Raji 
cell lines used in this study 
Invitrogen, Karlsruhe 
DMEM Cell culture medium for cultivation of U2OS cell lines 
used in this study 
Sigma-Aldrich, Munich 
Opti-MEM I Minimal culture medium for transfection reactions Invitrogen, Karlsruhe 
α-thioglycerole Antioxidant agents (additive for RPMI-1640) Sigma-Aldrich, Munich 
Bathocupproine-
disulfonic acid 
Antioxidant agents (additive for RPMI-1640) Sigma-Aldrich, Munich 
Fetal bovine serum Nutritive substance (additive for RPMI-1640) Invitrogen, Karlsruhe 
Sodium pyruvate Antioxidant agent (additive for RPMI-1640) Invitrogen, Karlsruhe 
Sodium selenite Antioxidant agent (additive for RPMI-1640) Sigma-Aldrich, Munich 
Penicillin/streptomycin Antibiotics (additives for RPMI-1640) Invitrogen, Karlsruhe 
Puromycin Antibiotic for the selection of stably transfected cell lines Invitrogen, Karlsruhe 
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2.7 Chemicals and enzymes 
The following list shows the used chemicals and enzymes in this work.  
Distributor Appellation 
Affymetrix, Santa Clara, USA T4 DNA Ligase 
Applichem, Darmstadt Lysozyme, RNAse A, Tris (C4H11NO3) 
Biochrome AG, Berlin PBS 
Bio Rad, Munich Bradford solution 
Carl Roth GmbH, Karlsruhe Bovine serum albumin fraction V (BSA) powder, chloroform (CHCl3), 
phenol (C6H6O), powdered milk, Rotiphorese Gel30 (acrylamide), 
Rotiphorese Gel40 (acrylamide) 
Difco Laboratories, Detroit, USA Bacto-agar, trypton, yeast extract 
Fermentas, St. Leon-Roth DNA ladders, loading dye for gel electrophoresis, restriction enzymes, T4 
Polynucleotide Kinase 
Finnzymes, Vantaa, Finland Phusion polymerase 
GE Healthcare, Munich Amersham ECL Select Western Blotting Detection Reagent, Hybond-ECL 
membrane 
Hartmann Analytik, 
Braunschweig 
[γ-32P] ATP 
IBA GmbH, Göttingen Desthiobiotin elution buffer (10x), Strep-Tactin Sepharose, wash buffer (10x) 
Invitrogen, Karlsruhe Agarose, calf thymus DNA, DNase I, trypsin-EDTA 
Merck, Darmstadt Acetic acid (C2H4O2), ammonium sulfate ((NH4)2SO4), Benzonase Nuclease, 
boric acid (H3BO3), caesium chloride (CsCl), calcium chloride (CaCl2), 
disodium phosphate (Na2HPO4), ethanol (C2H6O), ethidium bromide 
(C21H20BrN3), ethylenediaminetetraacetic acid (EDTA, C10H16N2O8), 
ethylene glycol tetraacetic acid (EGTA, C14H24N2O10), glucose (C6H12O6), 
glycerol (C3H8O3), glycine (C2H5NO2), HEPES (C8H18N2O4S), hydrochloric 
acid (HCl), isopropanol (C3H8O), lithium chloride (ClLi), magnesium 
chloride (MgCl2), magnesium sulfate (MgSO4), methanol (CH4O), 
monopotassium phosphate (KH2PO4), paraformaldehyde (OH(CH2O)nH (n = 
8-100)), N-lauroyl sarcosine (C15H29NO3), potassium acetate (C2H3KO2) 
potassium chloride (KCl), sodium acetate (C2H3NaO2), sodium chloride 
(NaCl), sodium dodecyl sulfate (SDS, NaC12H25SO4), sodium hydroxide 
(NaOH), sucrose (C12H22O11), tetramethylethylendiamin (TEMED, C6H16N2), 
Triton X-100 (C14H22O(C2H4O)n (n = 9-10), zink sulfate (ZnSO4) 
New England Biolabs, Frankfurt Alkaline Phosphatase Calf Intestinal (CIP), CpG Methyltransferase (M.SssI), 
restriction enzymes (AvaI, RsaI, XmnI) 
Promega, Mannheim RNAsin plus RNAse inhibitor 
Roche Diagnostics GmbH, 
Mannheim 
Asp718 restriction enzyme, Complete Mini Protease Inhibitor, desoxy-
nucleotides, LightCycler 480 SYBR Green I Master, Micrococcal Nuclease 
S7, PhosStop Phosphatase Inhibitor, poly(dI/dC) 
SERVA Electrophoresis GmbH, 
Heidelberg 
Ammonium persulfate (APS, (NH4)2S2O8) 
Sigma-Aldrich, Munich Ampicillin (C16H19N3O4S), beta-mercaptoethanol (C2H6SO), bromophenol 
blue (C19H10Br4O5S), dimethyl sulfoxide (DMSO, C2H6OS), dithiothreitol 
(DTT, C4H10O2S2), doxycycline (DOX, C22H24N2O8), kanamycin 
(C18H36N4O11), NP-40 ((C2H4O)nC14H22O), phenylmethanesulfonylfluoride 
(PMSF, C7H7FO2S), polyethylenimine (PEI, (C2H5N)n), Ponceau S 
(C22H16N4O13S4), Proteinase K, puromycin (C22H29N7O5), silver nitrate 
(AgNO3), sodium carbonate (Na2CO3), sodium deoxycholate (C24H39NaO4), 
sodium metabisulfite (Na2S2O5), sodium thiosulfate (Na2S2O3), xylene cyanol 
(C25H27N2NaO6S2) 
Thermo Scientific, Waltham, 
USA 
PageRuler Plus Prestained Protein Ladder, Phusion High-Fidelity DNA 
Polymerase 
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2.8 Buffers and solutions 
The following lists records the buffers and solutions used in my work.  
Buffer/solution Ingredients Application 
Agarose loading dye 1 mg/ml bromophenol blue, 1 mg/ml xylene cyanol, 50 % sucrose 
Alkaline phosphatase 
buffer (10x) 
500 mM Tris-HCl pH9.3, 10 mM MgCl2, 1 mM ZnSO4 
Ampicillin (1000x) 100 mg/ml ampicillin in 50 % ethanol, sterile filtered 
Kanamycin (1000x) 30 mg/ml kanamycin in ddH2O, sterile filtered 
M-STET 50 mM Tris-HCl pH8.0, 25 mM EDTA, 5 % sucrose, 0.5 % Triton X-100 
PBS, pH7.3 10 mM Na2HPO4, 1.8 mM KH2PO4, 140 mM NaCl, 2.7 mM KCl 
TAE 40 mM Tris-acetate, 1 mM EDTA 
TBE 89 mM Tris, 89 mM boric acid, 2 mM EDTA 
TE, pH8.0 10 mM Tris-HCl, 1 mM EDTA, 
General lab 
techniques 
ChIP lysis buffer 10 mM Tris-HCl pH7.5, 10 mM NaCl, 3 mM MgCl2, 0.5 % NP-40 
ChIP sonication buffer 50 mM Tris-HCl pH7.5, 10 mM EDTA, 1 % SDS, 1 % NP-40, 1x 
“Complete” proteinase inhibitor cocktail (Roche) 
ChIP dilution buffer 20 mM Tris-HCl pH8.0, 2 mM EDTA, pH 8.0, 1 % Triton X-100, 
150 mM NaCl, 1x “Complete” proteinase inhibitor cocktail (Roche) 
ChIP low salt buffer 20 mM Tris-HCl pH8.0, 2 mM EDTA pH8.0, 1 % Triton X-100, 150 mM 
NaCl, 0.1 % SDS 
ChIP high salt buffer 20 mM Tris-HCl pH8.0, 2 mM EDTA pH8.0, 1 % Triton X-100, 500 mM 
NaCl, 0.1 % SDS 
ChIP LiCl buffer 10 mM Tris-HCl pH8.0, 1 mM EDTA pH8.0, 250 mM LiCl, 0.5 % NP-
40, 0.5 % sodium deoxycholate  
ChIP elution buffer 25 mM Tris-HCl pH7.5, 10 mM EDTA pH8.0, 0.5 % SDS 
ChIP 
ReChIP lysis buffer 1 50 mM HEPES pH7.5, 140 mM NaCl, 1 mM EDTA pH8.0, 0.5 mM 
EGTA pH8.0, 10 % glycerol, 0.5 % NP-40, 0.25 % Triton X-100, 1x 
“Complete” proteinase inhibitor cocktail (Roche) 
ReChIP Lysis buffer 2 25 mM HEPES pH7.5, 200 mM NaCl, 1 mM EDTA pH8.0, 0.5 mM 
EGTA pH8.0, 1x “Complete” proteinase inhibitor cocktail (Roche) 
ReChIP lysis buffer 3 25 mM HEPES pH7.5, 140 mM NaCl, 1 mM EDTA pH8.0, 0.5 mM 
EGTA pH8.0, 0.25 % N-lauroyl sarcosine, 0.1 % sodium deoxycholate, 
0.25 % Triton X-100, 1x “Complete” proteinase inhibitor cocktail (Roche) 
ReChIP wash buffer 1 50 mM Tris-HCl pH8.0, 150 mM NaCl, 1 mM EDTA pH8.0, 0.1 % SDS, 
0.5 % sodium deoxycholate, 1 % NP-40 
ReChIP wash buffer 2 50 mM Tris-HCl pH8.0, 300 mM NaCl, 1 mM EDTA pH8.0, 0.1 % SDS, 
0.5 % sodium deoxycholate, 1 % NP-40 
ReChIP wash buffer 3 50 mM Tris-HCl pH8.0, 250 mM LiCl, 0.1 % SDS, 0.5 % sodium 
deoxycholate, 1 % NP-40 
ReChIP elution buffer 10 mM Tris-HCl pH8.0, 1 mM EDTA pH8.0, 1 % SDS 
ReChIP 
EMSA binding buffer 
(10x) 
100 mM Tris-HCl pH7.6, 10 mM MgCl2, 600 mM KCl, 30 mg/ml BSA, 
10 % glycerol, 10 % Ficoll, 10 mM DTT 
Native separation gel 
(10 %) 
16.6 ml Rotiphorese 30 (37.5:1), 2.5 ml 10x TBE, 400 µl 10 % APS, 50 
µl TEMED 
Native shift gel 
(5 %) 
5 ml Rotiphorese 30 (37.5:1), 5 ml Rotiphorese 40 (19:1), 3.2 ml 10x 
TBE, 66 ml ddH2O, 50 µl TEMED, 400 µl 10 % APS 
EMSA loading dye 20 mM Tris-HCl pH7.5, 8 mM EDTA, 25 % glycerol, 0.1 % NP-40  
Fixing solution 10 % acetic acid, 20 % methanol in ddH2O 
EMSA 
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RIPA buffer 
 
50 mM Tris-HCl pH8.0, 150 mM NaCl, 0.1 % SDS, 0.5 % sodium 
deoxycholate, 1 % NP-40, 1x “Complete” proteinase inhibitor cocktail 
(Roche) 
Wash buffer (10x) 100 mM Tris-HCl pH8.0, 150 mM NaCl, 1 mM EDTA, 1x “Complete” 
proteinase inhibitor cocktail (Roche) 
Desthiobiotin elution 
buffer (10x) 
100 mM Tris-HCl pH8.0, 150 mM NaCl, 1 mM EDTA, 2.5 mM 
desthiobiotin, 1x “Complete” proteinase inhibitor cocktail (Roche) 
Protein 
purification 
Lysis buffer 15 mM HEPES-KOH pH7.5, 10 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 
0.5 mM EGTA, 17.5 % (w/v) sucrose, 1 mM DTT, 0.2 mM PMSF, 1 mM 
sodium metabisulfite 
Suc buffer 15 mM HEPES-KOH pH7.5, 10 mM KCl, 5 mM MgCl2, 0.05 mM 
EDTA, 0.25 mM EGTA, 1.2 % (w/v) sucrose, 1 mM DTT, 0.1 mM PMSF 
Histone 
octamer 
preparation 
Hypotonic buffer 10 mM HEPES pH7.9, 1.5 mM MgCl2, 10 mM KCl, 340 mM sucrose, 1x 
“Complete” proteinase inhibitor cocktail (Roche) 
High salt buffer 10 mM HEPES pH7.9, 1.5 mM MgCl2, 1260 mM NaCl, 1x “Complete” 
proteinase inhibitor cocktail (Roche) 
Wash buffer 100 mM Tris-HCl pH8.0, 150 mM NaCl, 1 mM EDTA, 1x “Complete” 
proteinase inhibitor cocktail (Roche) 
Mass 
spectrometry 
analysis 
Impregnating solution 50 µl sodium thiosulfate solution (2.15 g in 5 ml ddH2O), 70 µl 37 % 
formaldehyde, ad 100 ml ddH2O 
Staining solution 0.2 g silver nitrate, 70 µl 37 % formaldehyde, ad 100 ml ddH2O 
Developing solution 6 g Na2CO3 (water-free), 2 µl sodium thiosulfate solution (2.15 g in 5 ml 
ddH2O), 50 µl 37 % formaldehyde, ad 100 ml ddH2O 
Silver 
staining 
CoIP lysis buffer 10 mM Tris-HCl pH7.5, 150 mM NaCl, 0.5 mM EDTA, 0.2 % NP-40, 1x 
“Complete” proteinase inhibitor cocktail (Roche) 
CoIP dilution/wash 
buffer 
10 mM Tris-HCl pH7.5, 150 mM NaCl, 0.5 mM EDTA, 1x “Complete” 
proteinase inhibitor cocktail (Roche) 
CoIP 
2.9 Commercial kits 
Commercial kits used in this work are listed below.  
Distributor Appellation 
GE-Healthcare, Munich ECL Select Western Blotting Detection Reagent, Illustra MicroSpin G50 columns 
Genomed, Bad Oeynhausen Jet-Star Plasmid purification Kit 
Invitrogen GmbH, Karlsruhe SuperScript III First Strand Synthesis SuperMix 
Macherey-Nagel, Düren NucleoSpin Extract II Kit, NTB Buffer 
Metabion, Planegg/Steinkirchen mi-Plasmid Miniprep Kit 
Qiagen, Hilden Endofree Plasmid Maxi Kit, QIAamp DNA Mini Kit, Rneasy MiniKit, QiaShredder 
Roche Diagnostics GmbH, Erlangen Rapid DNA Dephos and Ligation Kit 
Thermo Scientific, Waltham, USA CloneJET PCR Cloning Kit 
Whatman, Dassel ELUTRAP BT1000 STARTERKIT 
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2.10 Software 
Software tools that contributed to this work are listed below.  
Distributor Appellation 
Accelrys, Cambridge, UK MacVector 12.6 
Adobe Systems Inc., San Jose (USA) Illustrator CS5, Photoshop CS5 
Graphpad Software, La Jolla, USA Prism 6 
Microsoft, Redmond (USA) Microsoft Office 2008 
Raytest Isotopenmessgeräte GmbH, Straubenhardt AIDA Alias Software 
The R Foundation for Statistical Computing Vienna, Austria R 3.1.1 
Thomson Reuters, New York (USA) EndNote X2 
TreeStar Inc., Ashland (USA) FlowJo 9.1 
Vilber Lourmat, Marne-la-Vallée, France Quantum ST4 software  
2.11 Devices and consumables 
The list below comprises devices and consumables that were used in this work. 
Distributor Appellation 
AGFA, Cologne  CP1000 developer machine, Medical X-Ray Screen 
Beckman, Heidelberg Centrifuge Avanti J-25 and Avanti-26XP  
Becton Dickinson GmbH, Heidelberg FACS-Calibur, cell culture flasks, 6-/12-/24-/48- and 96-well plates 
Bio-Rad, Munich  Mini Protean II Tetra Gelelectrophorese Unit, Gene-Pulser II electroporation device 
Brand, Wertheim  Glass pipettes 5 ml, 10 ml, 20 ml and 25 ml  
Branson, Danbury, USA  Branson Sonifier S-250D  
Diagenode, Liège, Belgium Bioruptor (UCD-200) 
Eppendorf, Hamburg  BioPhotometer, PCR machine Mastercycler Personal, reaction tubes, desk centrifuge 5415, thermomixer comfort 
Eurofins MWG Operon, Ebersberg  DNA sequencing 
Hartenstein, Würzburg  Cover slips, glass slides, forceps, Whatman paper, Neubauer chamber 
Hewlett Packard, USA HP Scan-Jet G4050 
G. Heinemann, Schwäbisch Gmünd Sonifier nozzle 5 mM for Branson sonifier  
FujiFilm, Kleve  Phosphoimager FLA 5100, film cassettes, intensifier screen 
Invitrogen GmbH, Karlsruhe Qubit 2.0 Fluorometer, Neon Transfection System 
GE Healthcare, Munich  High performance autoradiography film  
Gilson Inc., Villiers le Bel Peristaltic Pump Minipuls 2, 2 µl, 20 µl, 200 µl and 1000 µl pipettes  
Greiner Bio One, Solingen  Plastic consumables for cell culture and laboratory work 
Metabion, Martinsried DNA oligonucleotides and primers 
Millipore, Schwalbach Water deionizing device Milli-RO 60 PLUS  
Montreal Biotec Inc., Montreal, Canada  Vacuum centrifuge univapo H150 
Nunc GmbH, Wiesbaden  Cell culture dishes, 6-/12-/24-/48- and 96-well plates, cryotubes 
Peqlab, Erlangen Agarose gel electrophoresis chambers, NanoDrop ND-1000 
Roche Diagnostics GmbH, Erlangen  Light Cycler 480 Real Time PCR System, Xcelligence RTCA DP 
Schleicher & Schüll, Dassel  0.8 µm and 1.2 µm filter 
Schott, Mainz Glass ware 
Stratagene, Heidelberg  Robocycler Gradient 96 
Thermo Scientific, USA  Heraeus Multifuge 3L-R, orbital shakers, incubators 
Vilber Lourmat, Marne-la-Vallée, France  Quantum ST4 
Zeiss, Göttingen  Axiovert 40C, Axiovert 200M 
 
3. METHODS 
3.1 Bacterial culture 
3.1.1 Growth and storage of bacterial cultures 
Escherichia coli (E.coli) suspensions were cultured in LB-medium at 37 °C and 200 rpm in 
orbital shakers. Single cell clones were isolated by streaking the bacteria on LB-agar using an 
inoculating loop or a glass spreader and incubating the agar plates at 37 °C over night. 
Antibiotics (100 µg/ml ampicillin or 30 µg/ml kanamycin) were added to autoclaved LB-
medium to select for bacteria harboring plasmid DNA with resistance genes. For long-term 
storage, bacterial stocks of over night cultures supplemented with 25 % glycerol were frozen 
at -80 °C.  
3.1.2 Transformation of bacteria 
According to the protocol of Hanahan et al. (1985) chemical competent E.coli cells were 
generated. For long-term storage, 200 µl aliquots were made, frozen immediately in liquid 
nitrogen and transferred to a -80 °C freezer. For a single transformation reaction, bacteria 
were thawn on ice, 50-100 µl were incubated with 2 µl (equivalent to 5-10 ng) of a ligation 
reaction or 1 ng of purified plasmid DNA on ice for 30 minutes. Heat shock reaction was 
performed by incubating on 42 °C for 90 seconds. Subsequently, the bacteria were transferred 
back on ice and 900 µl of LB-medium was added. The mixture was incubated at 37 °C 
allowing the expression of resistance genes. After 30 minutes bacteria were centrifuged at 
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3000 g for 30 seconds, resuspended in 100 µl and plated on LB-agar containing the adequate 
antibiotic. The LB-agar plates were incubated at 37  °C over night. 
3.2 Eukaryotic cell culture 
3.2.1 Cell culture conditions 
Eukaryotic cell culture was performed in lamina hoods using sterile pipettes, solutions and 
culture dishes. Cells were cultivated in 37 °C incubators in an atmosphere of 5 % CO2 and 
95 % air humidity. Centrifugation steps were carried out at 300 g for 5 minutes. Cells were 
washed with sterile PBS. Cell number was determined using a Neubauer cell chamber. All 
cell lines used in this work were cultured in RPMI-1640 medium supplemented with 10 % 
fetal bovine serum (FBS), 1 mM sodium pyruvate, 100 nM sodium selenite, 20 µM 
bathocupproine-disulfonic acid, 0.433 % α-thioglycerole, 100 µg/ml streptomycin and 
100 Units/ml penicillin (full medium). When the adherent HEK293 cells reached a 
confluency of 70-80 % they were washed with 10 ml PBS and subsequently incubated with 
2 ml of 0.05 % trypsin and 0.02 % EDTA. The detached cells were resuspended in 10 ml 
medium and 1 ml was transferred to a new culture vessel. Raji cells were cultivated in 
suspension at an average density of 3-5x105 cells/ml. The Raji cell lines 4816, 5693, or 5694 
were all selected with 1 µg/ml puromycin. 
3.2.2 Storage of eukaryotic cells 
For long term storage cells were trypsinized, washed and resuspended in a mixture of 90 % 
FBS and 10 % DMSO at a concentration of 1x107 cells/ml. Cells were transferred to a 2 ml 
CryoTube (Nunc) and gentle freezing was guaranteed by slowly cooling in a “Nalge Nunc 
Cryo 1 °C Mr. Frosty Freezing Container” (Nunc) with a cooling rate of -1 °C/min. In order 
to test cell viability, one vial was thawn after one week at -80 °C. The other vials were 
transferred to liquid nitrogen tanks and stored in the gas phase. For thawing, cells were 
warmed to 37 °C, washed with 50 ml of full medium, and taken up in 5 ml full medium. If 
required, an antibiotic for selection pressure was applied the day after thawing.  
3.2.3 Transient transfection of HEK293 cells 
HEK293 cells were transiently transfected with plasmid DNA using PEI (Sigma-Aldrich). 
For a 6-well scale, 5x105 cells were seeded per well one day before transfection. The 
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upcoming day the culture medium was replaced with 1 ml Opti-MEM I (Invitrogen) and 
following mixtures were set up:  
100 µl Opti-MEM I + 1 µg DNA 
100 µl Opti-MEM I + 6 µl PEI (1 mg/ml) 
For a 13 cm cell culture dish scale, 2x107 cells were seeded per dish one day before 
transfection. The upcoming day the culture medium was replaced with 10 ml Opti-MEM I 
(Invitrogen) and following mixtures were set up:  
3.6 ml Opti-MEM I + 30 µg DNA 
3.6 ml Opti-MEM I + 180 µl PEI (1 mg/ml) 
Both solutions were mixed, incubated for 15 minutes at room temperature and then added to 
the cells. After an incubation time of 4 hours, the transfection mixture was replaced either by 
2 ml (6-well) or 20 ml (13 cm dish) of full medium. 
3.2.4 Electroporation of eukaryotic cells 
Raji cells were electroporated with the gene pulser II electroporator (Biorad). 5x106 cells were 
spun down and resuspended in 250 µl Opti-MEM I. 5-10 µg plasmid DNA were added and 
cells were incubated on ice for 15 minutes. Electroporation was performed in 4 mM cuvettes 
at 230 V and 975 µF. After pulsing, cells were supplied with 400 µl FBS, transferred to 5 ml 
full medium, and cultivated at 37 °C.  
3.2.5 Establishment of stable cell lines 
For the generation of single cell clones electroporated cells (see chapter 3.2.4) were first 
grown in bulk culture for two days and then diluted in 96-well plates. The cells were 
cultivated under selection for four weeks, medium was changed if necessary, and outgrowing 
cells were expanded continuously. Expression of the transgene was evaluated using flow 
cytometry (see chapter 3.2.6).  
3.2.6 Flow cytometry 
Cells of the stable Raji cell lines 4816, 5693, or 5694 were washed with PBS and analyzed in 
a FACS Calibur (Beckton Dickinson) to detect and count GFP-positive cells. Data was 
evaluated with the FlowJo 9.1 software.  
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3.3 Nucleic acid techniques 
General methods like phenol/chloroform extraction, DNA precipitation with ethanol or 
isopropanol, electrophoretic separation of DNA, enzymatic restriction hydrolysis, ligation of 
free DNA ends, or radioactive labeling of DNA were performed according to standard 
protocols (Sambrook et al., 2001). 
3.3.1 DNA purification from E.coli 
Small-scale purification of plasmids was performed according to two different protocols. For 
evaluating a cloning procedure by enzymatic restriction digest, 2 ml of bacteria culture in the 
stationary phase were harvested, resuspended in M-STET buffer (50 mM Tris-HCl pH8.0, 
25 mM EDTA, 5 % sucrose, 0.5 % Triton X-100), incubated at 95 °C for 2 minutes and 
centrifuged for 10 minutes at 15000 rpm. 2 µl of plasmid DNA were used for an enzymatic 
control digest. Instead for evaluating a cloning procedure by sequencing, 2 ml of bacteria 
culture in the stationary phase was used to purify plasmid DNA according to the 
manufacturer’s protocol of the mi-Plasmid Miniprep Kit (Metabion). 
For large-scale purification of plasmid DNA, 400 ml of bacteria culture in the stationary 
phase was used. The purification was performed using either the Jet Star Plasmid Purification 
Kit (Genomed) for cloning or the EndoFree Plasmid Maxi Kit (Qiagen) for transfection of 
cells. 
3.3.2 DNA purification from eukaryotic cells 
Genomic DNA from eukaryotic cells was purified using the QIAamp DNA Mini Kit (Qiagen) 
according to the manufacturer’s protocol.  
3.3.3 Purification of DNA from PCR products and agarose gels 
Purification of DNA from PCR products or agarose gels was performed with the NucleoSpin 
Extract II Kit (Macherey-Nagel) following the manufacturer’s protocol. SDS containing 
samples were purified with five volumes of NTB buffer instead of the standard binding 
buffer.  
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3.3.4 Electroelution of DNA from native gels 
Large-scale purification of DNA fragments was performed by native gel electrophoresis. 
Using a UV lamp, the fragment of interest was visualized, excised with a scalpel and the 
DNA was electroeluted with the ELUTRAP BT1000 STARTERKIT (Whatman) according to 
the manufacturer’s recommendations. DNA concentration was measured by the Nanodrop 
method. 
3.3.5 Dephosphorylation and ligation 
For cloning procedures DNA fragments were dephosphorylated and ligated using the Rapid 
DNA Dephos and Ligation Kit (Roche) according to the company’s recommendations. 
3.3.6 Polymerase chain reaction (PCR) 
PCR amplifies defined nucleic acid fragments exponentially (Mullis et al., 1986). In this work 
the protocol of the Phusion High-Fidelity DNA polymerase (Finnzymes) was used. The 
components of a PCR reaction and a typical PCR program are listed below. 
Component 50 µl reaction 
H2O ad to 50 µl 
5x Phusion HF Buffer 10 µl 
10 mM dNTPs 1 µl (10 mM) 
Forward primer 0.5 µl (100 µM) 
Reverse primer 0.5 µl (100 µM) 
Template DNA 1 to 50 ng 
Phusion DNA polymerase 0.5 µl (0.02 U/µl) 
  
Cycle step Temperature Time Cycles 
Initial denaturation 98 °C 3 min 1 
Denaturation 
Annealing 
Extension 
98 °C 
50-60 °C (depending on primer pair) 
72 °C 
30 s 
30 s 
30 s – 1 min/kb 
30 
Final extension 72 °C 10 min 1 
Amplified DNA was separated on a 1 % TBE agarose gel to control the size of the PCR 
product or for preparative gel purification (see chapter 3.3.3).  
3.3.7 Quantitative real time PCR (qPCR) 
Immunoprecipitated DNA (see chapter 3.5.2) or cDNA (see chapter 3.3.10) was quantified 
with a Roche LightCycler 480 device. During DNA synthesis the fluorescent dye SYBR-
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Green I is incorporated into double-stranded DNA and therefore the amount of DNA can be 
quantified after each elongation cycle (Higuchi et al., 1993). 
The amount of DNA was analyzed with “absolute quantification”. This method allows the 
calculation of the sample concentration by comparing the crossing points (Cp) of the 
unknown sample with a defined standard curve, which encompasses different dilutions of 
either input (immunoprecipitated DNA) or a known amount of transcripts (cDNA). The 
analysis was done automatically with the LightCycler 480 software according to the second 
derivative maximum method.  
The PCR mix and the PCR program for qPCR are listed below.  
Component Amount 
Template DNA 1 µl immunoprecipitated DNA or cDNA 
Primer 5 pm each 
SYBR Green I Master (2x) 5 µl 
H2O 3.5 µl 
 
Program Target temperature (°C) 
Hold 
(sec) Acquisition mode 
RampRate 
(°C/sec) Cycles Analysis mode 
Pre-incubation 95 600 None 4.4 1 None 
Amplification 
95 
62 
72 
75 
1 
10 
10 
3 
None 
None 
None 
Single 
4.4 
2.2 
4.4 
4.4 
45 Quantification 
97 1 None 4.4 
67 10 None 2.2 Melting curve 
97 / Continuous 0.11 
1 Melting curve 
Cooling 37 15 None 2.2 1 None 
3.3.8 Mutagenesis PCR 
Single point mutations were introduced in plasmid DNA using the Phusion High-Fidelity 
DNA polymerase (Finnzymes). Primers were designed such that their 5’ ends are located 
close to each other, resulting in an amplification of the whole plasmid except the sequence 
between the primers. The sequence between the 5’ ends of the primers was replaced by 
adding the desired sequence to the 5’ end of one primer. The PCR procedure is described in 
chapter 3.3.6.  
3.3.9 Isolation of RNA from cells 
Isolation of RNA from cells was performed using the RNase Mini Kit (Qiagen). Per each 
sample the lysate of 1x107 cells was prepared and homogenized with QiaShredder columns 
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(Qiagen). All subsequent steps were performed according to the manufacturer’s 
recommendations. RNA was eluted in 80 µl of RNase-free water and stored at -80 °C. 
3.3.10 Reverse transcription of RNA 
RNA was transcribed into cDNA to determine expression levels of genes of interest. The 
removal of contaminating DNA from the RNA preparation was performed using the enzyme 
Desoxyribonuclease I (DNase I, Invitrogen). Therefore, 2 µg of extracted RNA were 
incubated at 37 °C with 2 U DNase I, 40 U RNase inhibitor and 1x DNase buffer in a 20 µl 
approach for 90 minutes. Remaining DNase I was heat inactivated by incubating at 65 °C for 
10 minutes and the efficiency of DNase treatment was controlled by PCR (see chapter 3.3.6). 
Reverse transcription of RNA was performed with the SuperScript III First Strand Synthesis 
SuperMix Kit (Invitrogen) according to the manufacturer’s protocol. cDNA was analyzed 
quantitatively using qPCR (see chapter 3.3.7). 
3.4 Protein analysis techniques 
3.4.1 Preparation of whole cell extracts 
For the preparation of whole cell extracts, 5x107 HEK293 cells were washed (7 min at 300 g 
and 4 °C) twice with ice-cold PBS and lysed in a volume of 1 ml RIPA buffer (50 mM Tris-
HCl pH8.0, 150 mM NaCl, 0.1 % SDS, 0.5 % sodium deoxycholate, 1 % NP-40, 1x 
“Complete” proteinase inhibitor cocktail (Roche)) for 20 minutes on ice. The lysate was 
sonified using a Branson sonifier 250-D (10 sec on/50 sec off, 1 min, 20 % amplitude, on ice). 
Cell debris was pelleted by centrifugation (15 min at 20000 g and 4 °C). The supernatant was 
transferred to a new tube and the protein concentration was measured with Bradford solution 
(Bio-Rad) in a BioPhotometer (Eppendorf). 
3.4.2 Preparation of nuclear cell extracts 
Nuclear cell extracts were prepared by harvesting 1x108 Raji cells (7 min at 1200 rpm and 
4 °C). Cells were washed twice with ice-cold PBS (7 min at 1200 rpm and 4 °C) and the 
pellet was resuspended in 2 ml hypotonic buffer (10 mM HEPES pH7.9, 1.5 mM MgCl2, 
10 mM KCl, 340 mM sucrose, 1x “Complete” proteinase inhibitor cocktail (Roche)). 
Swelling of the cells was checked after incubation on ice for 15 minutes under the 
microscope. Cell lysis was performed using a final concentration of 0.1 % Triton X-100. 
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After vortexing for 15 seconds, grey colored nuclei were controlled under the microscope. 
Nuclei were pelleted (5 min at 2000 rpm and 4 °C) and resuspended in 300 µl hypotonic 
buffer. To extract the nuclei, 150 µl of high salt buffer (10 mM HEPES pH7.9, 1.5 mM 
MgCl2, 1260 mM NaCl, 1x “Complete” proteinase inhibitor cocktail (Roche)) was added and 
incubated while rotating for 1 hour at 4 °C. After centrifugation (15 min at 13200 rpm and 
4 °C), the protein concentration of the nuclear extract containing supernatant was measured 
with Bradford solution (Bio-Rad) in a BioPhotometer (Eppendorf).  
3.4.3 Purification of Strep-tag fusion proteins 
The purification of Strep-tag fusion proteins in HEK293 cells was accomplished using Strep-
Tactin affinity chromatography according to the manufacturer’s recommendations (IBA). 
Briefly, four to six 13 cm culture dishes were transiently transfected with the expression 
plasmid coding for the desired tandem strep-tagged protein (see chapter 3.2.3). After 48 
hours, the cells were harvested (7 min at 1400 rpm and 4 °C) and whole cell extracts were 
prepared in 5 ml RIPA buffer (see chapter 3.4.1). A poly-prep chromatography column was 
loaded with a 200 µl column volume (CV) of Strep-Tactin sepharose beads and equilibrated 
with two CVs washing buffer (100 mM Tris-HCl pH8.0, 150 mM NaCl, 1 mM EDTA, 1x 
“Complete” proteinase inhibitor cocktail (Roche)). The protein lysate was loaded onto the 
column three times followed by five washing steps with one CV washing buffer each. The 
protein was eluted in six fractions by adding half a CV elution buffer (100 mM Tris-HCl 
pH8.0, 150 mM NaCl, 1 mM EDTA, 2.5 mM desthiobiotin, 1x “Complete” proteinase 
inhibitor cocktail (Roche)) each. The protein concentration was first measured with Bradford 
solution (BioRad) and then verified on a SDS gel by Coomassie staining in comparison to 
different amounts of a bovine serum albumin (BSA) standard.  
3.4.4 Electromobility shift assay (EMSA) for detecting protein-DNA 
interactions 
EMSAs were performed for analyzing protein-DNA interactions. According to Fried and 
Crothers (1981), the assay is based on altered migration behavior of a protein-DNA complex 
in comparison to unbound DNA in a native polyacrylamide gel. The electrophoretic 
separation of a protein DNA complex is determined by their size, charge and shape. Proteins 
were purified using Strep-Tactin affinity chromatography (see chapter 3.4.3). As DNA 
templates 156 bp fragments derived from digested, methylated plasmid DNAs (see chapter 
3.7.2) were used. The DNA fragments were radioactively labeled in a T4 polynucleotide 
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kinase reaction (T4-PNK) with [γ-32P] ATP as the phosphate group donor. Therefore, the 
following reaction was set up and incubated at 37 °C for 30 minutes to one hour.  
Component Amount 
Template DNA 1 µg 
PNK buffer A (10x) 5 µl 
T4-PNK (Fermentas) 2 µl [10 U/µl] 
[γ-32P] ATP (30 mCi/ml) 3 µl 
ddH2O ad 50 µl 
The labeled fragments were purified using G50-Sephadex columns (GE Healthcare) and 
radioactive emission was measured. The protein-DNA interaction was performed for ten 
minutes at room temperature with following binding conditions.  
Component Amount 
Protein solution 4 µl 
EMSA binding buffer (10x) 2 µl 
Poly (dI/dC) [1µg/µl] 1 µl 
Labeled template 0.8 ng (5000-20000 dpm) 
ddH2O ad 20 µl 
After incubation, EMSA loading dye (20 mM Tris-HCl pH7.5, 8 mM EDTA, 25 % glycerol, 
0.1 % NP-40) was added to the samples to a final concentration of 1x and the samples were 
loaded onto a 5 % native shift gel (5 ml Rotiphorese 30 (37.5:1), 5 ml Rotiphorese 40 (19:1), 
3.2 ml 10x TBE, 66 ml ddH2O, 50 µl TEMED, 400 µl 10 % APS), which had been pre-run 
for at least 60 minutes. Bromophenol blue in EMSA loading dye was loaded in one empty 
lane for estimating the run length. The gel was run at 4 °C and 130 V for five to six hours. 
The gel was incubated for 15 minutes in fixing solution (10 % acetic acid, 20 % methanol in 
ddH2O) and then dried in a vacuum gel dryer on Whatman paper.  
DNA was visualized using a high performance autoradiography film (GE Healthcare). For 
densitometric quantification of protein-DNA complexes an image plate (Fujifilm) was 
exposed and read with the aid of a Phosphoimager (Fujifilm). Quantitation of radioactive 
emission was done using the program AIDA (Raytest).  
3.4.5 Determination of the equilibrium dissociation constant (Kd value) 
According to Ryder at al. (2008), the Kd value defines the protein concentration needed to 
achieve a half-maximum binding at equilibrium, expressed here in nM concentration. The Kd 
value was experimentally assessed using EMSAs (see chapter 3.4.4). The amount of protein 
needed in nmol was converted in ng with the help of the website 
http://www.molbiol.ru/eng/scripts/01_04.html and the ratio of protein-DNA complex to 
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unbound DNA was determined. The Kd value was calculated using the program Prism6 
(Graphpad). The bound fraction was plotted against the protein concentration and the Kd 
value was calculated using the equation “One site – Specific binding with Hill slope”. 
3.4.6 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE was performed using a Mini Protean Tetra Cell (Bio-Rad). Acrylamide gels were 
cast as described in the table of chapter 2.8. Samples were prepared as described below and 
heat denatured for five minutes at 100 °C in a sand bath. 
Component Amount 
Protein lysate max. 30 µg 
Laemmli buffer (5x) 4 µl 
ddH2O ad 20 µl 
Proteins were separated at 100-130 V until the bromophenol blue dye migrated out of the gel. 
3.4.7 Western blot 
Western blot was performed using a Mini Trans-Blot Cell (Bio-Rad). Proteins separated by 
SDS-PAGE were transferred onto a Hybond ECL membrane (GE Healthcare) at 100 V for 
80 minutes. Afterwards, the membrane was incubated for 30 minutes in blocking solution (5 g 
milk powder in 100 ml PBS-T) at room temperature and then with the primary antibody, 
diluted in blocking solution, at 4 °C overnight. The next day, the membrane was washed five 
times for five minutes each in PBS-T and incubated with the HRP-conjugated secondary 
antibody, diluted in blocking solution, for 45 minutes at room temperature. The membrane 
was again washed five times for five minutes each in PBS-T. After incubating the membrane 
with ECL reagent (GE Healthcare) for five minutes, the bands were detected using a x-ray 
film. Used antibody dilutions are listed in the table of chapter 2.3.  
3.4.8 Silver staining 
The silver staining of SDS-PAGEs (see chapter 3.4.6) was performed at room temperature 
and constant shaking as follows. Incubating for 60 minutes in 50 % methanol and 12 % acetic 
acid, followed by washing with 50 % ethanol and 30 % ethanol for 20 minutes each, fixed the 
gel. Impregnation was performed using freshly made impregnation solution (50 µl sodium 
thiosulfate solution (2.15 g in 5 ml ddH2O), 70 µl 37 % formaldehyde, ad 100 ml ddH2O) for 
two minutes. After three washing steps with ddH2O the gel was stained in freshly made 
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staining solution (0.2 g silver nitrate, 70 µl 37% formaldehyde, ad 100 ml ddH2O) for 20 
minutes. Silver excess was removed by washing two times with ddH2O. Staining reaction was 
initiated by incubating in freshly made developing solution (6 g Na2CO3 (water-free), 2 µl 
sodium thiosulfate solution (2.15 g in 5 ml ddH2O), 50 µl 37 % formaldehyde, ad 100 ml 
ddH2O) until all bands were visible and stopped by 50 % methanol and 12 % acetic acid. 
3.5 Chromatin Immunoprecipitation (ChIP) 
3.5.1 Chromatin preparation 
For chromatin preparation 4x107 Raji 4816 cells were harvested (7 min at 300 g at 4 °C) and 
washed twice with ice-cold PBS (7 min at 300 g and 4 °C). Cross-linking was carried out in a 
total volume of 20 ml PBS (room temperature) and 1 % formaldehyde for seven minutes at 
room temperature with constant rotating.  The reaction was stopped with 2.5 ml of 1 M 
glycine while incubating and inverting for five minutes at room temperature. Afterwards all 
steps were performed on ice. The cells were pelleted and washed twice with ice-cold PBS 
(5 min at 500 g and 4 °C). The isolation of nuclei was accomplished by washing (10 min at 
300 g and 4 °C) the pellet three times with 10 ml ice-cold ChIP lysis puffer (10 mM Tris-HCl, 
pH7.5, 10 mM NaCl, 3 mM MgCl2, 0.5 % NP-40). After checking the grey colored nuclei 
under the microscope, the pellet was resuspended in 2 ml of ice-cold ChIP sonication buffer 
(50 mM Tris-HCl, pH7.5, 10 mM EDTA, 1 % SDS, 1 % NP-40, 1x “Complete” proteinase 
inhibitor cocktail (Roche)). Chromatin was fragmented by sonication with a BRANSON 
sonifier W-250 D (amplitude = 35 %, total pulse time 180 sec with 36 cycles of 5 sec pulse 
and 25 sec pause). The sonicated samples were centrifuged (10 min at maximum speed and 
4 °C), their protein concentration was measured with the Bradford method and subsequently 
frozen at -80 °C. The fraction size of the chromatin was analyzed after treatment of 10 µg 
chromatin with proteinase K at 68 °C for three hours and checked on a 1 % TBE agarose gel 
upon DNA purification with the NucleoSpin Extract kit II (Macherey-Nagel). 
3.5.2 Chromatin immunoprecipitation and purification of ChIP DNA 
For chromatin immunoprecipitation 100 µg of chromatin solution was adjusted with ChIP 
dilution buffer (20 mM Tris-HCl, pH8.0, 2 mM EDTA, pH8.0, 1 % TritonX-100, 150 mM 
NaCl, 1x “Complete” proteinase inhibitor cocktail (Roche)) to a final volume of 1 ml and a 
final concentration of 0.1 % SDS. After addition of the antibody, the chromatin was incubated 
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at 4 °C over night with constant overhead rotating. Used antibody concentrations are listed in 
the table of chapter 2.3. 100 µl of protein G or protein A resin (50 % slurry) were pre-
equilibrated with ChIP dilution buffer and incubated at 4 °C over night with overhead 
shaking. The next day, beads were spun down at 2000 rpm for two minutes, added to the 
antibody-chromatin mixture, and incubated at 4 °C for two hours by overhead rotating. To 
remove unspecific DNA and proteins, the beads were washed (2 min at 2000 rpm and RT) 
each time with 1 ml in the order of following buffers: ChIP low salt buffer (20 mM Tris-HCl, 
pH8.0, 2 mM EDTA, pH8.0, 1 % Triton X-100, 150 mM NaCl, 0.1 % SDS), ChIP high salt 
buffer (20 mM Tris-HCl, pH8.0, 2 mM EDTA, pH8.0, 1 % Triton X-100, 500 mM NaCl, 
0.1 % SDS), ChIP LiCl buffer (10 mM Tris-HCl, pH8.0, 1 mM EDTA, pH8.0, 250 mM LiCl, 
0.5 % NP-40, 0.5 % sodium deoxycholate) and TE buffer (10 mM Tris-HCl, pH8.0, 1 mM 
EDTA). Elution and removal of the cross-link was accomplished in 200 µl ChIP elution 
buffer (25 mM Tris-HCl, pH7.5, 10 mM EDTA, pH8.0, 0.5 % SDS) containing 20 µg 
proteinase K for three hours at 68 °C while shaking. DNA was purified with the NucleoSpin 
Extract II Kit (Macherey-Nagel) according to manufacturer’s protocol and eluted in 60 µl 
elution buffer. ChIP samples were immediately analyzed or stored at -20 °C. 
3.5.3 Quantitation of ChIP DNA by qPCR 
To quantify the DNA content of ChIP samples, qPCR with the LightCycler 480 system was 
performed (see chapter 3.3.7). Stepwise dilutions of total input DNA ranging from 0.1 % to 
10 % and ChIP DNA were analyzed with primer pairs specific for different loci of latent, 
early lytic and late lytic EBV regions. Oligonucleotides and their sequences are listed in the 
appendix. 
3.6 Sequential ChIP (ReChIP) 
The ReChIP method is a relatively new technique that enables sequential chromatin 
immunoprecipitations to be performed using two different antibodies to prove the co-
occupancy of two proteins or distinct histone modifications at the same genomic region of 
interest (Geisberg and Struhl, 2004).  
3.6.1 Chromatin preparation for BZLF1-directed ChIP 
For chromatin preparation 1x108 Raji 4816 cells were harvested (7 min at 300 g and 4 °C) and 
washed twice with ice-cold PBS (7 min at 300 g and 4 °C). Cross-linking was carried out in a 
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total volume of 40 ml PBS (room temperature) and a final concentration of 1 % formaldehyde 
for eight minutes at room temperature with constant rotating. The reaction was stopped with 
5 ml of 1 M glycine while incubating and rotating for one minute at room temperature, 
followed by incubation on ice for five minutes. Afterwards all steps were performed on ice. 
The cells were pelleted and washed twice with ice-cold PBS (5 min at 500 g and 4 °C). The 
isolation of nuclei was accomplished by washing (10 min at 300 g and 4 °C) the pellet with 
10 ml in the order of following buffers: ReChIP lysis buffer 1 (50 mM HEPES, pH7.5, 
140 mM NaCl, 1 mM EDTA, pH8.0, 0.5 mM EGTA, pH8.0, 10 % glycerol, 0.5 % NP-40, 
0.25 % Triton X-100, 1x “Complete” proteinase inhibitor cocktail (Roche)) and ReChIP lysis 
buffer 2 (25 mM HEPES, pH7.5, 200 mM NaCl, 1 mM EDTA, pH8.0, 0.5 mM EGTA, 
pH8.0, 1x “Complete” proteinase inhibitor cocktail (Roche)). Further, the nuclei containing 
pellet was resuspended in 5 ml ReChIP lysis buffer 3 (25 mM HEPES, pH7.5, 140 mM NaCl, 
1 mM EDTA, pH8.0, 0.5 mM EGTA, pH8.0, 0.25 % N-lauryl sarcosine, 0.1 % sodium 
deoxycholate, 0.25 % Triton X-100, 1x “Complete” proteinase inhibitor cocktail (Roche) and 
the grey colored nuclei were checked under the microscope. To obtain mononucleosomal 
fragment-sized chromatin, acid-washed glass beads (212-300 µm, Sigma-Aldrich) were added 
and chromatin was sonicated with a BRANSON sonifier W-250 D (amplitude = 35 %, total 
pulse time 240 sec with 120 cycles of 1 sec pulse and 1 sec pause). The sonicated samples 
were centrifuged (10 min at maximum speed and 4 °C) and chromatin was further digested 
with Micrococcal Nuclease (MNase) S7 (10 U/µl, Roche) and a final concentration of 4 mM 
CaCl for ten minutes at 37 °C. Adding EGTA pH8.0 to a final concentration of 40 mM 
stopped the reaction. The DNA concentration of the chromatin was measured with the 
Nanodrop method, the chromatin solution was adjusted to an amount of 1 mg/ml with a final 
concentration of 0.5 % Triton X-100, 10 % glycerol and ReChIP lysis buffer 3 and 
subsequently frozen at -80 °C. The mononucleosomal fraction size of the chromatin was 
analyzed after treatment of 30 µg chromatin with 20 µg proteinase K at 68 °C for three hours 
and checked on a 1 % TBE agarose gel upon DNA purification with the NucleoSpin Extract 
kit II (Macherey-Nagel). 
3.6.2 ReChIP starting with a BLZF1-directed antibody 
For the first round of chromatin immunoprecipitation 1500 µg of chromatin solution (see 
chapter 3.6.1) was adjusted with ReChIP lysis buffer 3 to a final volume of 5 ml. 25 µg of 
ZEBRA antibody (Santa Cruz) was added and incubated at 4 °C over night with constant 
overhead rotating. 500 µl of protein G resin (50 % slurry) were pre-equilibrated with 4.5 ml 
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ReChIP lysis buffer 3 and incubated at 4 °C over night with constant overhead rotating. The 
next day, beads were spun down at 2000 rpm for two minutes, added to the antibody-
chromatin mixture, and incubated at 4 °C for two hours by overhead rotating. To remove 
unspecific DNA and proteins, the beads were washed (2 min at 2000 rpm and RT) each time 
with 1 ml in the order of following buffers: ReChIP wash buffer 1 (50 mM Tris-HCl, pH8.0, 
150 mM NaCl, 1 mM EDTA, pH8.0, 0.1 % SDS, 0.5 % sodium deoxycholate, 1 % NP-40), 
ReChIP wash buffer 2 (50 mM Tris-HCl, pH8.0, 300 mM NaCl, 1 mM EDTA, pH8.0, 0.1 % 
SDS, 0.5 % sodium deoxycholate, 1 % NP-40), ReChIP LiCl buffer (50 mM Tris-HCl, pH8.0, 
250 mM LiCl, 0.1 % SDS, 0.5 % sodium deoxychlate, 1 % NP-40) and TE buffer (10 mM 
Tris-HCl, pH8.0, 1 mM EDTA). Elution of the BZLF1-ChIPed chromatin was performed 
with 100 µl ChIP sonication buffer by incubating for two hours at 37 °C under constant 
shaking.  
For the second round of chromatin immunoprecipitation, the first ChIPed chromatin solution 
was adjusted with ChIP sonication buffer to a final volume of 1 ml and a final concentration 
of 0.1 % SDS. 1 µg of H3K4me1 antibody (Abcam) was added and incubated at 4 °C over 
night with constant overhead rotating. 100 µl of protein A resin (50 % slurry) were pre-
equilibrated with 1 ml ChIP sonication buffer and incubated at 4 °C over night with constant 
overhead rotating. The next day, beads were spun down at 2000 rpm for two minutes, added 
to the antibody-chromatin mixture, and incubated at 4 °C for two hours by overhead rotating. 
To remove unspecific DNA and proteins, the beads were washed (2 min at 2000 rpm and RT) 
each time with 1 ml in the order of following buffers: ChIP low salt buffer (20 mM Tris-HCl, 
pH8.0, 2 mM EDTA, pH8.0, 1 % Triton X-100, 150 mM NaCl, 0.1 % SDS), ChIP high salt 
buffer (20 mM Tris-HCl, pH8.0, 2 mM EDTA, pH8.0, 1 % Triton X-100, 500 mM NaCl, 
0.1 % SDS), ChIP LiCl buffer (10 mM Tris-HCl, pH8.0, 1 mM EDTA, pH8.0, 250 mM LiCl, 
0.5 % NP-40, 0.5 % sodium deoxycholate) and TE buffer (10 mM Tris-HCl, pH8.0, 1 mM 
EDTA). Elution and removal of the cross-link was accomplished in 200 µl ChIP elution 
buffer (25 mM Tris-HCl, pH7.5, 10 mM EDTA, pH8.0, 0.5 % SDS) containing 20 µg 
proteinase K for three hours at 68 °C while shaking. The double ChIPed DNA was purified 
with the NucleoSpin Extract II Kit (Macherey-Nagel) according to manufacturer’s protocol 
and eluted in 60 µl elution buffer. ChIP samples were immediately analyzed or stored in the 
freezer at -20 °C. 
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3.6.3 ReChIP starting with an H3K4me1-directed antibody 
For the first round of chromatin immunoprecipitation 100 µg of chromatin solution (see 
chapter 3.5.1) was adjusted with ChIP sonication buffer to a final volume of 1 ml and a final 
concentration of 0.1 % SDS. 5 µg of H3K4me1 antibody (Abcam) was added and incubated 
at 4 °C over night with constant overhead rotating. 100 µl of protein A resin (50 % slurry) 
were pre-equilibrated with 1 ml ChIP dilution buffer and incubated at 4 °C over night with 
constant overhead rotating. The next day, beads were spun down at 2000 rpm for two 
minutes, added to the antibody-chromatin mixture, and incubated at 4 °C for two hours by 
overhead rotating. To remove unspecific DNA and proteins, the beads were washed (2 min at 
2000 rpm and RT) each time with 1 ml in the order of following buffers: ChIP low salt buffer, 
ChIP high salt buffer, ChIP LiCl buffer and TE buffer. Elution of the H3K4me1-ChIPed 
chromatin was accomplished with 100 µl ReChIP lysis buffer 3 and 1 % SDS by incubating 
for two hours at 37 °C under constant shaking. 
For the second round of chromatin immunoprecipitation, the first H3K4me1-ChIPed 
chromatin solution was adjusted with ReChIP buffer 3 to a final volume of 1 ml and a final 
concentration of 0.1 % SDS. 1 µg of ZEBRA antibody (Santa Cruz) was added and incubated 
at 4 °C over night with constant overhead rotating. 15 µl of protein G resin (50 % slurry) were 
pre-equilibrated with 1 ml ReChIP buffer 3 and incubated at 4 °C over night with constant 
overhead rotating. The next day, beads were spun down at 2000 rpm for two minutes, added 
to the antibody-chromatin mixture, and incubated at 4 °C for two hours by overhead rotating. 
To remove unspecific DNA and proteins, the beads were washed (2 min at 2000 rpm and RT) 
each time with 1 ml in the order of following buffers: ReChIP wash buffer 1, ReChIP wash 
buffer 2, ReChIP LiCl buffer and TE buffer. Elution and removal of the cross-link was 
accomplished in 200 µl ChIP elution buffer containing 20 µg proteinase K for three hours at 
68 °C while shaking. The double ChIPed DNA was purified with the NucleoSpin Extract II 
Kit (Macherey-Nagel) according to the manufacturer’s protocol and eluted in 60 µl elution 
buffer. ChIP samples were immediately analyzed or stored at -20 °C. 
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3.7 Co-Immunoprecipitation (CoIP) 
3.7.1 CoIPs of GFP-tagged bait proteins 
For Co-IPs the GFP-Trap_A for immunoprecipitation of GFP-fusion proteins (Chromotek) 
was used according to the manufacturer’s recommendations. Briefly, for one IP reaction, 
1x107 co-transfected HEK293 cells were harvested and washed three times with ice-cold PBS 
(7 min at 1200 rpm and 4 °C). The pellet was resuspended in 200 µl CoIP lysis buffer 
(10 mM Tris-HCl, pH7.5, 150 mM NaCl, 0.5 mM EDTA, 0.2 % NP-40, 1x “Complete” 
proteinase inhibitor cocktail (Roche) +/- 5 U/µl Benzonase and 0.5 µg/µl DNase I 
(Invitrogen)) and incubated on ice for 30 minutes with extensively pipetting every 10 minutes. 
The cell lysate was spun down and the protein-containing supernatant was adjusted with CoIP 
wash/dilution buffer (10 mM Tris-HCl, pH7.5, 150 mM NaCl, 0.5 mM EDTA, 1x 
“Complete” proteinase inhibitor cocktail (Roche)) to a final volume of 500 µl. For 
immunoblot analysis 5-10 % input material was used. 20 µl of GFP-Trap_A bead slurry was 
pre-equilibrated in 500 µl ice cold CoIP dilution/wash buffer and washed two more times 
with 500 µl of CoIP buffer dilution/wash buffer (2 min at 2500 g and 4 °C). The cell lysate 
was added to the pre-equilibrated beads and incubated under constant rotating for two hours at 
4 °C. Further, beads were spun down and washed five times with 500 µl CoIP dilution/wash 
buffer (2 min at 2500 g and 4 °C). To dissociate the immunocomplexes the beads were boiled 
for five minutes at 95 °C in 1x Laemmli buffer.  
To check the interaction of GFP-coupled bait proteins and prey candidates, western blot 
immunodetection (see chapter 3.4.7) with an anti-GFP antibody (Chromotek) as well as an 
antibody against the protein of interest were performed. 
3.7.2 CoIPs of Strep-tagged bait proteins 
For CoIPs of Strep-tag fusion proteins, Strep-Tactin affinity chromatography was performed 
using Strep-Tactin sepharose beads (IBA) according to the manufacturer’s recommendations. 
Briefly, for one reaction, 5x107 to 1x108 Raji 5693 or Raji 5694 cells were induced with 
100 ng/ml doxycycline over night for BZLF1 or bZIP expression, respectively. The next day 
cells were harvested and washed three times with ice-cold PBS (7 min at 1200 rpm and 4 °C). 
The pellet was resuspended in 200 µl CoIP lysis buffer and incubated on ice for 30 minutes 
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with extensively pipetting every ten minutes. The cell lysate was spun down and the protein-
containing supernatant was adjusted with CoIP wash/dilution buffer to a final volume of 
500 µl. For immunoblot analysis 5-10 % input material was used. 100 µl of Strep-Tactin 
sepharose beads were pre-equilibrated in 500 µl ice cold 1x wash buffer and washed two 
other times with 500 µl of 1x wash buffer (2 min at 2500 g and 4 °C). The cell lysate was 
added to the pre-equilibrated beads and incubated under constant rotating for two hours at 4 
 °C. Further, beads were spun down and washed five times with 500 µl 1x wash buffer (2 min 
at 2500 g and 4 °C). To dissociate the immunocomplexes the beads were boiled for five 
minutes at 95 °C in 1x Laemmli buffer. 
To check the interaction of the Strep-tagged BZLF1 bait proteins and prey candidates, 
western blot immunodetection (see chapter 3.4.7) with antibodies against BZLF1 (α-BZ1, 
Elisabeth Kremmer) as well as an antibody against the protein of interest were performed. 
3.8 In vitro reconstitution of chromatin 
3.8.1 Histone octamer preparation from Drosophila embryos 
Histone octamers from Drosophila embryos were prepared according to Krietenstein et al. 
(2012). A long-term storage of histone octamers is possible at -20 °C in a final concentration 
of 50 % glycerol. 
3.8.2 Purification of 156 bp DNA fragments 
DNA templates of interests with Asp718I restriction site flanks were cloned as multimers in 
pUC18 vector. The methylation of CpG dinucleotides was accomplished using the CpG 
Methyltransferase M.SssI (NEB) with following protocol. 
Component Amount 
Plasmid DNA 100 µg 
NeBuffer 2 (10x) 100 µl 
SAM (32 mM) 5 µl 
M.SssI [4 U/µl] 10 µl 
ddH2O ad 1000 µl 
After an over-night incubation at 37 °C, the methylation reaction was refreshed with 5 µl 
M.SssI [4 U/µl] and 5 µl 32 mM S-Adenosyl methionine (SAM) and further incubated at 
37 °C for two hours. According to standard protocols of Sambrook et al. (2001) 
phenol/chloroform extraction and DNA precipitation with ethanol was performed. The 
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precipitated, methylated plasmid DNA was resuspended in 100 µl ddH2O. To control the 
methylation degree of CpG dinucleotides, a control digest using methylation sensitive 
restriction enzymes (NEB) was carried out as follows. 
Component Amount 
Methylated plasmid DNA 500 ng 
NeBuffer 4 (10x) 20 µl 
BSA (100x) 0.2 µl 
AvaI [10 U/µl] 0.50 µl 
XmnI [20 U/µl] 0.25 µl 
ddH2O ad 20 µl 
After incubation for two hours at 37 °C, the restriction was controlled on an agarose gel. 
To liberate the monomeric fragments of the methylated plasmids and to obtain blunt ends, a 
methylation-insensitive restriction digest with RsaI (NEB) was performed. 
Component Amount 
Methylated plasmid DNA 100 µl 
NeBuffer 4 (10x) 50 µl 
RsaI [10 U/µl] 10 µl 
ddH2O ad 500 µl 
Complete digestion was achieved after two hours at 37 °C. A subsequent dephosphorylation 
of DNA was carried out with a buffer change to 1x Alkaline Phosphatase buffer (50 mM Tris-
HCl pH9.3, 1 mM MgCl2, 0.1 mM ZnSO4) and Alkaline Phosphatase Calf Intestinal (CIP, 
NEB) according to the following protocol. 
Component Amount 
Methylated, digested plasmid 
DNA 500 µl 
Alkaline Phosphatase buffer (10x) 50 µl 
CIP [10 U/µl] 10 µl 
Incubation was carried out for 30 minutes at 37 °C in the water bath and the reaction was 
stopped at 65 °C for several minutes. According to standard protocols of Sambrook et al. 
(2001) phenol/chloroform extraction and DNA precipitation with ethanol was performed. The 
precipitated, methylated plasmid DNA fragments were resuspended in 100 µl ddH2O and 
electrophoretically separated on a 10 % native separation gel (16.6 ml Rotiphorese 30 
(37.5:1), 2.5 ml 10x TBE, 400 µl 10 % APS, 50 µl TEMED) at 90 V for 15 hours. 
Electroelution of the 156 bp DNA fragment from the native gel was performed according to 
chapter 3.3.4. 
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3.8.3 Preparation of chromatin via salt gradient dialysis 
The in vitro reconstitution of DNA of interest with histone octamers was accomplished 
according to Krietenstein et al. (2012) via salt gradient dialysis. 
3.9 Mass spectrometry analysis 
Nuclear cell extracts of each Raji cell line (either 5693 or 5694) were prepared (see chapter 
3.4.2) and analyzed in triplicates (1,2,3) for mass spectrometry analysis. After centrifugation 
(15 min at 13200 rpm and 4 °C), proteins of the supernatant were precipitated using a 
purification protocol of Strep-tag fusion proteins with Strep-Tactin matrices (IBA). Briefly, 
the nuclear extract with a final volume of 450 µl was incubated with wash buffer (100 mM 
Tris-HCl pH8.0, 150 mM NaCl, 1 mM EDTA, 1x “Complete” proteinase inhibitor cocktail 
(Roche)) pre-equilibrated Streptavidin beads with a CV of 200 µl for two hours at 4 °C while 
rotating. The column was washed five times with five CVs of wash buffer. The analysis of 
lysate, wash fractions, and beads of each mass spectrometry sample was accomplished by 
silver staining (see chapter 3.4.8) and western blot immunodetection (see chapter 3.4.7) with 
an anti-BZLF1 antibody. Beads were frozen directly on dry ice and send for mass 
spectrometry analysis to the Zentrallabor für Proteinanalytik (ZfP, Munich). 
In order to remove detergents and unspecific binders, the beads were washed three times with 
100 µl of 50 mM NH4HCO3. Digestion of the beads was performed with 100 µl of 10 ng/µl 
trypsin in 1 M urea and 50 mM NH4HCO3 for 30 minutes at 25 °C and 800 rpm. The 
supernatant was collected, the beads were washed again two times with 50 µl 50 mM 
NH4HCO3 and all supernatants were pooled. Digestion of the supernatant was performed in a 
final concentration of 1 mM DTT at 25 °C and 800 rpm over night. The next day, 10 µl of 
5 mg/ml iodoacetamide (27 mM) was added and incubated for 30 minutes in the dark at 
25 °C. 1 µl of 1 M DTT was added and incubated for ten minutes at 25 °C. Upon addition of 
2.5 µl trifluoroacetic acid, the samples were desalted using 2x C18 stagetips. Liquid 
chromatography tandem mass spectrometry (LC-MS/MS) was performed with the ion trap 
mass analyzer Orbitrap. With the aid of the Mascot software the colleagues of the ZfP 
(Munich) identified BZLF1’s interacting proteins in the viral and human protein databases. 
 
 
 
4. RESULTS  
4.1 BZLF1 changes the epigenetic landscape in viral 
chromatin 
The Epstein-Barr Virus (EBV) life cycle is characterized by three major phases: the pre-
latent, latent and lytic phase. EBV persists lifelong in B cells of the host and is maintained 
during the latent phase. In this phase a number of latent viral genes is expressed but infectious 
virions are never synthesized. Only the lytic phase supports viral synthesis, which is 
mandatory for the virus to spread to uninfected cells. The EBV-encoded transcription factor 
BZLF1 governs the switch from the latent to the lytic phase and activates the expression of 
EBV’s lytic genes, which encode the enzymes for viral DNA replication and structural 
proteins of the virion. BZLF1 is not only expressed in latently infected cells, when it initiates 
lytic reactivation, but also during the pre-latent prior to the latent phase. BZLF1 binds 
sequence-specifically to two classes of (viral) DNA motifs. One class is exceptional in that it 
consists of BZLF1 Responsive Elements (ZREs) with a CpG dinucleotide. The binding of 
BZLF1 depends on the methylated state of this class of ZREs, which are prevalent in viral 
promoters of early lytic genes (Bergbauer et al., 2010; Kalla et al., 2010; Woellmer et al., 
2012). Paradoxically, methylation of viral DNA in the latent state is no hindrance but a must 
for lytic reactivation. During latency, a high nucleosomal occupancy and Polycomb silencing, 
responsible for the repressive histone mark H3K27me3, epigenetically silence the promoter 
regions of viral lytic genes. Upon lytic reactivation, BZLF1 binding induces a nucleosomal 
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loss, the removal of Polycomb repression, and the recruitment of RNA polymerase II 
(Woellmer et al., 2012). 
The epigenetic code of EBV’s DNA is not yet completely understood and needs further 
analysis. It is unclear, how BZLF1 reactivates silenced viral chromatin after induction of 
EBV’s lytic phase. It is equally unclear, how BZLF1 gets access to compacted 
heterochromatin, binds its ZRE motifs and induces the transition to open activated 
euchromatin of viral DNA. I wished to address these open questions in my PhD work. 
The initial aim of my thesis was the establishment of an improved conditional system for the 
induced expression of BZLF1. The Raji cell line is a good model to study epigenetic changes 
of viral DNA during the latent and lytic phases. Raji cells carry strict latent EBV genomes. 
The cells can be easily activated by a tetracycline-controlled BZLF1 expression system to 
initiate the viral lytic phase. Raji cells lack the viral BALF2 locus, which encodes the BALF2 
protein essential for the lytic DNA replication of the viral genome. As a consequence, the 
lytic phase ensues but viral genes downstream of the class of early lytic genes are blocked 
preventing the synthesis of viral progeny DNA. This aspect is important for the analysis of 
epigenetic modifications on EBV’s DNA upon lytic induction, because viral progeny DNA is 
epigenetically naïve, lacks histones or nucleosomes and is free of methylated cytosine 
residues. If Raji cells synthesized this type of viral DNA, the molecular analysis of viral DNA 
and its epigenetic modifications in the lytic phase would be close to impossible. 
My group reported a conditional expression system for BZLF1 (Woellmer et al., 2012). The 
problem of this previous conditional system was the epigenetic silencing of the inducible 
plasmid by the host cell machinery over time. The newly constructed conditional BZLF1 
expression plasmid (p4816, Fig. 4.1 panel A) contains the bicistronic coding sequence of the 
tetracycline controlled repressor rTS (instead of the previous KRAB repressor) and the 
transactivator rtTA2S-M2. In the absence of tetracycline (or the analogue doxycycline), the 
repressor binds tightly to the so-called tet promoter preventing its activation. After addition of 
doxycycline to the cells, the repressor rTS is replaced by the activator rtTA2S-M2, which 
induces bidirectional transcription and concomitant expression of three transgenes: enhanced 
green fluorescent protein (eGFP), the human truncated nerve growth factor-receptor (tNGF-
R) and BZLF1. BZLF1 expression can be monitored by flow cytometry and the detection of 
GFP-positive cells (Fig. 4.1 panel B). Additionally, the co-expressed tNGF-R transgene 
allows cell sorting by magnetic activated cell sorting (MACS). 
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Raji cells were stably transfected with the plasmid 4816. Single cell clones were selected with 
puromycin under condition of limiting dilution and analyzed for inducibility of the transgenes 
by flow cytometry. The single cell clone with the most robust and highest expression of the 
eGFP gene (about 90 %) was used for all my experiments (Fig. 4.1 panel B). The expression 
of BZLF1 protein in the Raji 4816 cells was monitored in a time kinetic experiment (Fig. 4.1 
panel C). The parental Raji cell line and Raji 4816 cells were induced with 100 ng/ml 
doxycycline at certain time points post induction and checked for BZLF1 expression by 
western blot immunodetection. BZLF1 protein became detectable as early as two hours post 
induction and reached its maximal expression after 15 hours. No spontaneous BZLF1 
expression could be detected in the parental Raji cell line or in Raji 4816 cells in the absence 
of tetra- or doxycycline. Quantitative RT-PCR experiments were performed in Raji 4816 cells 
in the time course of lytic induction to analyze the expression of selected transcripts (Fig. 4.1 
panel D). Raji 4816 cells were induced with 100 ng/ml doxycycline for different intervals as 
indicated. RNA was prepared and treated with DNase I to eliminate contaminating DNA from 
the samples, which was controlled by PCR. RNA was reversely transcribed into cDNA and 
the relative amount of transcripts per cell was quantified by qPCR. Expression of a set of 
early and late lytic genes was analyzed together with the housekeeping gene Cytochrome C 
(CytC). The kinetics of induction differed among the early lytic genes. The expression of the 
transgene BZLF1 responded immediately to doxycycline induction. The expression of 
BMRF1 and BNLF2a was equally fast and responded within three hours post induction. The 
levels of transcripts of the BRLF1 and BBLF4 genes were induced with a delayed kinetic. The 
expression levels of the viral late lytic gene BcLF1 and the cellular CytC genes were not 
influenced by BZLF1 and served as negative controls. The time course revealed different 
kinetics of activation suggesting functional grouping of the viral genes confirming an earlier 
report (Woellmer et al., 2012). 
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Fig. 4.1 Conditional expression of BZLF1 in Raji cells 
(A) The plasmid p4816 contains the bicistronic coding sequences of the tetracycline controlled repressor rTS and 
transactivator rtTA2S-M2. In the absence of tetracycline or its analogue doxycycline, the rTS repressor binds 
tightly to the tet promoter preventing its activation. After addition of doxycycline to the cells, the repressor rTS 
is replaced by the activator rtTA2S-M2, which induces bidirectional transcription and concomitant expression of 
three transgenes: enhanced green fluorescent protein (eGFP), the human truncated nerve growth factor-receptor 
(tNGF-R) and BZLF1. An internal ribosomal entry site (IRES) separates tNGF-R and BZLF1. β-lactamase (amp) 
and puromycin N-acetyl-transferase (puro) serve as resistance genes in bacteria and Raji cells, respectively. 
DNA replication in E.coli initiates at the prokaryotic origin of replication (ori). Epstein-Barr nuclear antigen 1 
(EBNA1) activates replication of the plasmid DNAs through binding to the origin of plasmid replication (oriP) 
and governs plasmid segregation. 
(B) GFP expression in Raji cells was a measure of the induced expression of BZLF1. Upon addition of 
100 ng/ml doxycycline to the cells for 15 hours, about 90 % turned GFP-positive.  
(C) BZLF1 protein expression was analyzed by western blot immunodetection upon lytic phase induction. 
Protein lysates of either parental or Raji 4816 cells were analyzed with an antibody recognizing BZLF1 (top 
panel) at different time points post induction. Tubulin served as a loading control (bottom panel). As early as two 
hours post induction, BZLF1 protein became detectable, reaching its maximum at 15 hours. No BZLF1 
expression could be detected in the parental Raji cell line. 
(D) Expression levels of selected transcripts were analyzed upon induction of the lytic phase in a time kinetic 
experiment. Raji 4816 cells were induced with doxycycline for different intervals as indicated, RNA was 
prepared, reverse transcribed, and analyzed by qPCR. The relative amount of transcripts per cell indicates the 
expression levels of individual transcripts. The temporal expression of different EBV genes suggests three 
different functional groups of viral genes: BZLF1 expression responds immediately to the addition of 
doxycycline (group 1, green), BMRF1 and BNLF2a respond within three hours (group 2, blue), BRLF1 and 
BBLF4 respond with a delayed kinetic (group 3, orange). The levels of mRNA induction of group 2 members are 
about tenfold higher than of group 3 members. The viral BcLF1 and the cellular Cytochrom C (CytC) genes 
served as negative controls. BZLF1 did not induce their expression.  
  RESULTS  61 
 
A chromatin immunoprecipitation (ChIP) protocol was established with cross-linked 
chromatin and a BZLF1-specific antibody. BZLF1 binds preferentially to the promoters of 
early lytic genes (Q/F, BRLF1, BZLF1, BMRF1, BBLF4 and BSRF1) upon lytic reactivation 
(Fig. 4.2 panel A). BZLF1 enhances especially the transcriptional activation of BMRF1 (ten-
fold), BBLF4 (13-fold) and BSRF1 (eight-fold). Control promoter regions of the cellular cen 
and GAPDH genes and the viral late lytic gene BcLF1 were not affected by BZLF1. In line 
with BZLF1 binding, I could detect the recruitment of the RNA polymerase II in the promoter 
regions of the above-mentioned early lytic genes (Q/F, BRLF1, BZLF1, BMRF1, BBLF4 and 
BSRF1) after the onset of the lytic phase (Fig. 4.2 panel B). RNA polymerase II binding could 
be detected at the promoters of Q/F, BRLF1, BMRF1, BBLF4 and BSRF1 with a 26-, seven-, 
eight-, six-, and four-fold enrichment, respectively. Control promoter regions did not show the 
BZLF1-induced recruitment of the RNA polymerase II. 
 
Fig. 4.2 Chromatin immunoprecipitations of BZLF1 and RNA polymerase II in Raji cells 
Shown are the results of ChIP experiments with BZLF1 and RNA polymerase II specific antibodies and 
formaldehyde cross-linked chromatin of Raji 4816 cells in latently infected cells and 15 hours post induction of 
EBV’s lytic cycle. Enrichment of EBV DNA was assessed with primer pairs covering latent, early lytic, and late 
lytic promoters as indicated. Controls encompassed two cellular loci, cen and GAPDH, which represent inactive 
and active cellular chromatin, respectively. The late lytic promoter BcLF1 served as a viral negative control. The 
y-axis shows the recovery of DNA in percentage [%] after ChIP as a function of input. Mean of three 
independent experiments are shown. The results of the three individual experiments can be found in the 
appendix. 
(A) BZLF1 preferentially binds to viral chromatin of early lytic promoters 15 hours after induction of the lytic 
phase. 
(B) BZLF1 induces the recruitment of RNA polymerase II at early lytic promoters 15 hours after induction of the 
lytic phase. 
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In previous studies Woellmer et al. (2012) analyzed histone modifications and chromatin-
modifying enzymes in EBV DNA by ChIP experiments. Early and late lytic promoters 
showed a high occupancy of histone H3 during latency. The control of lytic promoters was 
found to be mediated by Polycomb proteins, which introduced the repressive histone mark 
H3K27me3 during latency. Induction of the lytic phase caused a selective histone H3 loss at 
early lytic promoters, only, but also introduced the active histone mark H3K4me3, whereas 
the H3K27me3 marks were lost. Upon induction of EBV’s lytic phase the active histone mark 
H3K4me3 predominated whereas H3K27me3 was lost (Woellmer et al., 2012). With the aid 
of the newly established Raji 4816 cell line I could confirm these findings but wanted to look 
for additional dynamics of N-terminal histone modifications. As shown in Fig. 4.3 panel A, 
lytic induction causes the loss of histone octamers as indicated by the loss of histone H3 at 
early lytic gene promoters confirming our earlier report (Woellmer et al., 2012). The 
repressive N-terminal modification H3K27me2me3 (Fig. 4.3 panel B) strongly correlates with 
repressed early lytic promoters during latency. Upon BZLF1 expression and onset of the lytic 
phase, the repressive mark H3K27me2me3 is removed and replaced by the activation mark 
H3K4me1 (Fig. 4.3 panel C). There is also a strong correlation of the N-terminal acetlylation 
level of total histone H3 (Fig. 4.3 panel D) and the modification H3K27ac (Fig. 4.3 panel E) 
with the activation of early lytic gene promoters upon reactivation. The cellular and viral 
control promoters showed no or only a weak regulation. Taken together epigenetic changes, 
which lead to the activation of repressed viral chromatin, represent the switch from the latent 
to the lytic phase by BZLF1. 
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Fig. 4.3 Chromatin immunoprecipitations of histone H3 and its N-terminal modifications in Raji cells 
Shown are the results of ChIP experiments with histone 3 specific antibodies and formaldehyde cross-linked 
chromatin of Raji 4816 cells in latently infected cells and 15 hours post induction of EBV’s lytic cycle. 
Enrichment of EBV DNA was assessed with primer pairs covering latent, early lytic, and late lytic promoters as 
indicated. Controls encompassed two cellular loci, cen and GAPDH, which represent inactive and active cellular 
chromatin, respectively. The late lytic promoter BcLF1 served as a viral negative control. The y-axis shows the 
recovery of DNA in percentage [%] after ChIP as a function of input. Mean of three independent experiments 
are shown. The results of the three individual experiments can be found in the appendix. 
(A) Lytic induction caused the loss of histone octamers represented by histone H3 at early lytic gene promoters. 
BZLF1 expression showed no effect on cellular and viral control promoters as expected. 
(B) The repressive posttranslational modification H3K27me2me3 correlated with repressed early lytic and late 
lytic gene promoters in the latent phase. Upon lytic phase induction, the repressive mark was reduced. The 
cellular and viral control promoters showed no or only a weak regulation. 
(C) The posttranslational modification H3K4me1 correlated with active early lytic gene promoters in the lytic 
phase. The active mark was increased after the onset of the lytic phase. 
(D) and (E) The induction of the lytic phase by BZLF1 resulted in an increase of the N-terminal acetlylation 
level of total histone H3 in (D) and the gain of the H3K27ac modification in (E) in the promoter regions of early 
lytic genes. The acetlylation status correlated with active early lytic gene promoters upon lytic phase induction. 
Histone acetlylation of the cellular and viral control promoters did not change in the course of this experiment.
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4.2 BZLF1’s molecular role in chromatin remodeling in 
vitro and in vivo 
The viral transcription factor BZLF1 is an immediate-early gene product. In latently EBV-
infected cells it induces the switch to the lytic cycle and initiates the synthesis of virions. It is 
a transactivator, binds to viral promoters and induces the expression of essential early lytic 
genes. The structure of BZLF1 is modular and consists of three domains: the TAD, the bZIP 
domain containing the DNA-binding and dimerization domain, and the C-terminal domain 
with a so far unknown function (Petosa et al., 2006). As a homodimer BZLF1 binds two 
classes of BZLF1 Responsive Elements (ZREs), termed meZREs and ZREs, with or without a 
CpG-pair, respectively (Bergbauer et al., 2010). BZLF1’s dimerization ability of ZRE and 
meZRE sites is comparable, but in the latter the CpG dinucleotides must contain methylated 
cytosines for BZLF1 to bind efficiently (Bergbauer et al., 2010). BZLF1 has evolved to 
transactivate cytosine-methylated, hence repressed, silent promoters as a rule to overcome 
epigenetic silencing (Bergbauer et al., 2010; Kalla et al., 2012; Woellmer et al., 2012). 
In previous studies, Woellmer et al. (2012) found that a high nucleosome occupancy in the 
promoter regions of BZLF1 target genes correlated with their repressed state during latency. 
Upon induced expression of BZLF1 and its binding, the chromatin structures of BZLF1 target 
genes were altered and the density of high nucleosomal occupancy decreased. Based on these 
observations, I hypothesized that BZLF1 is capable of binding to its ZRE and/or meZRE 
motifs even when they are located within repressed chromatin in promoter regions of lytic 
genes. Binding of BZLF1 might cause the repositioning or even the eviction of nucleosomes 
to make the chromatin accessible for components of the transcription machinery. 
My first aim was to find out, if the viral transcription factor BZLF1 binds to or even evicts 
nucleosomes with or without the help of additional molecular machines. To address this 
question I performed electromobility shift assays (EMSAs), a common affinity 
electrophoresis technique used to study protein–DNA interactions. I adopted this technique to 
analyze the interaction of BZLF1 protein with mononucleosomal DNA. In order to mimic 
repressed chromatin, the binding reactions were conducted with mononucleosomes and 
template DNA that contained part of a BZLF1-regulated promoter with one or two meZRE 
motifs. 
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I prepared BZLF1 protein from HEK293 cells. I transiently transfected these cells with a 
CMV-promoter controlled expression vector system, where a Flag- and tandem Strep-tag is 
fused to the coding sequences of BZLF1 full-length (aa1-245) or the truncated BZLF1 version 
ZΔTAD (aa149-245) (Fig. 4.4 panel A). The purification of Strep-tag fusion proteins in 
HEK293 cells was accomplished using Strep-Tactin affinity chromatography. Fig. 4.4 panel B 
shows the results after the single steps of the purification process (lysate preparation, flow-
through check, washing and elution steps) of the Strep-tagged fusion proteins BZLF1 and 
ZΔTAD in HEK293 by western blot immunodetection with an antibody directed against Flag. 
Coomassie staining after SDS-PAGE (Fig. 4.4 panel C) visualized the quality of BZLF1 and 
ZΔTAD protein purifications and allowed to estimate the protein concentrations as compared 
to serial dilutions of BSA. 
      
Fig. 4.4 BZLF1 protein expression in HEK293 cells and its purification 
Expression plasmids encoding BZLF1 and its truncated version ZΔTAD were transiently transfected into 
HEK293 cells and the BZLF1 proteins were purified for the later use in EMSAs. 
(A) Shown is the modular structure of the BZLF1 full-length protein and the truncated version ZΔTAD used in 
my work. Numbers indicate the amino acid residues. 
(B) BZLF1 and ZΔTAD are Flag- and tandem Strep-tagged proteins, which can be purified by Strep-Tactin 
affinity chromatography. The figure shows the results after the different steps along the purification process 
(lysate preparation, flow-through check, washing and elution steps) of Strep-tag fusion proteins by 
immunodetection using an anti-Flag antibody. 
(C) Coomassie staining after SDS-PAGE shows the quality of BZLF1 and ZΔTAD protein purification and 
estimates the concentrations of BZLF1 proteins as compared to serial dilutions of BSA. 
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For the functional analysis of ZRE-containing nucleosomal templates, I chose the promoter of 
the early lytic gene BBLF4 encoding the viral DNA replication helicase. The BBLF4 promoter 
harbors five methylation-dependent CpG-pair containing meZREs that consist of nine 
nucleotides (Bergbauer et al., 2010). I generated a number of DNA templates of a total length 
of 156 bps each, which differ in the positioning of ZRE 3 and ZRE 4 or contain non-
functional mutations in these sites (Fig. 4.5).  
Histone octamers from Drosophila embryos, which can be easily prepared with high yield, 
high purity and already in form of histone octamers, i.e. with the exact 1:1:1:1 ratio of all four 
histones, are an essential component for the chromatin reconstitution of the ZRE-containing 
BBLF4 templates (Krietenstein et al., 2012). They contain certain histone modifications and 
histone variants (Bonaldi et al., 2004). Histone octamer preparations used in all subsequent 
experiments are shown in Fig. 4.6 panel A. In the next step, I performed salt gradient dialysis 
to assemble mononucleosomal DNA with the Drosophila histone octamers and the ZRE-
containing templates. The histone octamers interact with DNA mainly through electrostatic 
interactions (Luger et al., 1997). Both histones and DNA are highly charged molecules. 
Therefore, the chromatin assembly at physiological ionic strength would lead to aggregation. 
To prevent the electrostatic interactions, histones and DNA are mixed at high salt 
concentration. The slow, gradual dialysis with the aid of a salt gradient generates conditions 
that allow the histone DNA-interactions to be strong enough for nucleosome formation but 
weak enough to prevent aggregation (Krietenstein et al., 2012). Fig. 4.6 panel B illustrates the 
assembly of mononucleosomal chromatin with a DNA template and the Drosophila histone 
octamers by salt gradient dialysis. The titration of the histone octamer preparation and a given 
amount of DNA template identified the optimal conditions for the complete assembly of 
nucleosomal DNA. This was important for my following EMSA experiments, because the 
nucleosome-free DNA template would always interfere with the binding reactions of BZLF1 
protein and nucleosomal DNA. 
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Fig. 4.5 Functional analysis of two BZLF1 responsive elements (ZREs) in the promoter of BBLF4 
The figure schematically shows a part of the BBLF4 promoter with two ZRE sites, ZRE 3 and 4 (Bergbauer et 
al., 2010). Both ZRE sequences consist of nine nucleotides and encompass CpG motifs, which must be 
methylated in order to bind BZLF1. A number of DNA templates of a total length of 156 bps each were 
generated, which differ in the positioning of ZRE 3 and ZRE 4 or contain non-functional mutations in these sites. 
(A) The top line represents a part of the BBLF4 promoter with two ZREs. The numbers indicate the length of the 
elements shown. The ZRE motifs are 9 bps long and 113 bps apart. 
(B) ZRE 3 or ZRE 4 were inactivated by PCR-mediated mutagenesis to obtain the DNA templates shown. 
(C) A series of DNA templates with a “walking” ZRE 3 motif are depicted. The templates differ in the relative 
positions of ZRE 3 as indicated. 
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Fig. 4.6 Histone octamer preparation and chromatin assembly 
The preparation of histone octamers from Drosophila embryos and the chromatin assembly after salt gradient 
dialysis were performed according to Krietenstein et al. (2012).  
(A) The figure depicts two of my histone octamer preparations, pool II was used in all my experiments. The 
Coomassie stained gel after SDS-PAGE showed the correct ratio of all four histones (1:1:1:1) in the histone 
octamer. The concentrations of the histone octamer preparations were estimated with the aid of serial dilutions of 
BSA and a reference histone preparation. 
(B) The figure illustrates the assembly of mononucleosomal chromatin with a DNA template (ZRE 3+4) and 
Drosophila histone octamers by salt gradient dialysis. An ethidium bromide stained agarose gel shows the 
titration of the histone octamer preparation and a given amount of the DNA template (5 µg). 4.5 µl of histone 
octamer pool II, diluted 1:2, and 5µg of DNA were used for the assembly of mononucleosomal DNA templates 
in all my subsequent experiments. 
First, I performed EMSAs with wild-type BZLF1 (aa1-245) and three different DNA 
templates of the BBLF4 promoter with one (ZRE 3, ZRE 4) or two (ZRE 3+4) functional 
ZREs, which differ in the lengths of the flanks distal to the ZREs as indicated in Fig. 4.5 
panel A. A region of the BRLF1 coding sequence, which lacks ZRE motifs and which is not 
bound by BZLF1, served as a negative control. I compared the binding of BZLF1 (Fig 4.7 
panel A) with the DNA templates in their naked (upper row of panels) and compacted, 
nucleosomal (lower row of panels) state by measuring the equilibrium dissociation constant 
(KD). BZLF1 bound to naked DNA templates (ZRE 3, ZRE 4, and ZRE 3+4) with a similar 
Kd of 15 nM on average, independent of the number of ZRE motifs. The negative control 
showed hardly any interaction with BZLF1. 
The interaction of BZLF1 protein with mononucleosomal DNA templates differed. BZLF1 
did not bind to mononucleosomal DNA templates containing no (control) or only one ZRE 
(ZRE 3 or ZRE 4), but BZLF1 did interact with the ZRE 3+4 template with a 13 nM KD on 
average. The migration of complexes consisting of BZLF1 protein and naked DNA templates 
differed from the migration of complexes with BZLF1 and mononucleosomal DNA.  
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I repeated the same set of EMSA experiments with the BZLF1 version ZΔTAD (aa149-245) 
to investigate the importance of BZLF1’s TAD in this binding assay (Fig. 4.7 panel B). 
Again, BZLF1 binding to naked ZRE-containing DNA templates (upper row of panels) did 
not differ much and showed a similar KD of 16 nM on average. The negative control showed 
hardly any interaction with ZΔTAD. As seen with BZLF1 full-length protein, ZΔTAD bound 
only the mononucleosomal DNA template (lower row of panels) with two ZREs (ZRE 3+4), 
but not the mononucleosomal DNA templates ZRE 3 or ZRE 4. The KD of ZΔTAD was 
22 nM with the ZRE 3+4 template and similar to the binding constant with the naked DNAs. 
My results indicated that the TAD is not critical for BZLF1’s property to bind to 
mononucleosomal DNA. 
Fig 4.8 panel A summarizes the Kd values of three independent shift experiments of full-
length BZLF1 protein and the truncated BZLF1 version ZΔTAD with naked DNA (top panel) 
or mononucleosomal DNA (bottom panel). In addition, I performed super shift assays (Fig 4.8 
panel B) with BZLF1 full-length (upper panel) and the BZLF1 version ZΔTAD (bottom 
panel) with naked and mononucleosomal DNA templates containing two ZREs (ZRE 3+4). 
Very slowly migrating bands identified BZLF1 protein in the protein-nucleosomal DNA shift 
complexes. This trimeric complex (**) migrated differently as compared to bands of the 
BZLF1-nucleosomal DNA (*), BZLF1-naked DNA and the antibody-bound BZLF1-naked 
DNA complexes. 
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Fig. 4.7 BZLF1’s binding characteristics to mononucleosomal DNA templates in vitro 
The figure depicts the in vitro binding of BZLF1 protein to four different 156 bp DNA templates in their naked 
or compacted, mononucleosomal states. The DNA templates are derived of the viral BBLF4 promoter and 
encompass one or two meZRE motifs (see Figure 4.4 A). A region of the BRLF1 coding sequence, which lacks a 
ZRE motif and is not bound by BZLF1, served as a negative control. Mononucleosomal DNA templates were 
obtained after salt gradient dialysis. 
(f – free DNA; n – mononucleosomal DNA; c – complex of BZLF1 with free DNA or mononucleosomal DNA) 
(A) The upper row of panels shows the interaction of BZLF1 protein with naked DNA templates. BZLF1 
binding to templates containing only one ZRE (ZRE 3 or ZRE 4) or two ZREs (ZRE 3+4) showed a similar Kd 
of 15 nM on average. The negative control showed hardly any interaction with BZLF1. The lower row of panels 
shows the interaction of BZLF1 protein with mononucleosomal DNA templates. BZLF1 did not bind to 
mononucleosomal DNA templates containing only one ZRE (ZRE 3 or ZRE 4) but did interact with the ZRE 
3+4 template with two ZRE motifs. The Kd of this ZRE template was 13 nM in three independent experiments. 
Binding reactions with BZLF1 protein and naked DNA templates were performed to clearly identify the 
different complexes. 
(B) The upper row of panels shows the interaction of BZLF1’s truncated version lacking the TAD (ZΔTAD) 
with naked DNA templates. Binding to templates with two ZREs (ZRE 3+4) or with only one ZRE (ZRE 3 or 
ZRE 4) showed a Kd similar to full-length BZLF1. The negative control showed hardly any interaction with 
ZΔTAD. The lower row of panels shows the interaction of ZΔTAD protein with mononucleosomal DNA 
templates. ZΔTAD did bind to the template with two ZREs (ZRE 3+4) but not to these with one ZRE, only. The 
Kd was about 22 nM with the mononucleosomal DNA containing two ZREs and similar to the dissociation 
constant with naked DNA templates. Control binding reactions with ZΔTAD protein and naked DNA templates 
were performed to clearly distinguish the migration of the different complexes. 
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Fig. 4.8 Half maximum binding and supershift assay of BZLF1 and ZΔTAD protein to mononucleosomal 
DNA templates in vitro 
(A) The figure summarizes the Kd values of three independent shift experiments of full-length BZLF1 protein 
and ZΔTAD with naked DNA (top panel) or mononucleosomal DNA (bottom panel). EMSAs were performed 
with a final salt concentration of 90 mM and in the presence of competitor DNA. The Kd value was determined 
with a serial dilution of protein, a binding reaction without BZLF1 served as a negative control. The Kd values 
were calculated using the equation “One site – Specific binding with Hill slope” (Prism, Graphpad). The binding 
characteristics of BZLF1 full-length and its truncated version ZΔTAD are similar. The Kd values with naked 
DNA templates with one (ZRE 3 or ZRE 4) or two (ZRE 3+4) ZREs were 15 nM on average. Both proteins bind 
to mononucleosomal DNA with two ZREs (ZRE 3+4), only, with a Kd of about 18 nM similar to the KD values 
obtained with naked DNA templates. 
(B) The figure depicts the super shift assays of BZLF1 (top panel) and ZΔTAD (bottom panel) with naked and 
mononucleosomal DNA templates containing two ZREs (ZRE 3+4). As in Figure 4.6 (A) and (B), BZLF1 and 
ZΔTAD bind to the mononucleosomal ZRE 3+4 template as indicated by a slower migrating shift band (*). 
Addition of an α-Flag antibody shifted the complex (**), which migrated very slowly as expected. The detected 
BZLF1-mononucleosomal DNA complex as well as the antibody-bound BZLF1-mononucleosomal DNA 
complex could be clearly distinguished from shift bands of BZLF1-naked DNA and the antibody-bound BZLF1-
naked DNA complexes. 
Next, I assessed the specificity of my experimental setup with a well-studied transcription 
factor, known to be incapable of binding to nucleosomal DNA. The binding of the budding 
yeast transcription factor Pho4 (Fig. 4.9 panel A) to its target sites is significantly restricted 
by nucleosomes (Zhou and O’Shea, 2011) and served therefore as a negative control. The 
nucleosomal positioning sequence ‘601’ (Lowary and Widom, 1998; kindly provided by 
Daniela Rhodes, NTU, Singapore) is 197 bps long and contains a five nucleotide-long Pho4 
binding motif as indicated (Fig. 4.9 panel B). The ‘601`DNA template was reconstituted with 
histone octamers after salt gradient dialysis and used with Pho4 protein (kindly provided by 
Philipp Korber, LMU, München) in EMSA experiments. The binding reactions with Pho4 and 
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naked DNA template revealed a KD of 240 nM on average (Fig. 4.9 panel C). I could not 
detect binding of Pho4 to the mononucleosomal DNA template. 
     
Fig. 4.9 The transcription factor Pho4 does not bind nucleosomal DNA in vitro 
Nucleosomes significantly restrict binding of the budding yeast transcription factor Pho4, which served as a 
negative control in EMSAs (Zhou and O’Shea, 2011).  
(A) Shown is the modular structure of Pho4 with its basic helix-loop-helix (bHLH) domain. 
(B) The figure depicts the nucleosomal positioning sequence ‘601’ (Lowary and Widom, 1998). The ‘601’ 
sequence is a 197 bps long DNA template and contains a single Pho4 binding site. 
(C) The left and right panels show the interaction of Pho4 protein with the naked and the mononucleosomal 
“601” DNA templates, respectively. Mononucleosomal DNA templates were obtained after salt gradient 
dialysis. EMSAs were performed with a final salt concentration of 90 mM and in the presence of competitor 
DNA. Pho4’s Kd value was determined with serial dilutions of Pho4 protein, a binding reaction without any 
Pho4 protein served as a negative control. The Kd of Pho4 protein with naked DNA template was 240 nM on 
average in three independent experiments. The KD with mononucleosomal DNA template could not be 
determined, as Pho4 did not bind the mononucleosomal DNA template. 
(f – free DNA; n – mononucleosomal DNA; c – complex of Pho4 with free DNA) 
BZLF1 does not bind mononucleosomal DNA templates containing only one ZRE (ZRE 3, 
ZRE 4) but it does bind a template with two ZRE motifs (ZRE 3+4) (Fig. 4.7). This finding 
could mean that the positions of ZREs in the mononucleosomal template are critical. As 
shown in Fig. 4.5 panel A, the location of the single ZRE motifs ZRE 3 and ZRE 4 is more in 
the center of the mononucleosomal DNA templates in contrast to the two ZREs of the 
ZRE 3+4 template. There, the two ZREs are more distal, which could favor the access of 
BZLF1 to the mononucleosomal DNA template. To test this hypothesis, I performed EMSA 
experiments with synthetic DNA templates based on the ZRE 3+4 prototype. First, I mutated 
the sequences of ZRE 3 or ZRE 4 by PCR mutagenesis, which yielded the two new DNA 
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templates ZRE 3+0 and ZRE 0+4, respectively (Fig. 4.5 panel B). I chromatinized the DNA 
templates and investigated the binding of BZLF1 (Fig. 4.10 panel A). As in Fig 4.7, the 
EMSAs revealed that BZLF1 binds robustly ZRE 3+4, but interacts less efficiently with ZRE 
3+0 and weakly with ZRE 0+4. Fig. 4.10 panel B shows the deduced and calculated Hill 
slopes of BZLF1’s binding to the three mononucleosomal DNA templates. The half 
maximum binding of the mononucleosomal DNA template ZRE 3+4 was about 13 nM, 
ZRE 3+0 had a KD of ≥ 100 nM but no dissociation constant could be obtained with 
ZRE 0+4. The Kd values of BZLF1 with the naked DNA templates ZRE 3+4, ZRE 3+0 and 
ZRE 0+4 are 8 nM, 22 nM and 18 nM, respectively. Apparently, in the BBLF4 promoter 
ZRE 3 and ZRE 4 cooperate in binding BZLF1. 
The location of individual ZRE motifs within a mononucleosomal structure might be critical 
for the access and binding of BZLF1. To address this still open question, I generated a series 
of DNA templates with a “walking” ZRE 3 motif with the ZRE 3+0 DNA template as the 
prototype. The templates differ in the relative positions of ZRE 3 as indicated in Fig. 4.5 
panel C. The 9 bps long ZRE 3 motif was positioned at -5 nt upstream and +5, +10, +5, or 
+30 nt downstream with respect to its original location. I reconstituted the DNA templates 
with histone octamers after salt gradient dialysis and analyzed the binding of BZLF1 to the 
six different mononucleosomes (Fig. 4.11). BZLF1 bound the mononucleosomal ZRE 3+0 
DNA templates -5 nt, +15 nt, and +30 nt but not +5 nt or +10 nt. The results documented that 
BZLF1 is capable of binding ZRE sites in compacted DNA even if the ZRE motifs are located 
towards the center of a mononucleosome. Using the six naked DNA templates, the binding of 
BZLF1 did not differ much (Fig 4.11). 
Summarizing all my EMSA results, I could show that the viral transcription factor BZLF1 
binds the histone octamer of a compacted binding site in vitro. Interestingly, BZLF1 binding 
to mononucleosomes did not evict the histone octamer in vitro. 
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Fig. 4.10 BZLF1 shows cooperative binding to mononucleosomal DNA templates in vitro 
The figure depicts the EMSA results of BZLF1 protein with three different 156 bps long DNA templates (see 
Figure 4.5 panel B) in their naked or mononucleosomal and compacted state. The DNA templates are derived 
from the viral BBLF4 promoter and encompass the third and forth identified ZRE motifs (ZRE 3+4 in Bergbauer 
et al. (2010)). PCR mutagenesis eliminated the ZRE 3 or ZRE 4 motifs in the DNA templates ZRE 0+4 or ZRE 
3+0, respectively. Naked DNA templates were used and compared to templates, which had been chromatinized 
forming a single nucleosome. 
(A) EMSA results of BZLF1 protein and the DNA templates ZRE 3+4, ZRE 3+0 and ZRE 0+4 suggested a 
cooperative binding of ZRE 3 and ZRE 4 within the BBLF4 promoter region. The ZRE 3+4 template was 
robustly bound by BZLF1, which interacted less efficiently with ZRE 3+0 and weakly with ZRE 0+4. 
(B) Individual Hill slope curves of BZLF1’s binding characteristics to the mononucleosomal DNA templates 
ZRE 3+4, ZRE 3+0 and ZRE 0+4 summarize three independent experiments. The half maximum binding of the 
mononucleosomal DNA template ZRE 3+4 was about 13 nM. No half maximum binding could be determined 
with ZRE 0+4 but ZRE 3+0 had a KD about 100 nM. The Kd values of BZLF1 with the naked DNA templates 
ZRE 3+4, ZRE 3+0 and ZRE 0+4 were 8 nM, 22 nM and 18 nM, respectively. EMSAs were performed with a 
final salt concentration of 90 mM and in the presence of competitor DNA. BZLF1’s Kd value was determined 
with serial dilutions of purified BZLF1 protein, a binding reaction without BZLF1 protein served as a negative 
control. Kd value was calculated using the equation “One site – Specific binding with Hill slope” (Prism, 
Graphpad). 
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Fig. 4.11 The positions of ZREs in mononucleosomal DNA are critical for BZLF1’s cooperative binding to 
chromatin 
The figure depicts the EMSA results of BZLF1 protein with six different 156 bps long DNA templates (see 
Figure 4.5 panel C) in their naked or mononucleosomal and compacted state. The DNA templates are derived 
from the viral BBLF4 promoter and encompass the third ZRE motif (ZRE 3 in Bergbauer et al. (2010)). PCR 
mutagenesis eliminated the ZRE 4 motif obtaining the DNA template ZRE 3+0. The DNA template ZRE 3+0 
was modified to alter the position of the ZRE 3 motif. The 9 bps long ZRE 3 motif was positioned at -5 nt 
upstream or +5, +10, +5, or +30 nt downstream with respect to its original location. BZLF1 was capable of 
binding the modified mononucleosomal ZRE 3+0 DNA templates -5 nt, +15 nt, and +30 nt but not +5 nt or 
+ 10nt indicating that the factor can bind nucleosomally structured DNA. The binding of BZLF1 with the six 
naked DNA templates did not apparently differ. 
My in vitro assays with reconstituted mononucleosomes and BZLF1 protein indicated the 
function of a trimeric complex consisting of DNA, histone octamer and BZLF1. I wanted to 
scrutinize BZLF1’s binding characteristic to chromatin and mononucleosomes in vivo and 
performed ReChIPs meaning re-immunoprecipitations with two different antibodies. ReChIP 
is a relatively new technique and is used to assess the co-occupancy of two proteins at the 
same genomic region of interest in two consecutive ChIPs. The workflow and individual steps 
of the ChIP and ReChIP methods are shown in Fig. 4.12.  
                                 
Fig. 4.12 Workflow and individual steps of the ChIP and ReChIP methods 
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For my aims, I wanted to investigate if BZLF1 can bind to DNA in mononucleosomal 
structures in vivo. First, I performed ChIP experiments with antibodies directed against 
BZLF1 or H3K4me1 (Fig. 4.13 panel A). I chose the H3K4me1 modification-specific 
antibody because it proved to be very efficient in ChIP experiments in very contrast to cell 
pan H3 antibodies I tested. Upon addition of doxycycline and induction of the lytic phase, 
BZLF1 binding was detected at the early lytic gene promoters (Q/F, BRLF1, BZLF1, BMRF1, 
BBLF4 and BSRF1) as early as four hours after induction. The increase of H3K4me1 became 
detectable after seven hours post induction at the very same promoters. Late lytic (BcLF1) 
and latent (EBER) promoters showed little change, the cellular control promoters (cen, 
GAPDH) were not affected. Second, two ReChIP experiments were done, which differed in 
the order of antibodies used (Fig. 4.13 panel B). In the left panel, BZLF1 and H3K4me1 
specific antibodies were used in the first and second ChIP experiments, respectively. The 
right panel shows the reverse order. Third, I performed control ReChIPs using a non-specific 
IgG antibody as an unspecific second ReChIP antibody (Fig. 4.13 panel C). These controls 
are important to demonstrate that carry-over of the antigen-specific antibodies used in the first 
ChIP experiments does not take place in the following ReChIP experiment, which would lead 
to noninterpretable or false positive results. Specificity controls of the BZLF1+IgG and 
H3K4me1+IgG ReChIP experiments documented low (left panel) and no (right panel) carry-
over, respectively, resulting in the very low background in the second ChIP. 
The results of my ReChIP experiments documented the co-occupancy of BZLF1 and the 
histone octamer represented by histone mark H3K4me1 in the promoter regions of early lytic 
genes (Q/F, BRLF1, BZLF1, BMRF1, BBLF4 and BSRF1) as early as seven hours post 
induction. The late lytic gene (BcLF1) and the cellular control promoters (cen, GAPDH) did 
not show co-occupancy of BZLF1 and histones. 
Taken together, I could demonstrate that the viral transcription factor BZLF1 binds to 
nucleosomes in vitro and in vivo, which occupy the promoter regions of early lytic genes. 
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Fig. 4.13 Sequential chromatin immunoprecipitation (ReChIP) of BZLF1 and H3K4me1 
ChIPs and ReChIPs were performed with antibodies directed against BZLF1 and the histone mark H3K4me1 in 
a time kinetic experiment. DNA was analyzed by qPCR for enrichment at different loci in the human or the EBV 
genomes. PCR with Centromer1 (cen) specific primers served as control of an epigenetically repressed locus, the 
promoter of the housekeeping gene GAPDH is indicative of chromatin with active epigenetic marks. Enrichment 
of EBV DNA was assessed with primer pairs covering latent, early lytic, and late lytic promoters as indicated. 
Results of the individual experiments can be found in the appendix. 
(A) ChIP experiments with antibodies directed against BZLF1 or H3K4me1 are shown. Upon addition of 
doxycycline, BZLF1 was detected at certain promoters (e.g. BRLF1) as early as four hours after induction of 
EBV’s lytic phase. The increase of H3K4me1 became detectable after seven hours post induction at all 
promoters of early lytic genes (Q/F, BRLF1, BZLF1, BMRF1, BBLF4 and BSRF1). Late lytic (BcLF1) and latent 
(EBER) promoters showed little change, the cellular control promoters (cen, GAPDH) were not affected. The 
means of three independent experiments are shown. 
(B) Two ReChIP experiments are shown, which differ in the order of antibodies used. In the left panel, BZLF1 
and H3K4me1 specific antibodies were used in the first and second ChIP experiments, respectively. The right 
panel shows the reverse order. ReChIP experiments documented the co-occupancy of BZLF1 and the histone 
octamer represented by histone mark H3K4me1 in the promoter regions of early lytic genes (Q/F, BRLF1, 
BZLF1, BMRF1, BBLF4 and BSRF1) as early as seven hours post induction. The late lytic gene (BcLF1) and the 
cellular control promoters (cen, GAPDH) did not show co-occupancy of BZLF1 and histones. The means of 
three independent experiments are shown. 
(C) Specificity controls of the ReChIP experiments documented the low (left panel) and no (right panel) carry-
over of the antigen-specific antibodies used in the first ChIP experiments resulting in the very low background in 
the second ChIP shown in (C). The control ReChIPs were performed with a non-specific IgG antibody as an 
unspecific secondary antibody. The results of representative experiments are shown. 
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4.3 BZLF1 interacts with chromatin regulatory proteins in 
vivo 
The viral transcription factor BZLF1 binds compacted and chromatinized DNA binding 
motifs in vitro and co-locates with histone octamers in the promoter regions of early lytic 
genes in vivo upon lytic reactivation. The previous time kinetic experiments pointed out that 
BZLF1 binding precedes the loss of histones in the promoter regions of early lytic genes (Fig. 
4.3 panel A; Woellmer et al., 2012). Based on these observations, I hypothesized that BZLF1 
binds nucleosomal DNA in lytic gene promoter regions but is incapable of evicting 
nucleosomes without recruiting additional factors. Obviously, BZLF1 might recruit cellular 
chromatin remodelers directly or indirectly, which can reposition or eject nucleosomes and 
support the recruitment of the cellular transcriptional machinery and the expression of the 
lytic gene products. 
Chromatin remodeling complexes are ATP-driven molecular machines that introduce 
structural changes in chromatin. They disrupt histone-DNA contacts, slide or even move 
nucleosomes, and change the nucleosomal histone composition. These structural 
modifications change the accessibility of compacted DNA and promote the local recruitment 
of regulatory cellular protein complexes that support subsequent transcription, DNA 
replication and DNA repair. Chromatin remodelers are highly abundant in the cell and 
numerous different complexes exist that display distinct activity patterns. All eukaryotic cells 
contain at least four families of chromatin remodelers: SWI/SNF, ISWI, INO80, and CHD 
(Clapier and Cairns, 2009). 
In a candidate approach I analyzed the protein-protein interactions of BZLF1 with the 
catalytic ATPase subunits of two of the four chromatin remodeler families: SNF2H (ISWI) 
and hIno80 (INO80). I performed co-immunoprecipitations (coIPs) with BZLF1 and the key 
components of the two remodeler families acting as bait and prey proteins. In two different 
types of experiments I analyzed these interactions in transient co-transfection experiments in 
HEK293 cells (Fig. 4.14 panel A and B), but also checked for the presumed interactions in 
Raji cells in a more physiological setting (Fig. 4.14 panel C).  
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Fig. 4.14 Immunoprecipitations of the viral transcription factor BZLF1 and the cellular chromatin 
remodelers SNF2H or hIno80 
BZLF1 interacts in vivo with the core subunits of the cellular chromatin remodelers SNF2H and hIno80. The 
interaction was shown with GFP-tagged chromatin remodeler in HEK293 and in Raji cells with endogenous 
levels of SNF2H and hIno80. Western blot immunodetection with antibodies specific for BZLF1 and GFP or the 
chromatin remodeler core subunits identified the interacting proteins. 
(A) Expression plasmids encoding GFP (p1925), BZLF1 (p509) and GFP-SNF2H (p5906) were transfected or 
co-transfected into HEK293 cells as indicated. Protein lysates were prepared and analyzed for protein expression 
(input). After two days, immunoprecipitations with GFP-binder (Chromotek) coupled to sepharose beads were 
performed and the samples were analyzed with antibodies directed against GFP (second panel from the top, IP) 
and BZLF1 (upper panel, IP). BZLF1 co-precipitated with GFP-SNF2H but not with GFP, which served as a 
negative control. 
(B) Expression plasmids encoding GFP (p1925), BZLF1 (p509) and GFP-hIno80 (p5985) were transfected or 
co-transfected into HEK293 cells as indicated. Protein lysates were prepared and analyzed for protein expression 
(input). After two days, immunoprecipitations with GFP-binder (Chromotek) coupled to sepharose beads were 
performed and the samples were analyzed with antibodies directed against GFP (second panel from the top, IP) 
and BZLF1 (upper panel, IP). BZLF1 co-precipitated with GFP-hIno80 but not with GFP alone. 
(C) Raji cell lines stably transfected with the tetracycline regulated expression plasmids encoding the Strep-
tagged BZLF1 full-length (p5693) or bZIP (p5694) protein. bZIP contains aa175 to aa236 carrying the DNA 
binding and dimerization domains of BZLF1, only. Cells were induced with doxycycline over night. Protein 
lysates were prepared and immunoprecipitations of Strep-tag fusion proteins were performed with Strep-Tactin 
sepharose beads. The interaction of the Strep-tagged BZLF1 proteins and cellular proteins were analyzed with 
antibodies directed against SNF2H (left panel) and hIno80 (right panel). The results indicated that only the 
Strep-tagged BZLF1 full-length protein (p5693) but not the truncated bZIP protein (p5694) interacts with the 
endogenous chromatin remodeler SNF2H and hIno80. 
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In transiently transfected HEK293 cells immunoprecipitations were performed with GFP as 
the bait protein. The chromatin remodeler catalytic ATPase subunits SNF2H and hIno80 were 
GFP-tagged and precipitated with GFP-binder coupled sepharose beads. The interactions of 
GFP-SNF2H and GFP-hIno80 with BZLF1 were analyzed by western blot immunodetection 
using an antibody directed against BZLF1. Unmodified GFP protein served as a negative 
control. BZLF1 co-precipitated with GFP-SNF2H (Fig. 4.14 panel A) and GFP-hIno80 (Fig. 
4.14 panel B). BZLF1 did not show unspecific binding to the GFP-binder beads or GFP alone. 
The study of protein-protein interactions in HEK293 cells with the over-expression of both 
bait and prey proteins might be prone to artifacts. Hence, the interactions of BZLF1 with the 
chromatin remodeler components were also analyzed in Raji cells, in which the chromatin 
remodeler complexes are expressed at endogenous levels. I stably transfected Raji cells with 
conditional expression plasmids encoding the Strep-tagged BZLF1 wild-typ protein or the 
BZLF1 bZIP domain (aa175-236) to yield the two cell lines Raji 5693 and Raji 5694, 
respectively. Upon induction with doxycycline over night, the cells expressed the Strep-
tagged BZLF1 proteins, which were used as bait proteins in immunoprecipitations using 
Strep-Tactin sepharose beads. Western blot immunodetection with antibodies directed against 
the chromatin remodeler components analyzed the interactions of Strep-tagged BZLF1 
proteins with endogenous SNF2H or hIno80. The immunoprecipitation results (Fig. 4.14 
panel C) showed the protein-protein interaction of BZLF1 wild-type protein with endogenous 
SNF2H and hIno80 confirming the findings in HEK293 cells. The BZLF1 bZIP protein did 
not show any interaction with the ATPase catalytic subunits of both chromatin remodelers. 
My experiments revealed that BZLF1 interacts with at least two of the known chromatin 
remodeler to accomplish the process of lytic reactivation. 
Next, I performed additional immunoprecipitations to identify BZLF1’s domains, which 
mediate the interaction with the chromatin remodeler SNF2H. The modular structures that are 
part of the different BZLF1 variants are shown in Fig. 4.15 panel A. HEK293 cells were co-
transfected with GFP-SNF2H and the BZLF1 variants. Immunoprecipitations were performed 
again with GFP-SNF2H as bait and BZLF1 mutants as prey. In addition, cell lysates were 
treated with the enzymes benzonase and DNase I prior to immunoprecipitation in order to 
disrupt complexes that might be stabilized by protein-DNA-protein interactions. 
Precipitations were performed with GFP-binder coupled sepharose beads and the possible 
interactions were visualized by western blot immunodetection with an antibody directed 
against BZLF1. The GFP protein alone served as a negative control. 
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Fig. 4.15 Immunoprecipitations of the cellular chromatin remodeler SNF2H with BZLF1 full-length and 
truncated versions of BZLF1 
(A) The figure depicts the modular structures of the truncated BZLF1 variants used in the subsequent 
experiments. 
(B) BZLF1’s TAD but also the C-terminus are involved in the protein interaction with the cellular chromatin 
remodeler SNF2H. The expression plasmid of the GFP-tagged chromatin remodelers SNF2H (p5906) was co-
transfected in HEK293 cells together with expression plasmids encoding BZLF1 versions (p5406, p6014, p3928, 
p6013 and p5686) as shown in (A). Cell lysates were treated with the enzymes benzonase and DNase I prior to 
immunoprecipitation in order to disrupt complexes that might occur via protein-DNA-protein interactions. 
Immunoprecipitation of the GFP-tagged chromatin remodeler SNF2H was performed with GFP-binder beads. 
The analysis of input and immunoprecipitated material was done by western blot immunodetection with 
antibodies directed against GFP or BZLF1. The immunoblots showed the interaction of cellular SNF2H with 
wild-type BZLF1 (BZLF1 aa1-245) and the BZLF1 mutant (BZLF1 aa149-245). No interaction could be seen 
with BZLF1 aa1-236, BZLF1 aa175-245 or BZLF1 aa175-236 proteins. BZLF1 did not show unspecific binding 
to the GFP-binder beads or GFP (p1925) alone. 
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The immunoblots showed the interaction of cellular SNF2H with wild-type BZLF1 (BZLF1 
aa1-245) and the BZLF1 mutant (BZLF1 aa149-245). No interaction could be detected 
between SNF2H and the BZLF1 versions aa1-236, BZLF1 aa175-245 or BZLF1 aa175-236. 
BZLF1 did not show unspecific binding to the GFP-binder beads or GFP alone. The results in 
Fig. 4.15 panel B indicated that the interactions of the viral transcription factor BZLF1 and 
the cellular chromatin remodeler SNF2H are mediated by a combination of BZLF1’s TAD 
and its C-terminus. This is an interesting finding because the importance of BZLF1’s C-
terminus has been described (Petosa et al., 2006) but its molecular function has been elusive 
so far.  
My candidate approach was successful but is limited to the presumed interactors, only. In 
order to identify additional and unknown chromatin factors, which interact with BZLF1 in 
vivo, I performed mass spectrometry analysis. I made use of the conditional expression 
system in Raji 4816 cell line described in Fig. 4.1 panel A. I constructed two conditional 
expression plasmids with BZLF1 wild-type (p5693, BZLF1 aa1-245) or BZLF1’s bZIP 
domain (p5694, BZLF1 aa175-236) fused to functional Flag- and tandem Strep-tags as shown 
in Fig. 4.16 panel A. BZLF1 or bZIP expression was monitored with the detection of GFP 
positive cells by flow cytometry (Fig. 4.16 panel C). First, protein expression of the 
conditional expression plasmids (p5693 and p5694) was confirmed in HEK293 cells by 
western blot immunodetection upon lytic phase induction. Both proteins (BZLF1 and bZIP) 
were equally expressed with a functional Flag-tag (Fig. 4.16 panel B). Second, Raji cells were 
stably transfected with the plasmids 5693 and 5694. Single cell clones were analyzed for 
viability and inducibility of the transgenes by flow cytometry. The single cell clones with the 
most robust and highest expression of the eGFP gene (about 70 %) were used for all my 
following experiments (Fig. 4.16 panel C). Immunoprecipitations of nuclear extracts were 
performed with Strep Tactin sepharose beads. I did immunoprecipitations of each cell line in 
triplicates. Fig. 4.16 panel D shows single steps along the mass spectrometry sample 
preparation indicating an (barely visible) enrichment of the bait proteins BZLF1 and bZIP. I 
sent these samples for mass spectrometry analysis to the Zentrallabor für Proteinanalytik 
(ZfP, Munich), where liquid chromatography tandem mass spectrometry (LC-MS/MS) with 
the ion trap mass analyzer Orbitrap was performed. With the aid of the Mascot software the 
colleagues identified BZLF1’s interacting proteins in the viral and human protein databases. 
The data that I received from ZfP were analyzed as follows. The two data sets with three 
experiments each (5693 (1,2,3) and 5694 (1,2,3)) were analyzed by the R program. First, the 
protein names were made unique, deleting multiple entries. Second, the triplicates (1,2,3) 
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were checked for proteins, which were identified in at least two out of three samples. As 
expected the protein scores of distinct samples differed. Therefore, the mean of the protein 
scores were calculated in a pair-wise comparison. The pair with the highest mean was used. 
The outputs were sorted by mean values in decreasing order. Only if the highest mean had a 
score ≥100, the interaction was considered as credible. Third, all proteins that turned up in the 
data sets from 5693 and 5694 samples were sorted in three different lists (including viral and 
cellular interactors) in the following manner: The first list (BZLF1_5693_minus_5694) 
contains proteins present in 5693 but not in 5694 data sets. This list should encompass 
proteins that interact with BZLF1’s TAD or C-terminus, only. The second list 
(BZLF1_5694_minus_5693) contains proteins present in 5694 but not in 5693 data sets. This 
list should encompass proteins that bound exclusively to BZLF1’s bZIP domain but did not 
interact with other BZLF1 domains. The third list (BZLF1_5693_intersect_5694) contains 
proteins present in 5693 and 5694 samples. This list encompasses all proteins that were found 
to interact with all BZLF1 domains. All lists can be found in the appendix. 
The viral proteins BMRF1 (DNA polymerase processivity factor), BALF5 (DNA polymerase 
catalytic subunit), TK (thymidine kinase), and BSLF2 (mRNA export factor) were identified 
as BZLF1 interaction partners. With the exception of TK all these interactions are known 
from the literature (Baumann et al., 1999) supporting my experimental setup and the 
credibility of the mass spectrometry data of cellular interactors. BZLF1 wild-type (but not the 
bZIP domain alone) interacts with the histones H2B type 1-C (score: 364.0) and H2A type 1-
D (score: 160.5). This finding is in line with my previous data of BZLF1 binding to 
mononucleosomal DNA in vitro (Fig. 4.7) and co-locating with histone octamers in the lytic 
promoter regions in vivo (Fig. 4.13). The interaction of BZLF1 with the histone-binding 
protein RBBP4 (RbBP4, score: 95.5) and chromodomain helicase DNA-binding protein 4 
(CHD4, score: 55,5) supports the assumption that BZLF1 interacts with various chromatin 
remodelers in the nucleus but the low score values in these cases argue for independent 
experimental confirmation. From the preliminary data I can conclude that the N- and C-
terminal domains of BZLF1 are responsible for these interactions. Unexpectedly three 
chromatin regulatory proteins exclusively interact with the bZIP domain of BZLF1 but not 
with full-length BZLF1: the nucleosome assembly protein 1-like 1 (NP1L1, score: 502.0), the 
histone linker protein histone H1.2 (score: 167.5) and the histone H3.3C (score: 81.5). 
Histone H4 (score: 242.5) and histone H1.5 (score: 121.5) interacted with BZLF1 full-length 
version and also the bZIP domain. Again these data need independent experimental 
confirmation but my mass spectrometry results strongly confirmed BZLF1’s role as an 
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important chromatin player, which activates the viral chromatin and enables the rapid and 
strong expression of EBV’s lytic genes. 
        
Fig. 4.16 Mass spectrometry analysis identified chromatin regulatory proteins as potential BZLF1 
interaction partners 
(A) Conditional expression plasmids of Flag- and tandem strep-tagged versions of BZLF1 full-length (aa1-245, 
p5693) and its bZIP domain (aa175-236, p5694) were cloned. The plasmids contain the bicistronic coding 
sequence of the tetracycline controlled repressor rTS and transactivator rtTA2-M2. In the absence of tetracycline 
(or its analogue doxycycline), the repressor binds tightly to the so-called tet promoter preventing its activation. 
After addition of doxycycline to the cells, the repressor rTS is replaced by the activator rtTA2-M2, which 
induces bidirectional transcription and simultaneous expression of three transgenes: enhanced green fluorescent 
protein (eGFP), the human truncated nerve growth factor-receptor (tNGF-R) and BZLF1 (or bZIP). An internal 
ribosomal entry site (IRES) separates tNGF-R and BZLF1 or bZIP. β-lactamase (amp) and puromycin N-acetly-
transferase (puro) serve as resistance genes in bacteria and Raji cells, respectively. DNA replication in E. coli 
initiates at the prokaryotic origin of replication (ori). Epstein-Barr nuclear antigen 1 (EBNA1) activates 
replication of the plasmid DNAs through binding to the origin of plasmid replication (oriP) and governs their 
segregation by mediating attachment to host cell metaphase chromosomes. 
(B) Protein expression of the conditional expression plasmids (p5693 and p5694) was confirmed by western blot 
immunodetection in HEK293 cells upon lytic phase induction. Protein lysates were analyzed with an antibody 
recognizing either BZLF1 (top panel) or Flag-tag (bottom panel) 15 hours post induction. The plasmid p4816 
served as a control for BZLF1 expression. Tubulin was used as a loading control (bottom panel). Both proteins 
(BZLF1 and bZIP) were equally expressed with a functional Flag-tag.  
(C) The conditional expression plasmids (p5693 and p5694) were stably introduced to Raji cells and single cell 
clones were selected by limiting dilution, expanded and analyzed further. GFP expression in Raji cells was a 
measure of the induced expression of BZLF1 or bZIP. Upon addition of 100 ng/ml doxycycline to the cells for 
15 hours, about 70 % of the cells turned GFP-positive.  
(D) Nuclear cell extracts of Raji 5693 or 5694 cells were prepared and BZLF1 was precipitated using a 
purification protocol of Strep-tag fusion proteins with Strep-Tactin matrices. Streptavidin beads were incubated 
with the nuclear extracts and washed five times. Beads were frozen directly on dry ice and used for mass 
spectrometry analysis. The results can be found in the appendix. Lysates, first and last washing fractions, and 
beads were controlled for BZLF1 or bZIP expression (*) by silver staining after SDS-PAGE (top panel) and 
western blot immunodetection with an α-BZLF1 antibody (bottom panel). 
 
5. DISCUSSION 
5.1 Scope and aim of my thesis work 
The Epstein-Barr Virus (EBV) is a very successful human tumor virus that infects more than 
95 % of the adult population worldwide with a lifelong persistence in human B cells. The key 
to EBV’s success lies in its ingenious life cycle consisting of three major phases. Upon 
cellular infection the virus enters the pre-latent phase, in which the expression of latent genes, 
repression of lytic genes and the short-term transcriptional activation of cellular target genes 
by BZLF1 help the virus to activate the resting infected B lymphocyte and escape from the 
human immune system (Kalla et al., 2010). Viral interaction activates quiescent 
B lymphocytes but induces their proliferation in vitro. After one to two weeks, the virus 
establishes a strictly latent infection, in which no virus is synthesized and the viral genome is 
maintained in the infected and proliferating cells as nuclear plasmid copies. Only latent genes 
supporting proliferation and genome maintenance are expressed, all lytic genes are repressed. 
Upon induction of the lytic phase, all three classes of viral lytic genes are expressed: 
immediate-early, early and late lytic genes. The lytic phase is accomplished within 48 hours 
and results in viral synthesis and spread of viral progeny to uninfected cells (Kieff and 
Rickinson, 2007; Rickinson and Kieff, 2007). 
All three phases of EBV’s life cycle rely on the different epigenetic states of viral DNA and 
the availability of viral and cellular factors (Woellmer and Hammerschmidt, 2013). In a smart 
way, the virus takes advantage of the host cell’s epigenetic machinery to establish a stable 
latent infection but is still capable to escape from it. Upon infection, the viral DNA is first 
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completely naïve, i.e. free of histones and devoid of methylated CpG dinucleotides (Kintner 
and Sugden, 1981; Fernandez et al., 2009; Kalla et al., 2010). In the course of the pre-latent 
phase, the host cell’s epigenetic machinery compacts the viral DNA into nucleosomal arrays, 
modifies the histones over time and intensively methylates the majority of all viral CpG 
dinucleotides (Kalla et al., 2010). Apart from the promoters of a few latent genes, all other 
viral promoters are silenced during latency. Densely positioned nucleosomes, the 
establishment of repressive histone marks by Polycomb proteins and extensive DNA 
methylation keep the virus in the strictly latent, dormant mode (Ramasubramanyan et al., 
2011; Woellmer et al., 2012). 
Surprisingly, DNA methylation is a prerequisite for the induction of EBV’s lytic phase in 
order to escape from latency and initiate the lytic reactivation process (Bergbauer et al., 2010; 
Kalla et al., 2010; Woellmer et al., 2012). In the lytic phase, the loss of nucleosomes 
increases the accessibility of the viral DNA. The removal of repressive histone marks and the 
establishments of active histone marks reactivate the promoter regions of viral lytic genes and 
enable the virus to replicate and produce viral progeny to infect new B cells (Woellmer et al., 
2012). 
It is well accepted that the viral transcription factor BZLF1 triggers the switch from the latent 
to the lytic phase (Countryman and Miller, 1985; Chevallier-Greco et al., 1986; Takada et al., 
1986; Countryman et al., 1987). First, BZLF1 enhances the expression of more than 50 early 
lytic genes by binding sequence-specifically to BZLF1 Responsive Elements (ZREs), which 
are located in promoter regions of certain lytic genes (Miller, 1989; Speck et al., 1997; 
Schwarzmann et al., 1998). Second, BZLF1 enables viral DNA replication via two 
mechanisms: it binds to the lytic origin of DNA replication and promotes the recruitment of 
components of the viral DNA replication machinery (Schepers et al., 1993a, b; Schepers et 
al., 1996; Zhang et al., 1996; Gao et al., 1998; Baumann et al., 1999; Liao et al., 2001). 
Third, BZLF1 indirectly or directly causes the loss of nucleosomes in the promoter region of 
viral lytic genes, which correlates with their expression (Woellmer et al., 2012). It has been 
hypothesized that the observed reactivation of silenced, inactive chromatin is forced by a 
pioneer function of the BZLF1 transcription factor (Woellmer et al., 2012) and/or the 
additional recruitment of chromatin remodelers (Adamson and Kenney, 1999; Zerby et al., 
1999; Schelcher et al., 2007; McDonald et al., 2009; Woellmer et al., 2012). 
Pioneer factors belong to a special class of transcription factors, which establish competence 
for gene expression (Magnani et al., 2011; Zaret and Carroll, 2011). Peculiar structural 
characteristics of pioneer factors promote binding to their cognate binding motifs even in 
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nucleosome-dense regions and cause the remodeling of the silenced chromatin. Remodeling 
can be the consequence of DNA binding and opening of chromatin or of site-specific 
recruitment of cellular chromatin remodelers. Only very few examples of this type of factors 
have been identified and studied so far, among them FoxA, PBX1 and PU.1. 
The central hypothesis of my PhD work was, if the viral transcription factor BZLF1 might 
have functions similar or identical to known pioneer factors during the process of lytic gene 
activation. If BZLF1 itself could act as a chromatin remodeler or, alternatively, could recruit 
cellular chromatin regulatory factors, which might assist in the reactivation process of 
silenced chromatin.  
In the subsequent chapters, I shall discuss my data in the light of these questions and discuss 
and integrate my new findings in the context of the known epigenetic mechanisms and 
principles of EBV’s life style. 
5.2 Novel findings of BZLF1 and the regulation of 
meZREs 
5.2.1 BZLF1 shows characteristics of a pioneer factor 
Pioneer factors find access to their DNA binding sites in nucleosome-dense chromatin prior to 
other factors binding and prior to the time of transcriptional activation. These factors are 
defined as nucleosome-binding proteins that pioneer the subsequent binding of other 
transcription factors, chromatin modifiers, and nucleosome remodelers involved in chromatin 
remodeling. Alternatively, certain pioneer factors can actively open local chromatin by 
themselves (Zaret and Carroll, 2011). The regulation of cell development and differentiation 
is often mediated by pioneer factors that promote cell type-specific transcriptional programs 
(Magnani et al., 2011). 
The preliminary work for my PhD project was conducted in my group (Woellmer et al., 
2012), when Anne Woellmer analyzed the nucleosomal occupancy at various ZRE sites of 
lytic promoters in latently infected versus lytically induced Raji cells. During latency, Anne 
found very dense nucleosomes at and in close vicinity of ZRE sites. The high nucleosomal 
occupancy was interpreted to mean that nucleosomes shield the ZRE sites within the lytic 
promoters during lartency preventing their transcriptional activation. Upon expression of 
BZLF1 and the onset of the lytic phase, the nucleosomal occupancy abruptly diminishes 
resulting in a more open conformation of viral chromatin. Based on these observations, we 
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hypothesized that the viral transcription factor BZLF1 is involved in chromatin remodeling. 
BZLF1 could actively eject nucleosomes or recruit cellular chromatin remodeler. I performed 
a number of in vitro and in vivo experiments to scrutinize if BZLF1 acts as a pioneer factor. 
First, I performed in vitro electro mobility shift assays (EMSAs) with purified BZLF1 protein 
and compacted, 156 bps long mononucleosomal DNA templates containing one or two ZRE 
sites. I made use of the principle that the stable complex of BZLF1 and the mononucleosome 
would migrate more slowly than the mononucleosome alone. I used a number of DNA 
templates, which differ in the number of ZRE sites and their positioning within the 
mononucleosomal-sized DNA templates. My EMSA results documented that the viral 
transcription factor BZLF1 does bind the histone octamer of a compacted binding site in vitro, 
but BZLF1’s binding does not seem to reposition or even eject the mononucleosome without 
the help of other molecular machines (Fig. 4.7 panel A). Under certain conditions, even ZRE 
sites located within the core of the histone octamer can be accessed by the BZLF1 protein 
(Fig. 4.11). In addition, I could show that the nucleosome-binding activity does not depend on 
BZLF1’s transactivation domain (TAD) but is encoded within the C-terminal part of BZLF1 
encompassing the bZIP domain and C-terminus (Fig. 4.7 panel B). Only very few of the many 
known and studied DNA binding transaction factors are capable of binding their cognate sites 
in vitro in a nucleosomal context underlining the exceptional property of BZLF1. 
Second, using two sequential chromatin immunoprecipitations (ReChIPs) I could document 
that BZLF1 binds to histone octamers in vivo at certain viral lytic promoters upon lytic 
reactivation of Raji cells. BZLF1’s binding to the viral lytic promoter regions and the loss of 
nucleosomes are two distinct events that can be detected at four and 15 hours post induction, 
respectively (Fig. 4.13 panel A and unpublished data of A. Woellmer), indicating that BZLF1 
binds to nucleosomal DNA prior to the removal of the histone octamer in vivo. 
Third, I performed mass spectrometry analysis to identify BZLF1’s interaction partner 
involved in the formation and regulation of chromatin. I could confirm the in vivo interaction 
of BZLF1 with the histone octamer and identify the responsible domains of BZLF1 (see 
according lists in the appendix). My results suggested that BZLF1’s TAD and/or C-terminus 
bind the histone H2A-H2B dimer, whereas the bZIP domain interacts with the linker histone 
H1.2 and the histone variant H3.3. H2A and H2B histones are core components of the histone 
octamer (Kornberg, 1977). The linker histone H1.2 is responsible for the higher packaging of 
chromatin (Kornberg, 1974). The interaction of BZLF1 with H1.2 likely supports the access 
of BZLF1 to silenced, repressed chromatin. The substitution of the canonical core histone H3 
with the histone variant H3.3 provides a mechanism for the immediate activation of genes, 
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which are silenced by histone modifications (Ahmad and Henikoff, 2002). The presence of 
H3.3 might assist BZLF1 to recognize its ZRE motifs within repressed chromatin. 
The nucleosome-binding activity of known pioneer factors is based on their peculiar structural 
features that are more or less understood in chromatin opening. The fork head-like 
transcription factor FoxA regulates the transcriptional activation of the albumin gene, which 
is indispensable for liver cell function. Nucleosomal occupancy in the promoter region of 
albumin results in an equal or even favored binding of FoxA (Cirillo et al., 1998) suggesting 
that the complex formation of FoxA with nucleosomes serves as a positive architectural signal 
for the recruitment of complexes of gene regulation (Chaya et al., 2001). The N-terminus of 
FoxA contains a binding motif for core histones (Cirillo et al., 2002), but the pioneer factor 
activity stems from its C-terminus. The winged helix DNA-binding domain contains a helix-
turn-helix (HTH) motif, which mediates DNA contacts and structurally resembles the linker 
histone H1 (Cirillo et al., 1998). In that way the DBD is capable to disrupt internucleosomal 
interactions (Cirillo et al., 2002; Sekiya et al., 2009). 
The Pre-B-cell leukemia homeobox 1 (PBX1) plays crucial roles in cell type-specific 
transcriptional regulation of genes involved in organogenesis (Magnani et al., 2011). PBX1 
occupies chromatin prior to other factors, mediates nucleosome depletion, and recruits 
additional chromatin factors involved in transcriptional regulation. As a member of three 
amino acid loop extension (TALE)-class homeodomain family, PBX1 contains also a HTH 
motif for DNA binding. The nucleosome binding characteristics have been reported to drive 
from its charge that promotes chromatin openness at specific genomic locations but the exact 
binding mechanistic is not reported yet (Magnani et al., 2011). 
PU.1 belongs to the family of ETS-domain transcription factors that regulates gene expression 
during growth and development (Kodandapani et al., 1996; Sharrocks, 2001). The factor 
plays an important role in the cell-type specific transcriptional program that promotes B cell 
or macrophage differentiation (Magnani et al., 2011). At early stages of B cell differentiation 
and development PU.1 binds the enhancer of the Paired box protein Pax-5 gene in 
multipotent hematopoietic progenitors (Zaret and Carroll, 2011). The structure of PU.1 
contains an ETS DNA-binding domain with a variant of the winged HTH motif. As a pioneer 
factor it expands the linker region, initiates nucleosome repositioning and chromatin opening 
in the course of macrophage and B cell differentiation (Ghisletti et al., 2010; Heinz et al., 
2010). 
The viral transcription factor BZLF1 belongs to the basic leucine-zipper (bZIP) family of 
transcription factors (Farrell et al., 1989; Chang et al., 1990; Lieberman and Berk, 1990). The 
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DNA-binding domain of BZLF1 does not contain a HTH motif, but a variant of the leucin 
zipper motif responsible for the coiled-coil structure. BZLF1 forms homodimers and binds the 
DNA via its two long bZIP helices (Morand et al., 20006; Petosa et al., 2006). The basic 
region of each helix contacts the major groove and the zipper region forms a coiled-coil. The 
C-terminal tail forms an additional structured motif stabilizing the coiled-coil. 
It seems that a HTH motif mimicking the structure of a linker histone facilitates the 
remodeling activity of a pioneer factor. No pioneer factor with a bZIP domain is known, but I 
want to discuss the similarities and differences of a HTH motif and a leucine zipper motif 
compared to the structure of a linker histone to provide a possible explanation and a model for 
BZLF1’s nucleosome-binding activity. 
The HTH motif contains two α-helices connected by a short extended chain of amino acids, 
which constitutes the “turn”. The two helices interact and are held together at a fixed angle. 
The more C-terminal recognition helix fits into the major groove of DNA and its residues 
play an important part in recognizing the specific DNA sequence to which the protein binds. 
In contrast the leucine zipper motif contains two α-helices (one from each monomer), which 
are joined to form a short coiled-coil. The helices are held together by interactions between 
hydrophobic amino acid side chains, primerly leucines. Beyond the dimerization interface the 
two α-helices separate from each other to form a Y-shaped structure allowing their side 
chains to contact the major groove of the DNA molecule. 
Most eukaryotic linker histones H1 share a similar, tripartite structure. A globular domain is 
flanked by a short N-terminal and long C-terminal lysine-rich domain (Kasinsky et al., 2001). 
Linker histones H1 attach close to the entry and exit sites of linker DNA on the nucleosome 
core, bringing together the two linker DNA segments (Allan et al., 1980; Wolffe et al., 1997; 
Thomas, 1999). The globular domain contains a three-helix bundle with structural homology 
to HTH DNA-binding proteins and is essential for binding of H1 with the nucleosome 
(Ramakrishnan et al., 1993). With the help of the highly positively charged C-terminal 
domain, the linker histone H1 binds to linker DNA through nonspecific electrostatic 
interactions (Allan et al., 1980; Allan et al., 1986; Subirana, 1990). 
According to the linker histone H1’s positively charged C-terminus, the viral transcription 
factor BZLF1 could facilitate binding to the linker DNA through its basic bZIP domain. My 
results from the mass spectrometry analysis revealed that the bZIP domain of BZLF1 interacts 
with the linker histone H1.2, which would support the hypothesis that BZLF1 acts on linker 
regions of silenced chromatin. The N- or C-terminal ends of the α-helices of BZLF1’s dimer 
could provide the interaction with the nucleosome. Since the C-terminal tail is known to 
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stabilize the coiled-coil through numerous interactions (Petosa et al., 2006), it could also be 
involved in the binding to the nucleosome. The mass spectrometry data revealed that 
BZLF1’s TAD or C-terminus bind to the histone dimer H2A-H2B supporting the 
hypothesized nucleosome-binding function. My speculations of BZLF1’s binding 
characteristics to nucleosomes have to be structurally verified by approaches such as electron 
microscopy of the BZLF1-mononucleosome complex in the future. 
5.2.2 BZLF1 might read epigenetic modifications in silenced chromatin 
Recent reports support the assumption that pioneer factors can penetrate repressive chromatin 
to recognize and bind their DNA-binding sites and regulate the transcriptional activation of 
the relevant genes. The cell type-specific distribution of the histone marks H3K4me1 and 
H3K4me2 plays an important role in the recruitment of pioneer factors, as they are capable of 
reading them. 
The recruitment of FoxA to enhancers is dependent on epigenetic changes of enhancer 
hallmarks (Serandour et al., 2011). The nucleosome-binding activity of FoxA is facilitated by 
the histone marks H3K4me1 and H3K4me2 but not by histone acetylation (Cirillo and Zaret, 
1999; Lupien et al., 2008). FoxA can even favor H3K4me2 deposition (Smale, 2010). The 
pioneer factor PBX1 is also capable of reading specific epigenetic signatures like H3K4me2 
(Berkes et al., 2004; Magnani et al., 2011), and PU.1 reprograms the chromatin landscape 
through the induced deposition of H3K4me1 (Magnani et al., 2011). 
Summarizing my chromatin immunopecipitation (ChIP) data regarding the histone H3 and its 
N-terminal modifications in latent and lytically induced Raji cells, I speculate that the pioneer 
factor BZLF1 can read and decipher epigenetic modifications and penetrate repressive 
chromatin. Upon lytic reactivation, BZLF1 binds to viral promoters as early as four hours post 
induction (Fig. 4.13 panel A). The nucleosomal loss shown by the decrease of histone H3 in 
the viral promoters appears later about 15 hours post induction (unpublished data of Anne 
Woellmer). During latency, viral lytic genes are repressed by very densely positioned 
nucleosomes and repressive histone marks like H3K27me3 in the promoters of lytic genes 
(Woellmer et al., 2012). Upon lytic phase induction, the repressive histone mark is removed 
as early as seven hours post induction (data not shown) and replaced by active histone marks. 
The activation of viral lytic promoters starts with the establishment of the active histone 
marks H3K4me1 (Fig. 4.13 panel A) and H3K27ac (data not shown) as early as seven hours 
post induction followed by H3K4me3 (unpublished data, Anne Woellmer) about 15 hours 
post induction. One could hypothesize that initially the viral transcription factor BZLF1 reads 
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its target sites in nucleosome-dense and H3K27me3-enriched promoter regions and penetrates 
the repressive chromatin. In a second step, BZLF1 promotes the removal of repressive histone 
marks and the deposition of active histone marks like H3K4me1, H3K27ac and H3K4me3. 
The change of histone modifications increases the accessibility of the viral DNA for the 
transcriptional machinery and enables gene expression of the viral lytic genes. 
5.2.3 BZLF1’ s binding to meZREs in silenced chromatin 
The crystal structure of the nucleosome core particle and all its protein-protein as well as 
protein-DNA interactions has been solved (Luger et al., 1997). A common conserved 
structural motif, termed the histone fold, has been identified in all four core histones (Arents 
and Moudrianakis, 1995). This motif exists also in eukaryotic transcription factors e.g. TFII 
TATA box-binding protein-associated factors (TAF’s) (Xie et al., 1996). In 1.65 turns of a 
left-handed superhelix, DNA is wrapped around the histone octamer, termed the nucleosomal 
DNA. DNA bases that are not directly in contact with the protein guarantee a high degree of 
mobility. In the nucleosome core particle the histone fold dimers of the H3-H4 and H2A-H2B 
pairs mediate the structural unit for the protein-protein and protein-DNA interactions. Each 
histone fold dimer has three independent DNA-binding sites. As a consequence, the histone 
folds are responsible for DNA binding at twelve of the 14 minor groove locations that face the 
histone octamer (Luger and Richmond, 1998). Over 121 bps within the inner face of the DNA 
supercoil establish all the interactions of the histone folds. The 13 bps at each entry and exit 
point of the superhelix are bound by an α-helical histone fold extension of H3 and its N-
terminal tail. Structural variability stems from the regions flanking the histone fold motif. 
Histone-fold extensions form an integral part of the histone octamer and provide specific 
formation of the histone octamer. Histone tails contact the DNA outside of the nucleosome 
core particle contributing to six of the 14 DNA-binding sites (Luger and Richmond, 1998). 
Neighboring nucleosome core particles can make contact via their tails of H3 and H4 (Luger 
et al., 1997). There are 142 hydrogen bond interactions between histone and DNA within the 
14 binding sites. The protein main-chain and the phosphodiester backbone atoms provide the 
first half of these interactions (Luger et al., 1997). Lysine and arginine residues of histones 
maintain the second half. 
The energetic cost of DNA bending into a superhelix must be partially compensated. This is 
done through the neutralization of the phosphate charge by the basic side chains and the N-
termini of α-helices located only on one side of the double helix (Strauss and Maher, 1994). 
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The number and nature of the protein main-chain interactions are very similar in nucleosome 
core particles containing different DNA sequences. The protein main-chain interactions 
dominate the intrinsic sequence variability in the structure of DNA. As a consequence, 
nucleosomes can form independent of the underlying DNA sequence (Luger et al., 1997). 
How the histone octamer positions according to DNA sequence preferences depends on three 
issues. First, the energetic cost that arises of DNA bending at each of the 14 histone contact 
sites. Second, the distortion of the DNA bridging between binding sites that lead to fewer 
direct histone-DNA contacts. Third, the hydrogen bond interactions mediated by side chains 
reaching into the minor groove. 
Recapitulating all my EMSA results, I can postulate that BZLF1 shows pioneer factor activity 
and binds nucleosomal DNA in vitro, even if the ZRE is located in the nucleosomal core 
particle (Fig. 4.7; Fig. 4.11). Nevertheless, it seems that the exact ZRE location within the 
nucleosomal core particle is critical for BZLF1 binding in silenced chromatin (Fig. 4.11). 
Since the 156 bps long DNA templates are longer than the normally 147 bps long 
nucleosomal DNA, the exact nucleosome position within the used DNA templates is 
uncertain. With the help of the nucleosome positioning prediction engine (NuPOP; 
http://nucleosome.stats.northwestern.edu/), I tried to predict the nucleosome occupancy within 
the DNA templates. NuPoP is built upon a duration hidden Markov model, in which the linker 
DNA length is explicitly modeled. The nucleosome or linker DNA state model was chosen as 
a 4th orderMarkov chain (Wang et al., 2008; Xi et al., 2010). 
Table 6.1 Overview of the DNA templates, their ZRE, CpG dinucleotides, and predicted nucleosome 
positions and their BZLF1 binding in my EMSA experiments 
DNA template (156 bps) ZRE position CpG position Nucleosome prediction BZLF1 binding 
Control - - 2-148 No 
ZRE 3 48-56 53-54 6-152 No 
ZRE 4 69-77 74-75 9-155 No 
ZRE 3+4 9-17; 131-139 14-15; 136-137 7-153 Yes 
ZRE 0+4 131-139 136-137 7-153 Reduced 
ZRE 3+0 -5nt 4-12 9-10 6-152 Yes 
ZRE 3+0 9-17 14-15 7-153 Yes 
ZRE 3+0 +5nt 14-22 19-20 7-153 No 
ZRE 3+0 +10nt 19-27 24-25 7-153 No 
ZRE 3+0 +15nt 24-32 29-30 7-153 Yes 
ZRE 3+0 +30nt 39-47 44-45 7-153 Yes 
All mononucleosomal DNA templates used in EMSA experiments were 156 bps long. The precise location of 
ZRE motifs and CpG dinucleotides within the 156 bps are noted. The nucleosome prediction was performed 
using the NuPOP engine. The result of BZLF1 binding in EMSAs is noted. 
Except for the DNA template ZRE 3+0 -5 nt, all ZRE sites seem to be located within the 
nucleosome core particle supporting the findings that BZLF1 does bind to nucleosomal DNA. 
  DISCUSSION  94 
It has been reported that pioneer factors bind their compacted binding sites in the major 
groove, which makes them more accessible for factor binding in the chromatin context. 
Unfortunately, it is not clear from my data, if the ZRE is located in the major or minor groove 
for the access of BZLF1. The analysis of the EMSA data does not show a five-bp-periodicity, 
which would explain the BZLF1 binding constriction for some ZRE locations. Further 
analysis has to clarify these questions. It would be interesting to know, if BZLF1’s binding to 
nucleosomal DNA moves or slides the histone octamer. To address this question further 
EMSA experiments coupled with enzymatic digestion should be performed. In that way the 
sliding process of the histone octamer upon BZLF1 binding could be captured using longer 
multi-nucleosomal DNA templates. 
Additionally, it appears that two ZRE sites in the lytic promoters may have a cooperative or, 
at least, an additive effect for BZLF1’s binding (Fig. 4.10). In contrast to the ZRE template 
ZRE 3+4 with two functional ZRE motifs, the non-functional mutations in the DNA 
templates ZRE 3+0 and ZRE 4+0 resulted in reduced and almost eliminated nucleosome-
binding activity of BZLF1, respectively. It seems that not only the ZRE location within the 
nucleosome core particle but also the number of ZRE’s and probably the distance between 
two ZRE sites play a role in the efficiency of BZLF1’s pioneer factor activity. The promoter 
regions of lytic EBV genes usually contain several ZREs but I could not delineate a clear 
distinct and consensed ZRE spacing, which would underline this hypothesis. 
5.2.4 BZLF1 and its interactions with chromatin regulatory proteins 
The viral transcription factor BZLF1 binds nucleosome-dense regions in the promoter regions 
of viral lytic genes but does not evict nucleosomes. Previous data showed that the 
nucleosomal occupancy of these promoter sites drops later upon lytic induction (Woellmer et 
al., 2012). This let me hypothesize that BZLF1 might recruit chromatin remodelers explaining 
the removal of histones. I addressed this uncertainty with two in vivo approaches: co-
immunoprecipitation and mass spectrometry analysis. 
Since there are four major remodeler families (SWI/SNF, ISWI, INO80 and CHD), I first 
decided to examine the in vivo interactions of BZLF1 using SNF2H of the ISWI family and 
hIno80 of the INO80 family in a candidate approach. The ISWI family is involved in 
chromatin assembly and nucleosomal spacing (Cairns, 2005; Clapier and Cairns, 2009). ISWI 
has been shown to regulate transcription and is involved in DNA replication and chromatin 
assembly. SNF2H has been previously reported to promote herpes simplex virus 1 (HSV-1) 
immediate-early gene expression and replication. SNF2H might also interact with VP16, the 
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cousin of BZLF1 and immediate-early gene product in herpes simplex virus 1 (HSV-1; 
Bryant et al., 2011). The INO80 remodelers are able to slide nucleosomes and exchange 
histones (Shen et al., 2003; Tsukuda et al., 2005; van Attikum et al., 2007). INO80 
remodelers regulate transcription and are involved in DNA repair and cell cycle checkpoint 
adaption. So far there is no report that this chromatin remodeler family plays a role in the 
reactivation process of herpes viruses, but EBV nuclear proteins EBNA-LP and EBNA2 were 
found associated with a INO80 remodeler complex necessary for lymphoblastoid cell line 
growth and survival (Portal et al., 2013). Performing co-immunoprecipitations I could prove 
that BZLF1 interacts with SNF2H (Fig. 4.14 panel A and C) and also with hIno80 (Fig. 4.14 
panel B and C) in two different experimental models and two cell types. In preliminary 
experiments, I could narrow down the responsible domains for the interaction of BZLF1 with 
SNF2H to the N- and C-terminus of BZLF1 (Fig. 4.15 panel B). 
Next, I performed immunoprecipitations followed by mass spectrometry analysis at the ZfP 
(Munich) in order to identify chromatin regulatory factors as BZLF1’s interaction partners. 
The data showed an interaction of BZLF1 with CHD4 and RBBP4, components of the CHD 
family (data see appendix). This family is involved in nucleosome sliding and histone 
deacetylation important for transcriptional regulation (Brehm et al., 2000; Guschin et al., 
2000; Bowen et al., 2004). BZLF1’s TAD, C-terminus or a combination of both mediate the 
interaction of BZLF1 with the components of the CHD remodeler family. I identified yet 
another chromatin regulatory protein as an interaction partner of BZLF1. The nucleosome 
assembly protein 1-like 1 (NP1L1) seems to interact exclusively with the bZIP domain of 
BZLF1 (data see appendix). The histone chaperone NP1L1 stimulates transcription factor 
binding to nucleosomal DNA and histone displacement (Walter et al., 1995). An additional 
report showed that NP1L1 positively contributes to EBV reactivation through the induction of 
BZLF1 expression (Mansouri et al., 2013). 
Summarizing the newly identified interaction partners, it appears that BZLF1 recruits not only 
one but several chromatin regulatory factors to disrupt the nucleosome-dense regions of the 
viral promoters upon lytic reactivation. Interestingly, the C-terminus of BZLF1 seems to play 
a substantial role in this remodeling process. The C-terminal tail folds towards the coiled-coil 
to stabilize it (Petosa et al., 2006). In that way the C-terminus could also contribute to the 
interaction with chromatin remodelers. If confirmed this finding would identify the first 
molecular function of BZLF1’s C-terminus. 
 
6. SUMMARY 
The Epstein-Barr Virus (EBV), a member of the herpes virus family, is a human tumor virus 
that efficiently infects and immortalizes human B cells to yield proliferating B cell lines in 
vitro. Infection is initially non-productive and only after several weeks the infected cells 
support de novo viral synthesis. EBV uses cellular epigenetic processes of the host to 
establish latency in infected B cells and an exceptional mechanism to escape from it. 
Upon infection, the host cell machinery packages the viral DNA in nucleosomal arrays and 
methylates it extensively resulting in silenced viral chromatin in order to maintain the state of 
latent infection. EBV’s transcription factor BZLF1 is crucial and unique in overcoming the 
repressed latent state and inducing epigenetic reprogramming to allow transactivation of all 
viral lytic genes. BZLF1 binds to its preferred target motif, which is a cytosine-methylated 
meZRE sequence embedded in epigenetically silenced heterochromatin, in order to overcome 
transcriptional repression.  
The aim of my PhD thesis was to investigate the molecular mechanisms of the viral 
transcription factor BZLF1 during the process of lytic reactivation. I wanted to address the 
question, if BZLF1 alone is capable of binding nucleosomes to open regulatory regions of 
viral genes, reactivate them and induce the lytic cycle. My results suggested that BZLF1 binds 
in vitro and in vivo to meZRE motifs even if they are embedded in nucleosomes. BZLF1’s 
modular structure supports the access to histone octamers and histone linker regions. The 
transactivation domain and/or the C-terminus of BZLF1 bind the H2A-H2B histone dimer, 
whereas the bZIP domain is capable of binding the linker histone H1.2 and the histone variant 
H3.3. The binding of BZLF1 to nucleosomes does not result in their ejection, but rather
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 BZLF1 recruits cellular chromatin regulatory factors, which open these regions and facilitate 
access of the transcription machinery. With the help of its transactivation domain and/or C-
terminus BZLF1 binds the catalytic subunits of the chromatin remodeler families ISWI, 
INO80 and CHD. In addition, the bZIP domain of BZLF1 provides an interaction with a 
member of the nucleosome assembly protein (NP1L1) family, which might positively regulate 
the viral reactivation process. 
According to my findings, the viral transcription factor BZLF1 can be defined as a pioneer 
factor, it fulfills all peculiar characteristics of this special class of transcription factors. First, 
BZLF1 finds access to its target sites in condensed chromatin prior to other factors binding 
and prior to the time of transcriptional activation. Second, it enables the subsequent binding of 
chromatin modifiers and nucleosome remodelers involved in chromatin reprogramming and 
transcriptional activation. Together with BZLF1, these factors co-operatively contribute to the 
induction of EBV’s lytic phase and promote viral synthesis. The structural details, how the 
transcription factor BZLF1 binds its target sites in condensed chromatin, if it modulates 
nucleosomal positioning and how exactly it interacts with chromatin regulatory factors will be 
of interest in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. ABBREVIATIONS 
α anti (in context of antibody specifity) 
A adenosine (in context of  nucleotides) 
A alanine (in context of amino acids) 
aa amino acid 
ac acetylation 
ad adde 
ACF ATP-utilizing chromatin assembly and remodeling factor 
amp β-lactamase 
AP-1 activator protein 1 
ATF activating transcription factor 
ATP adenosine-5’-triphosphate 
bHLH basic helix-loop-helix 
bp base pair 
BSA bovine serum albumin 
bZIP basic leucine zipper 
C cysteine (in context of amino acids) 
C cytosine (in context of nucleotides) 
C/EBPα CCAAT/enhancer-binding protein alpha 
C-terminus carboxy-terminus 
CBP CREB binding protein 
cDNA complementary DNA 
cen centromer 
CHD chromodomain helicase DNA-binding 
ChIP chromatin immunoprecipitation 
CHRAC chromatin accessibility complex 
chromo chromatin organization modifier 
CMV cytomegalovirus 
coIP co-immunoprecipitation 
Cp crossing point 
CpG cytosine-phosphatidyl-guanosine 
CREB cAMP response element binding protein 
CTCF CCCTC-binding factor 
CV column volume 
CytC cytochrome C 
DBD DNA-binding domain 
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DMEM Dulbecco’s modified eagle medium 
DMSO dimethylsulfoxid 
DNA deoxyribonucleic acid 
DNase  deoxyribonuclease 
dox doxycycline 
DTT dithiothreitol 
E. coli Escherichia coli 
e.g. exempli gratia 
EBER EBV-encoded RNA 
EBNA EBV-encoded nuclear antigen 
EBV Epstein-Barr virus 
ECL enhanced chemiluminescence 
EDTA ethyldiamintetraacetic acid 
eGFP enhanced green fluorescent protein 
EGTA ethylene glycol tetraacetic acid 
EMSA electromobility shift assay 
ERα estrogen receptor alpha 
et al. et alii 
ETS E-twenty-six 
F farad 
FBS fetal bovine serum 
Fig.  figure 
g gram 
G guanosine (in context of nucleotides) 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GFP green fluorescent protein 
h hour 
H2A histone H2A 
H2AX histone H2AX 
H2A.Z histone H2A.Z 
H2B histone H2B 
H2O water 
H3 histone H3 
H3ac acteylated histone H3 
H3K9ac acteylated histone H3 at lysine 9 
H3K9me1 monomethylated histone H3 at lysine 9 
H3K27 histone H3 lysine 27 
H3K27ac acteylated histone H3 at lysine 27 
H3K27me2me3 di/trimethylated histone H3 at lysine 27 
H3K27me3 trimethylated histone H3 at lysine 27 
H3K36me3 trimethylated histone H3 at lysine 36 
H3K4 histone H3 lysine 4 
H3K4me1 monomethylated histone H3 at lysine 4 
H3K4me2 dimethylated histone H3 at lysine 4 
H3K4me3 trimethylated histone H3 at lysine 4 
H3K79me2 dimethylated histone H3 at lysine 79 
H3K9 histone H3 lysine 9 
H3K9me2 dimethylated histone H3 at lysine 9 
H3K9me3 trimethylated histone H3 at lysine 9 
H4 histone H4 
H4K16ac acteylated histone H4 at lysine 16 
H4K20me1 monomethylated histone H4 at lysine 20 
H4K20me3 trimethylated histone H4 at lysine 20 
HAT histone acetyltransferase 
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HDAC histone deacetylase 
HEK293 human embryonic kidney 293 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HP1 heterochromatin protein 1 
HSA helicase/SANT-associated 
HRP horseradish peroxidase 
HSV-1 herpes simplex virus 1 
HTH helix-turn-helix 
i.e. id est 
IgG immune globuline G 
INO80 inositol requiring 80 
IRES internal ribosomal entry site 
ISWI imitation switch 
JDP2 Jun dimerization protein 2 
K lysine (in context of amino acids) 
KD equilibrium dissociation constant 
kDa kilo dalton 
l litre 
LB Luria broth 
LCL lymphoblastoid cell line 
LC-MS/MS liquid chromatography tandem mass spectrometry 
LMP latent membrane protein 
M molar 
MACS magnetic activated cell sorting 
MBD methyl-CpG binding domain 
me methylation 
meZRE methylated BZLF1 responsive element 
min minute 
mM millimolar 
mRNA messenger RNA 
MTA metastasis associated 
ng nanogram 
nm nanometre 
nmol nanomole 
NFΚB nuclear factor „kappa-light-chain-enhancer“ of activated B cells 
NoRC nucleolar remodeling complex 
NP1L1 nucleosome assembly protein 1-like 1 
nt nucleotide 
N-terminus amino-terminus 
NuPOP nuclesosome positioning prediction 
NURF nucleosome remodeling factor 
ori prokaryotic origin of replication 
oriP origin of plasmid replication 
PAA polyacrylamide 
Pax paired box protein 
PBS phosphate buffered saline 
PBX1 pre-B cell leukemia homeobox 1 
PCR polymerase chain reaction 
PEI polyethylenimine 
PHD plant homeodomain 
PHO phosphate metabolism 
PKC protein kinase C 
PML promyelocytic leukemia protein 
PMSF phenylmethanesulfonylfluoride 
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PNK polynucleotide kinase 
puro puromycin N-acetyl-transferase 
qPCR quantitative PCR 
R arginine (in context of amino acids) 
RbAp retinoblastoma associated protein 
RNA ribonucleic acid 
RNA Pol II RNA polymerase II 
rpm rounds per minute 
RPMI Roswell Park Memorial Institute 
RT room temperature 
RT-PCR reverse transcriptase PCR 
S serine (in context of amino acids) 
SDS sodium dodecyl sulfate 
SDS-PAGE SDS polyacrylamide gel electrophoresis 
sec second 
SUMO small ubiquitin-like modifier 
SWI/SNF switch/sucrose nonfermentable 
T threonine (in context of amino acids) 
T thymine (in context of nucleotides) 
TAD transactivation domain 
TALE three amino acid loop extension 
TBE buffer containing Tris base, boricacid and EDTA 
TBP TATA box binding protein 
TEMED tetramethylendiamine 
tet ten-eleven translocation proteins 
tNGF-R truncated nerve growth factor-receptor 
TORC transducer of regulated CREB activity 
Tris 2-amino-2-hydroxymethyl-propane-1,3-diol 
TSS transcription start site 
U units 
UV ultra violett 
V volt 
WB western blot 
WD tryptophan/aspartic acid 
w/v weight per volume 
ZEB zinc finger E-box-binding homeobox 
ZRE BZLF1 responsive element 
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9. APPENDIX 
9.1 Oligonucleotides 
9.1.1 RT-PCR primer 
Tab. A1 Primer pairs for reverse transcript PCR (RT-PCR) 
Locus Forward Primer Reverse Primer 
BZLF1 GGTTTCCGTGTGCGTCGTG AGCCTGCTCCTGAGAATGCTT 
BMRF1 TTGAGGTTTTACAGGTCTGGCATC GGTGGCGGAGGTGAAGGAG 
BNLF2a TGCTGACGTCTGGGTCCT TGCTTTGCTAGAGCAGCAGT 
BRLF1 CCTGTCTTGGACGAGACCAT AAGGCCTCCTAAGCTCCAAG 
BBLF4 GTCCTCCGTGGCTAAAAGCG CAAGACCAAAAAGTCCATCTG 
BcLF1 CCTCCCTGACCGTTCCCAG GCAGTTTGAGACCGCCACATC 
CytC CAATGCTCCGTTGTTGGCAG  CCTGGTGGGCGTGTGCTAC 
9.1.2 qPCR primer 
Tab. A2 Primer pairs for quantitative PCR (qPCR) analysis 
Locus Forward Primer Reverse Primer 
cen AAGGTCAATGGCAGAAAAGGA CAACGAAGGCCACAAGATGTC 
GAPDH  CCCCGGTTTCTATAAATTGAGC GGCTGACTGTCGAACAGGA 
EBER CGCTACATCAAACAGGACAGC AGCCGAATACCCTTCTCCCAG 
Q/F TGTCACCACCTCCCTGATAATGTC CATACACCGTGCGAAAAGAAGC 
BRLF1 CCGGCTGACATGGATTACTGG AGGAACCAAAATAACCGAGCCTC 
BZLF1 GGTGCAATGTTTAGTGAGTTACCTGTC TGACACCAGCTTATTTTAGACACTTCTG 
BMRF1 CACACCACCCCCCAAGGAC GCAGCAGCAGAAGCCAACG 
BBLF4 GAGGCAGGTGTTTACCCATTTG CAGGTCACGCACGGTCAGC 
BSRF1 CCAAAAATAGTAAGCAGCCGTGA GAAACAGCCACAGGGGGATG 
BcLF1  AATCAAATGGTTGGACACGGC TCAGGGTGGGCAGAGGACC 
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9.1.3 EMSA DNA template primer 
Tab. A3 Primer pairs for EMSA DNA templates generation by common, mutagenesis and nucleotide shift 
PCR 
Locus Forward Primer Reverse Primer 
BRLF1 ZRE 0 
Asp718 
GGTACCGGTCTCTCATCGCTC GGTACCAGAGGCCAGGGCCGA 
BBLF4 ZRE 3 
Asp718 
GGTACCAAGTTCGAGGCCTGC GGTACCGCTGTGTAGCACTCG 
BBLF4 ZRE 3+4 
Asp718 
GGTACCGACTCGTGTGCGAGC GGTACCGATCCAGTCCACATA 
BBLF4 ZRE 4 
Asp718 
GGTACCGACCGTGCGTGACCT GGTACCATCTTGGAGTGGAGC 
BBLF4 ZRE 0+4 
Asp718 
P-ATACACGAGTCGGTACCATCT CAGCCGGTTTCGTGAGTCCAC 
BBLF4 ZRE 3+0 
Asp718 
P-ATTCATAGGAGAGCACGGAGC CTTATGTGGACTGGATCGGTA 
BBLF4 ZRE 3+0  
-5 nt Asp718 
GGTACCGTGTGCGAGATCAGCCGGTTTC
GTGAGTCCACCTTC 
GGTACCGATCCAGTCCACATAAGAT
TC 
BBLF4 ZRE 3+0 
+5 nt Asp718 
GGTACCGACTCGTGTAGTGTGCGAGTTC
GTGAGTCCACCTTCGAG 
GGTACCGATCCAGTCCACATAAGAT
TC 
BBLF4 ZRE 3+0 
+10 nt Asp718 
GGTACCGACTCGTGTATCAGCGTGTGCG
AGGAGTCCACCTTCGAGTCGTG 
GGTACCGATCCAGTCCACATAAGAT
TC 
BBLF4 ZRE 3+0 
+15 nt Asp718 
GGTACCGACTCGTGTATCAGCCGGTTGT
GTGCGAGCACCTTCGAGTCGTGGTCCAC 
GGTACCGATCCAGTCCACATAAGAT
TC 
BBLF4 ZRE 3+0  
+30 nt Asp718 
GGTACCGACTCGTGTATCAGCCGGTTTC
GTGAGTCCACCTTGTGTGCGAGGTCCAC
GACCATGAAGCTGAC 
GGTACCGATCCAGTCCACATAAGAT
TC 
9.2 Sequences of EMSA DNA templates (156 bps long) 
Control: 
ACCGGTCTCTCATCGCTCTCTTGGTGGACCGCTGCTATCCAAGGCTGTTCAGGTTC
CGCCGCGTTGGAAGGACATGGAGTTTGACCACGGTTGGGCCTGGATGTCCGGCGC
GACTTTGGGGCCCGCAGGCGCGGGGCCTCGGCCCTGGCCTCTGGT 
BBLF4 ZRE 3: 
ACCAAGTTCGAGGCCTGCATCCAGAAGCGATGGCCGAGCGATGACTCgtgtgcgagCC
GGTTTCGTGAGTCCACCTTCGAGTCGTGGTCCACGACCATGAAGCTGACCGTGCG
TGACCTGCTGACCACCAACATCTACCGAGTGCTACACAGCGGT 
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BBLF4 ZRE 3+4: 
ACCGACTCgtgtgcgagCCGGTTTCGTGAGTCCACCTTCGAGTCGTGGTCCACGACCAT
GAAGCTGACCGTGCGTGACCTGCTGACCACCAACATCTACCGAGTGCTACACAGC
CGCTCCGTGCTCTCCTatgagcgttATGTGGACTGGATCGGT 
BBLF4 ZRE 4: 
ACCGACCGTGCGTGACCTGCTGACCACCAACATCTACCGAGTGCTACACAGCCGC
TCCGTGCTCTCCTatgagcgttATGTGGACTGGATCTGCGCCACCGGCATGGTGCCCGC
CGTTAAGAAGCCCATAACCCAAGAGCTCCACTCCAAGATGGT 
BBLF4 ZRE 0+4: 
ACCGACTCgtgtatcagCCGGTTTCGTGAGTCCACCTTCGAGTCGTGGTCCACGACCAT
GAAGCTGACCGTGCGTGACCTGCTGACCACCAACATCTACCGAGTGCTACACAGC
CGCTCCGTGCTCTCCTatgagcgttATGTGGACTGGATCGGT 
BBLF4 ZRE 3+0: 
ACCGACTCgtgtgcgagCCGGTTTCGTGAGTCCACCTTCGAGTCGTGGTCCACGACCAT
GAAGCTGACCGTGCGTGACCTGCTGACCACCAACATCTACCGAGTGCTACACAGC
CGCTCCGTGCTCTCCTatgaatcttATGTGGACTGGATCGGT 
BBLF4 ZRE 3+0 -5nt: 
ACCgtgtgcgagATCAGCCGGTTTCGTGAGTCCACCTTCGAGTCGTGGTCCACGACCA
TGAAGCTGACCGTGCGTGACCTGCTGACCACCAACATCTACCGAGTGCTACACAG
CCGCTCCGTGCTCTCCTatgaatcttATGTGGACTGGATCGGT 
BBLF4 ZRE 3+0 +5nt: 
ACCGACTCGTGTAgtgtgcgagTTCGTGAGTCCACCTTCGAGTCGTGGTCCACGACCAT
GAAGCTGACCGTGCGTGACCTGCTGACCACCAACATCTACCGAGTGCTACACAGC
CGCTCCGTGCTCTCCTatgaatcttATGTGGACTGGATCGGT 
BBLF4 ZRE 3+0 +10nt: 
ACCGACTCGTGTATCAGCgtgtgcgagGAGTCCACCTTCGAGTCGTGGTCCACGACCA
TGAAGCTGACCGTGCGTGACCTGCTGACCACCAACATCTACCGAGTGCTACACAG
CCGCTCCGTGCTCTCCTatgaatcttATGTGGACTGGATCGGT 
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BBLF4 ZRE 3+0 +15nt: 
ACCGACTCGTGTATCAGCCGGTTgtgtgcgagCACCTTCGAGTCGTGGTCCACGACCA
TGAAGCTGACCGTGCGTGACCTGCTGACCACCAACATCTACCGAGTGCTACACAG
CCGCTCCGTGCTCTCCTatgaatcttATGTGGACTGGATCGGT 
BBLF4 ZRE 3+0 +30nt: 
ACCGACTCGTGTATCAGCCGGTTTCGTGAGTCCACCTTgtgtgcgagGTCCACGACCAT
GAAGCTGACCGTGCGTGACCTGCTGACCACCAACATCTACCGAGTGCTACACAGC
CGCTCCGTGCTCTCCTatgaatcttATGTGGACTGGATCGGT 
9.3 (Re)ChIP qPCR triplicates 
BZLF1 ChIPs: 
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RNA polymerase II ChIPs: 
 
H3 ChIPs: 
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H3K27me2me2 ChIPs: 
 
H3K4me1 ChIPs: 
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H3ac ChIPs: 
 
H3K27ac ChIPs: 
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BZLF1 time kinetic ChIPs: 
 
H3K4me1 time kinetic ChIPs: 
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BZLF1+H3K4me1 time kinetic ReChIPs: 
 
H3K4me1+BZLF1 time kinetic ReChIPs: 
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9.4 Mass spectrometry analysis (data tables) 
Viral interaction partners of BZLF1: 
Tab. A4 BZLF1_5693_minus_5694 
prot_acc BZLF1_5693_minus_5694_prot_desc highest_mean 
EAD_EBVG DNA polymerase processivity factor BMRF1 OS=Epstein-Barr virus (strain 
GD1) GN=BMRF1 PE=3 SV=1 
401,5 
DPOL_EBVG DNA polymerase catalytic subunit OS=Epstein-Barr virus (strain GD1) 
GN=BALF5 PE=3 SV=1 
162,0 
KITH_EBVG Thymidine kinase OS=Epstein-Barr virus (strain GD1) GN=TK PE=1 SV=1 100,0 
EB2_EBVA8 mRNA export factor EB2 OS=Epstein-Barr virus (strain AG876) 
GN=BSLF2 PE=3 SV=1 
96,0 
HSP70_MIMIV Heat shock 70 kDa protein homolog OS=Acanthamoeba polyphaga 
mimivirus GN=HSP70 PE=3 SV=1 
78,5 
RDRP_PRV RNA-directed RNA polymerase OS=Pieris rapae virus PE=3 SV=1 66,0 
CASPD_HPVKA Capsid protein OS=High plains virus (isolate Kansas 2004) PE=1 SV=2 52,5 
Y094_OSHVF Uncharacterized protein ORF94 OS=Ostreid herpesvirus 1 (isolate France) 
GN=ORF94 PE=4 SV=1 
51,0 
VP6_ROTHC Intermediate capsid protein VP6 OS=Rotavirus C (isolate Human/United 
Kingdom/Bristol/1989) PE=2 SV=1 
49,0 
VF706_ASFB7 Putative ATP-dependent RNA helicase Q706L OS=African swine fever 
virus (strain Badajoz 1971 Vero-adapted) GN=Ba71V-122 PE=3 SV=1 
48,5 
PB2_I97A0 Polymerase basic protein 2 (Fragment) OS=Influenza A virus (strain 
A/Chicken/Hong Kong/220/1997 H5N1 genotype Gs/Gd) GN=PB2 PE=3 
SV=1 
47,0 
POL_CERV Enzymatic polyprotein OS=Carnation etched ring virus GN=ORF V PE=3 
SV=1 
44,0 
U79_HHV7J Protein U79 OS=Human herpesvirus 7 (strain JI) GN=U79 PE=3 SV=1 43,0 
POLG_YEFV8 Genome polyprotein (Fragment) OS=Yellow fever virus (isolate 
Peru/1899/1981) PE=3 SV=1 
40,5 
POLG_YEFVA Genome polyprotein OS=Yellow fever virus (strain Ghana/Asibi/1927) 
PE=1 SV=1 
38,0 
RDRP_ROTGI RNA-directed RNA polymerase OS=Rotavirus B (isolate Rat/United 
States/IDIR/1984) PE=3 SV=1 
37,0 
YORF1_NORAV Uncharacterized ORF1 protein OS=Nora virus GN=ORF1 PE=4 SV=1 36,5 
RPOA_PRRSL Replicase polyprotein 1ab OS=Porcine reproductive and respiratory 
syndrome virus (strain Lelystad) GN=rep PE=1 SV=3 
36,0 
VP4_ROTF1 Outer capsid protein VP4 OS=Rotavirus A (isolate Cat/Japan/FRV-1/1986 
G3-P3[9]-Ix-Rx-Cx-Mx-Ax-Nx-Tx-E3-Hx) PE=2 SV=1 
34,5 
SUNT_BPSPB Sublancin-168-processing and transport ATP-binding protein sunT 
OS=Bacillus phage SPbeta GN=sunT PE=3 SV=1 
34,0 
INTG_SSV1 Probable integrase OS=Sulfolobus virus-like particle SSV1 GN=d335 PE=3 
SV=1 
33,5 
VA51_VACCA Protein A51 OS=Vaccinia virus (strain Ankara) GN=MVA164R PE=3 
SV=1 
33,5 
Y014_AMEPV Uncharacterized leucine-rich repeat-containing protein AMV014/Q3 
OS=Amsacta moorei entomopoxvirus GN=AMV014 PE=4 SV=2 
33,5 
LT_POVMA Large T antigen OS=Murine polyomavirus (strain A2) PE=3 SV=1 29,5 
VF358_IIV6 Uncharacterized protein 358L OS=Invertebrate iridescent virus 6 GN=IIV6-
358L PE=3 SV=1 
28,0 
VF113_ASFK5 Putative ATP-dependent RNA helicase D1133L OS=African swine fever 
virus (isolate Pig/Kenya/KEN-50/1950) GN=Ken-118 PE=3 SV=1 
27,0 
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Tab. A5 BZLF1_5694_minus_5693 
prot_acc BZLF1_5694_minus_5693_prot_desc highest_mean 
U17_HHV6U Protein U17 OS=Human herpesvirus 6A (strain Uganda-1102) 
GN=U17/U16 PE=4 SV=1 
65,5 
POLG_RTSVA Genome polyprotein OS=Rice tungro spherical virus (strain A) PE=1 
SV=1 
52,5 
POLG_RTSVT Genome polyprotein OS=Rice tungro spherical virus (strain Vt6) PE=1 
SV=1 
52,5 
NCAP_CVMDV Nucleoprotein OS=Murine coronavirus (strain DVIM) GN=N PE=3 SV=1 46,0 
L_PIRVV RNA-directed RNA polymerase L OS=Pirital virus (isolate 
Rat/Venezuela/VAV-488/1995) GN=L PE=3 SV=1 
44,5 
IBMP_CERV Transactivator/viroplasmin protein OS=Carnation etched ring virus 
GN=ORF VI PE=3 SV=1 
44,0 
L_HENDH RNA-directed RNA polymerase L OS=Hendra virus (isolate 
Horse/Autralia/Hendra/1994) GN=L PE=3 SV=2 
44,0 
1A_BBMV Replication protein 1a OS=Broad bean mottle virus GN=ORF1a PE=3 
SV=1 
43,0 
VGLC_GAHVB Secretory glycoprotein GP57-65 OS=Gallid herpesvirus 2 (strain bc-1) 
GN=GA PE=3 SV=1 
39,5 
L_HRSVB RNA-directed RNA polymerase L OS=Human respiratory syncytial virus 
B (strain B1) GN=L PE=3 SV=1 
38,0 
YR508_MIMIV Putative SWIB domain-containing protein R508 OS=Acanthamoeba 
polyphaga mimivirus GN=MIMI_R508 PE=4 SV=1 
37,5 
Z_JUNIN RING finger protein Z OS=Junin arenavirus GN=Z PE=3 SV=1 37,5 
VA51_VACCW Protein A51 OS=Vaccinia virus (strain Western Reserve) 
GN=VACWR177 PE=3 SV=1 
37,0 
VP4B_FOWPV Major core protein P4b OS=Fowlpox virus GN=FPV167 PE=3 SV=1 36,5 
VP2_BTV3V Outer capsid protein VP2 OS=Bluetongue virus 3 (isolate South Africa 
vaccine) GN=S2 PE=3 SV=1 
36,0 
PHOSP_CDVO Phosphoprotein OS=Canine distemper virus (strain Onderstepoort) 
GN=P/V PE=3 SV=1 
35,0 
PHOSP_PHODV Phosphoprotein OS=Phocine distemper virus GN=P/V PE=2 SV=1 35,0 
POL1_GCMV RNA1 polyprotein OS=Grapevine chrome mosaic virus PE=3 SV=1 34,5 
TOP2_MIMIV DNA topoisomerase 2 OS=Acanthamoeba polyphaga mimivirus 
GN=TOP2 PE=3 SV=1 
33,5 
VP5_BTV1A Outer capsid protein VP5 OS=Bluetongue virus 1 (isolate Australia) 
GN=S6 PE=3 SV=1 
32,5 
DPOL_ADE40 DNA polymerase OS=Human adenovirus F serotype 40 GN=POL PE=3 
SV=1 
32,0 
DEN_EBVG Deneddylase BPLF1 OS=Epstein-Barr virus (strain GD1) GN=BPLF1 
PE=3 SV=1 
30,5 
R1AB_CVBM Replicase polyprotein 1ab OS=Bovine coronavirus (strain Mebus) GN=rep 
PE=3 SV=1 
28,0 
GAG_FUJSV Gag polyprotein OS=Fujinami sarcoma virus GN=gag PE=4 SV=1 26,5 
POL_RSVP Gag-Pro-Pol polyprotein OS=Rous sarcoma virus (strain Prague C) 
GN=gag-pro-pol PE=1 SV=2 
26,5 
POLG_BSTV1 Genome polyprotein OS=Brome streak virus (strain 11-Cal) PE=3 SV=1 22,5 
TEGU_HHV7J Large tegument protein OS=Human herpesvirus 7 (strain JI) GN=U31 
PE=3 SV=1 
21,5 
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Tab. A6 BZLF1_5693_intersect_5694 
prot_acc BZLF1_5694_intersect_5693_prot_desc_only highest_mean 
BZLF1_EBVB9 Trans-activator protein BZLF1 OS=Epstein-Barr virus (strain B95-8) 
GN=BZLF1 PE=1 SV=2 
810,5 
FGR_FSVGR Tyrosine-protein kinase transforming protein Fgr OS=Feline sarcoma virus 
(strain Gardner-Rasheed) GN=V-FGR PE=3 SV=1 
259,0 
VE6_HPV41 Protein E6 OS=Human papillomavirus type 41 GN=E6 PE=3 SV=1 40,5 
YL630_MIMIV Uncharacterized protein L630 OS=Acanthamoeba polyphaga mimivirus 
GN=MIMI_L630 PE=4 SV=1 
40,5 
084L_IIV6 Uncharacterized protein 084L OS=Invertebrate iridescent virus 6 GN=IIV6-
084L PE=4 SV=1 
36,5 
VF030_IIV6 Uncharacterized protein 030L OS=Invertebrate iridescent virus 6 GN=IIV6-
030L PE=3 SV=1 
36,0 
RPO1_VACCA DNA-directed RNA polymerase 147 kDa polypeptide OS=Vaccinia virus 
(strain Ankara) GN=RPO147 PE=4 SV=1 
35,0 
NSP1_ROTHL Non-structural protein 1 OS=Rotavirus A (strain 
Human/Philippines/L26/1987 G12-P1B[4]-I2-R2-C2-M1/M2-A2-N1-T2-
E2-H1) PE=3 SV=1 
33,5 
36011_ASFK5 Protein MGF 360-11L OS=African swine fever virus (isolate 
Pig/Kenya/KEN-50/1950) GN=Ken-034 PE=3 SV=1 
32,0 
VP3_ROTHC Protein VP3 OS=Rotavirus C (isolate Human/United 
Kingdom/Bristol/1989) PE=2 SV=1 
31,5 
ICP22_HHV11 Transcriptional regulator ICP22 OS=Human herpesvirus 1 (strain 17) 
GN=US1 PE=1 SV=1 
27,5 
VG51_ICHVA Putative membrane protein ORF51 OS=Ictalurid herpesvirus 1 (strain 
Auburn) GN=ORF51 PE=4 SV=1 
27,5 
 
Cellular interaction partners of BZLF1: 
Tab. A7 BZLF1_5693_minus_5694 
prot_acc BZLF1_5693_minus_5694_prot_desc highest_mean 
TBA1A_HUMAN Tubulin alpha-1A chain OS=Homo sapiens GN=TUBA1A PE=1 SV=1 617,0 
MCCA_HUMAN Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial 
OS=Homo sapiens GN=MCCC1 PE=1 SV=3 
402,0 
HS71L_HUMAN Heat shock 70 kDa protein 1-like OS=Homo sapiens GN=HSPA1L PE=1 
SV=2 
397,5 
H2B1C_HUMAN Histone H2B type 1-C/E/F/G/I OS=Homo sapiens GN=HIST1H2BC 
PE=1 SV=4 
364,0 
TBA8_HUMAN Tubulin alpha-8 chain OS=Homo sapiens GN=TUBA8 PE=1 SV=1 312,5 
HNRH2_HUMAN Heterogeneous nuclear ribonucleoprotein H2 OS=Homo sapiens 
GN=HNRNPH2 PE=1 SV=1 
231,0 
ILF2_HUMAN Interleukin enhancer-binding factor 2 OS=Homo sapiens GN=ILF2 PE=1 
SV=2 
224,5 
MCCB_HUMAN Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial OS=Homo 
sapiens GN=MCCC2 PE=1 SV=1 
223,5 
K1C9_HUMAN Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 213,5 
HNRPF_HUMAN Heterogeneous nuclear ribonucleoprotein F OS=Homo sapiens 
GN=HNRNPF PE=1 SV=3 
202,0 
CH60_HUMAN 60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 
PE=1 SV=2 
161,5 
H2A1D_HUMAN Histone H2A type 1-D OS=Homo sapiens GN=HIST1H2AD PE=1 SV=2 160,5 
TERA_HUMAN Transitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP 
PE=1 SV=4 
158,0 
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GRPE1_HUMAN GrpE protein homolog 1, mitochondrial OS=Homo sapiens GN=GRPEL1 
PE=1 SV=2 
151,5 
RNPS1_HUMAN RNA-binding protein with serine-rich domain 1 OS=Homo sapiens 
GN=RNPS1 PE=1 SV=1 
136,0 
GRP75_HUMAN Stress-70 protein, mitochondrial OS=Homo sapiens GN=HSPA9 PE=1 
SV=2 
128,5 
LRC59_HUMAN Leucine-rich repeat-containing protein 59 OS=Homo sapiens 
GN=LRRC59 PE=1 SV=1 
115,0 
RBM33_HUMAN RNA-binding protein 33 OS=Homo sapiens GN=RBM33 PE=1 SV=3 109,0 
RLA0L_HUMAN 60S acidic ribosomal protein P0-like OS=Homo sapiens GN=RPLP0P6 
PE=5 SV=1 
102,5 
CALX_HUMAN Calnexin OS=Homo sapiens GN=CANX PE=1 SV=2 101,5 
TCOF_HUMAN Treacle protein OS=Homo sapiens GN=TCOF1 PE=1 SV=3 99,5 
PCBP1_HUMAN Poly(rC)-binding protein 1 OS=Homo sapiens GN=PCBP1 PE=1 SV=2 96,5 
RBBP4_HUMAN Histone-binding protein RBBP4 OS=Homo sapiens GN=RBBP4 PE=1 
SV=3 
95,5 
RBM39_HUMAN RNA-binding protein 39 OS=Homo sapiens GN=RBM39 PE=1 SV=2 93,0 
BCLF1_HUMAN Bcl-2-associated transcription factor 1 OS=Homo sapiens GN=BCLAF1 
PE=1 SV=2 
75,5 
TFAM_HUMAN Transcription factor A, mitochondrial OS=Homo sapiens GN=TFAM 
PE=1 SV=1 
75,0 
RSMB_HUMAN Small nuclear ribonucleoprotein-associated proteins B and B~ OS=Homo 
sapiens GN=SNRPB PE=1 SV=2 
73,5 
ERH_HUMAN Enhancer of rudimentary homolog OS=Homo sapiens GN=ERH PE=1 
SV=1 
72,5 
K2C8_HUMAN Keratin, type II cytoskeletal 8 OS=Homo sapiens GN=KRT8 PE=1 SV=7 71,0 
ELAV1_HUMAN ELAV-like protein 1 OS=Homo sapiens GN=ELAVL1 PE=1 SV=2 70,0 
PIMT_HUMAN Protein-L-isoaspartate(D-aspartate) O-methyltransferase OS=Homo 
sapiens GN=PCMT1 PE=1 SV=4 
68,0 
XPO2_HUMAN Exportin-2 OS=Homo sapiens GN=CSE1L PE=1 SV=3 68,0 
LRC53_HUMAN Leucine-rich repeat-containing protein 53 OS=Homo sapiens 
GN=LRRC53 PE=4 SV=2 
64,5 
PTPRK_HUMAN Receptor-type tyrosine-protein phosphatase kappa OS=Homo sapiens 
GN=PTPRK PE=1 SV=2 
62,0 
F1892_HUMAN Protein FAM189A2 OS=Homo sapiens GN=FAM189A2 PE=2 SV=3 57,5 
NEK10_HUMAN Serine/threonine-protein kinase Nek10 OS=Homo sapiens GN=NEK10 
PE=2 SV=2 
57,5 
CBLN4_HUMAN Cerebellin-4 OS=Homo sapiens GN=CBLN4 PE=1 SV=1 55,5 
CHD4_HUMAN Chromodomain-helicase-DNA-binding protein 4 OS=Homo sapiens 
GN=CHD4 PE=1 SV=2 
55,5 
SRRM2_HUMAN Serine/arginine repetitive matrix protein 2 OS=Homo sapiens 
GN=SRRM2 PE=1 SV=2 
53,5 
BZW2_HUMAN Basic leucine zipper and W2 domain-containing protein 2 OS=Homo 
sapiens GN=BZW2 PE=1 SV=1 
53,0 
TMEDA_HUMAN Transmembrane emp24 domain-containing protein 10 OS=Homo sapiens 
GN=TMED10 PE=1 SV=2 
52,0 
CALCA_HUMAN Calcitonin gene-related peptide 1 OS=Homo sapiens GN=CALCA PE=1 
SV=3 
49,5 
CU129_HUMAN Uncharacterized protein C21orf129 OS=Homo sapiens GN=C21orf129 
PE=2 SV=2 
49,5 
MINA_HUMAN MYC-induced nuclear antigen OS=Homo sapiens GN=MINA PE=1 
SV=1 
49,5 
RUXF_HUMAN Small nuclear ribonucleoprotein F OS=Homo sapiens GN=SNRPF PE=1 
SV=1 
49,5 
ZBED1_HUMAN Zinc finger BED domain-containing protein 1 OS=Homo sapiens 
GN=ZBED1 PE=1 SV=1 
46,5 
SNUT1_HUMAN U4/U6.U5 tri-snRNP-associated protein 1 OS=Homo sapiens GN=SART1 
PE=1 SV=1 
45,0 
COQ6_HUMAN Ubiquinone biosynthesis monooxygenase COQ6 OS=Homo sapiens 
GN=COQ6 PE=1 SV=2 
44,5 
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PRDX1_HUMAN Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 44,0 
RAB7A_HUMAN Ras-related protein Rab-7a OS=Homo sapiens GN=RAB7A PE=1 SV=1 44,0 
FEN1_HUMAN Flap endonuclease 1 OS=Homo sapiens GN=FEN1 PE=1 SV=1 41,5 
DKC1_HUMAN H/ACA ribonucleoprotein complex subunit 4 OS=Homo sapiens 
GN=DKC1 PE=1 SV=3 
40,5 
DYH11_HUMAN Dynein heavy chain 11, axonemal OS=Homo sapiens GN=DNAH11 
PE=1 SV=3 
40,5 
KDSR_HUMAN 3-ketodihydrosphingosine reductase OS=Homo sapiens GN=KDSR PE=1 
SV=1 
40,5 
RHES_HUMAN GTP-binding protein Rhes OS=Homo sapiens GN=RASD2 PE=1 SV=1 39,5 
YB052_HUMAN Putative uncharacterized protein LOC100130201 OS=Homo sapiens 
PE=5 SV=1 
39,5 
EST3_HUMAN Carboxylesterase 3 OS=Homo sapiens GN=CES3 PE=1 SV=1 39,0 
MOS_HUMAN Proto-oncogene serine/threonine-protein kinase mos OS=Homo sapiens 
GN=MOS PE=1 SV=1 
38,5 
GPR62_HUMAN Probable G-protein coupled receptor 62 OS=Homo sapiens GN=GPR62 
PE=2 SV=2 
37,0 
SYNE1_HUMAN Nesprin-1 OS=Homo sapiens GN=SYNE1 PE=1 SV=3 37,0 
CN102_HUMAN UPF0614 protein C14orf102 OS=Homo sapiens GN=C14orf102 PE=1 
SV=3 
36,5 
SAFB1_HUMAN Scaffold attachment factor B1 OS=Homo sapiens GN=SAFB PE=1 SV=4 36,0 
TTC5_HUMAN Tetratricopeptide repeat protein 5 OS=Homo sapiens GN=TTC5 PE=1 
SV=2 
35,5 
CV031_HUMAN Uncharacterized protein C22orf31 OS=Homo sapiens GN=C22orf31 
PE=2 SV=1 
35,0 
RBM3_HUMAN Putative RNA-binding protein 3 OS=Homo sapiens GN=RBM3 PE=1 
SV=1 
30,0 
 
Tab. A8 BZLF1_5694_minus_5693 
prot_acc BZLF1_5694_minus_5693_prot_desc highest_mean 
TBA1B_HUMAN Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 721,0 
NP1L1_HUMAN Nucleosome assembly protein 1-like 1 OS=Homo sapiens GN=NAP1L1 
PE=1 SV=1 
502,0 
RL12_HUMAN 60S ribosomal protein L12 OS=Homo sapiens GN=RPL12 PE=1 SV=1 380,5 
RLA0_HUMAN 60S acidic ribosomal protein P0 OS=Homo sapiens GN=RPLP0 PE=1 
SV=1 
357,5 
RL22_HUMAN 60S ribosomal protein L22 OS=Homo sapiens GN=RPL22 PE=1 SV=2 345,5 
RLA2_HUMAN 60S acidic ribosomal protein P2 OS=Homo sapiens GN=RPLP2 PE=1 
SV=1 
323,0 
TBB2C_HUMAN Tubulin beta-2C chain OS=Homo sapiens GN=TUBB2C PE=1 SV=1 288,0 
RS9_HUMAN 40S ribosomal protein S9 OS=Homo sapiens GN=RPS9 PE=1 SV=3 280,5 
PTBP1_HUMAN Polypyrimidine tract-binding protein 1 OS=Homo sapiens GN=PTBP1 
PE=1 SV=1 
262,5 
G3BP1_HUMAN Ras GTPase-activating protein-binding protein 1 OS=Homo sapiens 
GN=G3BP1 PE=1 SV=1 
201,0 
RL36_HUMAN 60S ribosomal protein L36 OS=Homo sapiens GN=RPL36 PE=1 SV=3 200,5 
RL26L_HUMAN 60S ribosomal protein L26-like 1 OS=Homo sapiens GN=RPL26L1 
PE=1 SV=1 
200,0 
RL31_HUMAN 60S ribosomal protein L31 OS=Homo sapiens GN=RPL31 PE=1 SV=1 176,0 
EZRI_HUMAN Ezrin OS=Homo sapiens GN=EZR PE=1 SV=4 172,5 
H12_HUMAN Histone H1.2 OS=Homo sapiens GN=HIST1H1C PE=1 SV=2 167,5 
NOG1_HUMAN Nucleolar GTP-binding protein 1 OS=Homo sapiens GN=GTPBP4 PE=1 
SV=3 
166,0 
SND1_HUMAN Staphylococcal nuclease domain-containing protein 1 OS=Homo sapiens 
GN=SND1 PE=1 SV=1 
163,0 
PP1A_HUMAN Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 
OS=Homo sapiens GN=PPP1CA PE=1 SV=1 
161,5 
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IF2B3_HUMAN Insulin-like growth factor 2 mRNA-binding protein 3 OS=Homo sapiens 
GN=IGF2BP3 PE=1 SV=2 
161,0 
PABP4_HUMAN Polyadenylate-binding protein 4 OS=Homo sapiens GN=PABPC4 PE=1 
SV=1 
159,0 
RCC2_HUMAN Protein RCC2 OS=Homo sapiens GN=RCC2 PE=1 SV=2 158,5 
RRP1B_HUMAN Ribosomal RNA processing protein 1 homolog B OS=Homo sapiens 
GN=RRP1B PE=1 SV=3 
157,5 
RRMJ3_HUMAN Putative rRNA methyltransferase 3 OS=Homo sapiens GN=FTSJ3 PE=1 
SV=2 
155,5 
ACTBM_HUMAN Putative beta-actin-like protein 3 OS=Homo sapiens GN=POTEKP PE=5 
SV=1 
154,5 
DHX15_HUMAN Putative pre-mRNA-splicing factor ATP-dependent RNA helicase 
DHX15 OS=Homo sapiens GN=DHX15 PE=1 SV=2 
152,0 
RS26L_HUMAN Putative 40S ribosomal protein S26-like 1 OS=Homo sapiens 
GN=RPS26P11 PE=5 SV=1 
151,5 
RS13_HUMAN 40S ribosomal protein S13 OS=Homo sapiens GN=RPS13 PE=1 SV=2 151,0 
WIBG_HUMAN Partner of Y14 and mago OS=Homo sapiens GN=WIBG PE=1 SV=1 145,0 
MOES_HUMAN Moesin OS=Homo sapiens GN=MSN PE=1 SV=3 141,5 
RADI_HUMAN Radixin OS=Homo sapiens GN=RDX PE=1 SV=1 141,5 
NPM3_HUMAN Nucleoplasmin-3 OS=Homo sapiens GN=NPM3 PE=1 SV=3 140,5 
POTEE_HUMAN POTE ankyrin domain family member E OS=Homo sapiens GN=POTEE 
PE=1 SV=3 
140,0 
TCPA_HUMAN T-complex protein 1 subunit alpha OS=Homo sapiens GN=TCP1 PE=1 
SV=1 
126,5 
PPIB_HUMAN Peptidyl-prolyl cis-trans isomerase B OS=Homo sapiens GN=PPIB PE=1 
SV=2 
124,5 
ACACB_HUMAN Acetyl-CoA carboxylase 2 OS=Homo sapiens GN=ACACB PE=1 SV=3 123,5 
GNL3_HUMAN Guanine nucleotide-binding protein-like 3 OS=Homo sapiens GN=GNL3 
PE=1 SV=2 
123,5 
RS12_HUMAN 40S ribosomal protein S12 OS=Homo sapiens GN=RPS12 PE=1 SV=3 123,5 
YBOX1_HUMAN Nuclease-sensitive element-binding protein 1 OS=Homo sapiens 
GN=YBX1 PE=1 SV=3 
120,0 
NOP56_HUMAN Nucleolar protein 56 OS=Homo sapiens GN=NOP56 PE=1 SV=4 118,0 
RL35A_HUMAN 60S ribosomal protein L35a OS=Homo sapiens GN=RPL35A PE=1 
SV=2 
113,5 
IMA2_HUMAN Importin subunit alpha-2 OS=Homo sapiens GN=KPNA2 PE=1 SV=1 110,0 
HG2A_HUMAN HLA class II histocompatibility antigen gamma chain OS=Homo sapiens 
GN=CD74 PE=1 SV=3 
109,0 
CPSF2_HUMAN Cleavage and polyadenylation specificity factor subunit 2 OS=Homo 
sapiens GN=CPSF2 PE=1 SV=2 
105,5 
RLA1_HUMAN 60S acidic ribosomal protein P1 OS=Homo sapiens GN=RPLP1 PE=1 
SV=1 
105,5 
G3BP2_HUMAN Ras GTPase-activating protein-binding protein 2 OS=Homo sapiens 
GN=G3BP2 PE=1 SV=2 
104,0 
ERF1_HUMAN Eukaryotic peptide chain release factor subunit 1 OS=Homo sapiens 
GN=ETF1 PE=1 SV=3 
103,5 
RL3L_HUMAN 60S ribosomal protein L3-like OS=Homo sapiens GN=RPL3L PE=1 
SV=3 
103,5 
DDX3X_HUMAN ATP-dependent RNA helicase DDX3X OS=Homo sapiens GN=DDX3X 
PE=1 SV=3 
102,5 
IF2B2_HUMAN Insulin-like growth factor 2 mRNA-binding protein 2 OS=Homo sapiens 
GN=IGF2BP2 PE=1 SV=2 
98,5 
PA2G4_HUMAN Proliferation-associated protein 2G4 OS=Homo sapiens GN=PA2G4 
PE=1 SV=3 
98,5 
TOP2B_HUMAN DNA topoisomerase 2-beta OS=Homo sapiens GN=TOP2B PE=1 SV=3 98,5 
PHF8_HUMAN Histone lysine demethylase PHF8 OS=Homo sapiens GN=PHF8 PE=1 
SV=3 
97,5 
DRA_HUMAN HLA class II histocompatibility antigen, DR alpha chain OS=Homo 
sapiens GN=HLA-DRA PE=1 SV=1 
94,5 
SF3A3_HUMAN Splicing factor 3A subunit 3 OS=Homo sapiens GN=SF3A3 PE=1 SV=1 94,0 
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MSH6_HUMAN DNA mismatch repair protein Msh6 OS=Homo sapiens GN=MSH6 PE=1 
SV=2 
91,5 
BRX1_HUMAN Ribosome biogenesis protein BRX1 homolog OS=Homo sapiens 
GN=BRIX1 PE=1 SV=2 
89,0 
PTBP2_HUMAN Polypyrimidine tract-binding protein 2 OS=Homo sapiens GN=PTBP2 
PE=1 SV=1 
88,5 
EF2_HUMAN Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 87,0 
RS27_HUMAN 40S ribosomal protein S27 OS=Homo sapiens GN=RPS27 PE=1 SV=3 86,5 
BA2L2_HUMAN Protein BAT2-like 2 OS=Homo sapiens GN=BAT2L2 PE=1 SV=3 85,5 
RL28_HUMAN 60S ribosomal protein L28 OS=Homo sapiens GN=RPL28 PE=1 SV=3 83,0 
H3C_HUMAN Histone H3.3C OS=Homo sapiens GN=H3F3C PE=1 SV=3 81,5 
RS27A_HUMAN Ubiquitin-40S ribosomal protein S27a OS=Homo sapiens GN=RPS27A 
PE=1 SV=2 
81,5 
TIF1B_HUMAN Transcription intermediary factor 1-beta OS=Homo sapiens GN=TRIM28 
PE=1 SV=5 
80,5 
CNTP4_HUMAN Contactin-associated protein-like 4 OS=Homo sapiens GN=CNTNAP4 
PE=1 SV=3 
76,0 
GTF2I_HUMAN General transcription factor II-I OS=Homo sapiens GN=GTF2I PE=1 
SV=2 
75,5 
RCC1_HUMAN Regulator of chromosome condensation OS=Homo sapiens GN=RCC1 
PE=1 SV=1 
75,0 
EDF1_HUMAN Endothelial differentiation-related factor 1 OS=Homo sapiens GN=EDF1 
PE=1 SV=1 
74,0 
DTD2_HUMAN Probable D-tyrosyl-tRNA(Tyr) deacylase 2 OS=Homo sapiens 
GN=C14orf126 PE=2 SV=1 
70,0 
MND1_HUMAN Meiotic nuclear division protein 1 homolog OS=Homo sapiens 
GN=MND1 PE=1 SV=1 
67,5 
SR140_HUMAN U2-associated protein SR140 OS=Homo sapiens GN=SR140 PE=1 SV=2 67,5 
RRP15_HUMAN RRP15-like protein OS=Homo sapiens GN=RRP15 PE=1 SV=2 64,5 
APOB_HUMAN Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2 60,0 
CHM4A_HUMAN Charged multivesicular body protein 4a OS=Homo sapiens 
GN=CHMP4A PE=1 SV=3 
60,0 
RIC8A_HUMAN Synembryn-A OS=Homo sapiens GN=RIC8A PE=1 SV=3 60,0 
GTR12_HUMAN Solute carrier family 2, facilitated glucose transporter member 12 
OS=Homo sapiens GN=SLC2A12 PE=2 SV=1 
58,0 
SEPT6_HUMAN Septin-6 OS=Homo sapiens GN=SEPT6 PE=1 SV=4 58,0 
SEPT7_HUMAN Septin-7 OS=Homo sapiens GN=SEPT7 PE=1 SV=2 58,0 
VPRBP_HUMAN Protein VPRBP OS=Homo sapiens GN=VPRBP PE=1 SV=3 58,0 
ROA0_HUMAN Heterogeneous nuclear ribonucleoprotein A0 OS=Homo sapiens 
GN=HNRNPA0 PE=1 SV=1 
57,0 
EF1D_HUMAN Elongation factor 1-delta OS=Homo sapiens GN=EEF1D PE=1 SV=5 54,0 
K1C10_HUMAN Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 
SV=6 
53,0 
RRP5_HUMAN Protein RRP5 homolog OS=Homo sapiens GN=PDCD11 PE=1 SV=3 53,0 
SMD3_HUMAN Small nuclear ribonucleoprotein Sm D3 OS=Homo sapiens GN=SNRPD3 
PE=1 SV=1 
53,0 
COJA1_HUMAN Collagen alpha-1(XIX) chain OS=Homo sapiens GN=COL19A1 PE=1 
SV=3 
52,0 
MAZ_HUMAN Myc-associated zinc finger protein OS=Homo sapiens GN=MAZ PE=1 
SV=1 
50,0 
RL7L_HUMAN 60S ribosomal protein L7-like 1 OS=Homo sapiens GN=RPL7L1 PE=1 
SV=1 
50,0 
MYBPP_HUMAN MYCBP-associated protein OS=Homo sapiens GN=MYCBPAP PE=1 
SV=2 
49,5 
LARP1_HUMAN La-related protein 1 OS=Homo sapiens GN=LARP1 PE=1 SV=2 48,5 
SC31A_HUMAN Protein transport protein Sec31A OS=Homo sapiens GN=SEC31A PE=1 
SV=3 
48,5 
PESC_HUMAN Pescadillo homolog OS=Homo sapiens GN=PES1 PE=1 SV=1 48,0 
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ROCK2_HUMAN Rho-associated protein kinase 2 OS=Homo sapiens GN=ROCK2 PE=1 
SV=4 
46,5 
CUL2_HUMAN Cullin-2 OS=Homo sapiens GN=CUL2 PE=1 SV=2 45,5 
LSM12_HUMAN Protein LSM12 homolog OS=Homo sapiens GN=LSM12 PE=1 SV=2 45,5 
RL40_HUMAN Ubiquitin-60S ribosomal protein L40 OS=Homo sapiens GN=UBA52 
PE=1 SV=2 
45,5 
CD63_HUMAN CD63 antigen OS=Homo sapiens GN=CD63 PE=1 SV=2 45,0 
PPOX_HUMAN Protoporphyrinogen oxidase OS=Homo sapiens GN=PPOX PE=1 SV=1 45,0 
TNIK_HUMAN TRAF2 and NCK-interacting protein kinase OS=Homo sapiens 
GN=TNIK PE=1 SV=1 
45,0 
RBM28_HUMAN RNA-binding protein 28 OS=Homo sapiens GN=RBM28 PE=1 SV=3 44,5 
FACD2_HUMAN Fanconi anemia group D2 protein OS=Homo sapiens GN=FANCD2 
PE=1 SV=1 
41,5 
UBF1_HUMAN Nucleolar transcription factor 1 OS=Homo sapiens GN=UBTF PE=1 
SV=1 
41,5 
ANO2_HUMAN Anoctamin-2 OS=Homo sapiens GN=ANO2 PE=1 SV=2 40,5 
CCPG1_HUMAN Cell cycle progression protein 1 OS=Homo sapiens GN=CCPG1 PE=1 
SV=3 
40,0 
DYH2_HUMAN Dynein heavy chain 2, axonemal OS=Homo sapiens GN=DNAH2 PE=1 
SV=3 
40,0 
HRH4_HUMAN Histamine H4 receptor OS=Homo sapiens GN=HRH4 PE=1 SV=2 39,0 
AMGO2_HUMAN Amphoterin-induced protein 2 OS=Homo sapiens GN=AMIGO2 PE=1 
SV=1 
38,0 
UGGG2_HUMAN UDP-glucose:glycoprotein glucosyltransferase 2 OS=Homo sapiens 
GN=UGGT2 PE=1 SV=4 
38,0 
CQ085_HUMAN Uncharacterized protein C17orf85 OS=Homo sapiens GN=C17orf85 
PE=1 SV=2 
37,5 
SETD5_HUMAN SET domain-containing protein 5 OS=Homo sapiens GN=SETD5 PE=1 
SV=2 
37,5 
MYO3A_HUMAN Myosin-IIIa OS=Homo sapiens GN=MYO3A PE=1 SV=2 37,0 
TYK2_HUMAN Non-receptor tyrosine-protein kinase TYK2 OS=Homo sapiens 
GN=TYK2 PE=1 SV=3 
37,0 
RM03_HUMAN 39S ribosomal protein L3, mitochondrial OS=Homo sapiens GN=MRPL3 
PE=1 SV=1 
36,5 
B4GT5_HUMAN Beta-1,4-galactosyltransferase 5 OS=Homo sapiens GN=B4GALT5 PE=2 
SV=1 
36,0 
CB039_HUMAN UPF0407 protein C2orf39 OS=Homo sapiens GN=C2orf39 PE=2 SV=2 36,0 
DC8L2_HUMAN DDB1- and CUL4-associated factor 8-like protein 2 OS=Homo sapiens 
GN=DCAF8L2 PE=2 SV=1 
36,0 
DOCK5_HUMAN Dedicator of cytokinesis protein 5 OS=Homo sapiens GN=DOCK5 PE=1 
SV=3 
36,0 
MUC12_HUMAN Mucin-12 OS=Homo sapiens GN=MUC12 PE=1 SV=2 36,0 
ELL_HUMAN RNA polymerase II elongation factor ELL OS=Homo sapiens GN=ELL 
PE=1 SV=1 
35,0 
SEM3G_HUMAN Semaphorin-3G OS=Homo sapiens GN=SEMA3G PE=1 SV=1 33,5 
CAC1E_HUMAN Voltage-dependent R-type calcium channel subunit alpha-1E OS=Homo 
sapiens GN=CACNA1E PE=1 SV=3 
33,0 
CU025_HUMAN C2 domain-containing protein 2 OS=Homo sapiens GN=C2CD2 PE=1 
SV=2 
33,0 
AP3D1_HUMAN AP-3 complex subunit delta-1 OS=Homo sapiens GN=AP3D1 PE=1 
SV=1 
30,5 
RELL2_HUMAN RELT-like protein 2 OS=Homo sapiens GN=RELL2 PE=1 SV=1 30,5 
RRP7A_HUMAN Ribosomal RNA-processing protein 7 homolog A OS=Homo sapiens 
GN=RRP7A PE=1 SV=2 
30,5 
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Tab. A9 BZLF1_5693_intersect_5694 
prot_acc BZLF1_5694_intersect_5693_prot_desc_only highest_mean 
HSP7C_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 
SV=1 
981,0 
ROA1_HUMAN Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens 
GN=HNRNPA1 PE=1 SV=5 
698,0 
PDIP3_HUMAN Polymerase delta-interacting protein 3 OS=Homo sapiens GN=POLDIP3 
PE=1 SV=2 
696,0 
ROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens 
GN=HNRNPA2B1 PE=1 SV=2 
649,5 
NUCL_HUMAN Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 635,5 
NPM_HUMAN Nucleophosmin OS=Homo sapiens GN=NPM1 PE=1 SV=2 595,5 
EF1A1_HUMAN Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=1 584,5 
RBM25_HUMAN RNA-binding protein 25 OS=Homo sapiens GN=RBM25 PE=1 SV=3 547,0 
HNRPU_HUMAN Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens 
GN=HNRNPU PE=1 SV=6 
488,0 
DDX5_HUMAN Probable ATP-dependent RNA helicase DDX5 OS=Homo sapiens 
GN=DDX5 PE=1 SV=1 
420,5 
DDX21_HUMAN Nucleolar RNA helicase 2 OS=Homo sapiens GN=DDX21 PE=1 SV=5 414,0 
ATX2L_HUMAN Ataxin-2-like protein OS=Homo sapiens GN=ATXN2L PE=1 SV=2 410,0 
SFPQ_HUMAN Splicing factor, proline- and glutamine-rich OS=Homo sapiens 
GN=SFPQ PE=1 SV=2 
406,5 
TBB2A_HUMAN Tubulin beta-2A chain OS=Homo sapiens GN=TUBB2A PE=1 SV=1 405,0 
GRP78_HUMAN 78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 
SV=2 
385,0 
HNRPM_HUMAN Heterogeneous nuclear ribonucleoprotein M OS=Homo sapiens 
GN=HNRNPM PE=1 SV=3 
377,0 
ACTB_HUMAN Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 363,0 
HSP71_HUMAN Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A 
PE=1 SV=5 
358,0 
NONO_HUMAN Non-POU domain-containing octamer-binding protein OS=Homo sapiens 
GN=NONO PE=1 SV=4 
353,5 
HNRH1_HUMAN Heterogeneous nuclear ribonucleoprotein H OS=Homo sapiens 
GN=HNRNPH1 PE=1 SV=4 
333,5 
HNRPC_HUMAN Heterogeneous nuclear ribonucleoproteins C1/C2 OS=Homo sapiens 
GN=HNRNPC PE=1 SV=4 
323,0 
NOLC1_HUMAN Nucleolar and coiled-body phosphoprotein 1 OS=Homo sapiens 
GN=NOLC1 PE=1 SV=2 
323,0 
TBB5_HUMAN Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 321,0 
HSP76_HUMAN Heat shock 70 kDa protein 6 OS=Homo sapiens GN=HSPA6 PE=1 SV=2 308,0 
HNRPK_HUMAN Heterogeneous nuclear ribonucleoprotein K OS=Homo sapiens 
GN=HNRNPK PE=1 SV=1 
307,5 
K2C1_HUMAN Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 300,0 
RL4_HUMAN 60S ribosomal protein L4 OS=Homo sapiens GN=RPL4 PE=1 SV=5 296,0 
RL23_HUMAN 60S ribosomal protein L23 OS=Homo sapiens GN=RPL23 PE=1 SV=1 286,0 
RS3_HUMAN 40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=1 SV=2 285,0 
DDX17_HUMAN Probable ATP-dependent RNA helicase DDX17 OS=Homo sapiens 
GN=DDX17 PE=1 SV=1 
278,0 
RS8_HUMAN 40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 PE=1 SV=2 252,0 
HNRPL_HUMAN Heterogeneous nuclear ribonucleoprotein L OS=Homo sapiens 
GN=HNRNPL PE=1 SV=2 
251,5 
PARP1_HUMAN Poly [ADP-ribose] polymerase 1 OS=Homo sapiens GN=PARP1 PE=1 
SV=4 
249,0 
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens 
GN=GAPDH PE=1 SV=3 
243,5 
H4_HUMAN Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 242,5 
RL7_HUMAN 60S ribosomal protein L7 OS=Homo sapiens GN=RPL7 PE=1 SV=1 235,5 
PAIRB_HUMAN Plasminogen activator inhibitor 1 RNA-binding protein OS=Homo 
sapiens GN=SERBP1 PE=1 SV=2 
216,0 
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RL13_HUMAN 60S ribosomal protein L13 OS=Homo sapiens GN=RPL13 PE=1 SV=4 206,5 
PR40A_HUMAN Pre-mRNA-processing factor 40 homolog A OS=Homo sapiens 
GN=PRPF40A PE=1 SV=2 
203,5 
RL21_HUMAN 60S ribosomal protein L21 OS=Homo sapiens GN=RPL21 PE=1 SV=2 202,5 
HNRPD_HUMAN Heterogeneous nuclear ribonucleoprotein D0 OS=Homo sapiens 
GN=HNRNPD PE=1 SV=1 
201,0 
RL15_HUMAN 60S ribosomal protein L15 OS=Homo sapiens GN=RPL15 PE=1 SV=2 199,0 
RS25_HUMAN 40S ribosomal protein S25 OS=Homo sapiens GN=RPS25 PE=1 SV=1 191,5 
HNRPR_HUMAN Heterogeneous nuclear ribonucleoprotein R OS=Homo sapiens 
GN=HNRNPR PE=1 SV=1 
186,0 
LYAR_HUMAN Cell growth-regulating nucleolar protein OS=Homo sapiens GN=LYAR 
PE=1 SV=2 
182,0 
ACTBL_HUMAN Beta-actin-like protein 2 OS=Homo sapiens GN=ACTBL2 PE=1 SV=2 181,5 
RS19_HUMAN 40S ribosomal protein S19 OS=Homo sapiens GN=RPS19 PE=1 SV=2 179,0 
RS15_HUMAN 40S ribosomal protein S15 OS=Homo sapiens GN=RPS15 PE=1 SV=2 175,0 
PRP19_HUMAN Pre-mRNA-processing factor 19 OS=Homo sapiens GN=PRPF19 PE=1 
SV=1 
173,5 
POTEF_HUMAN POTE ankyrin domain family member F OS=Homo sapiens GN=POTEF 
PE=1 SV=2 
166,0 
ENOA_HUMAN Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 163,5 
ENOB_HUMAN Beta-enolase OS=Homo sapiens GN=ENO3 PE=1 SV=4 163,5 
TOP2A_HUMAN DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3 163,5 
RL14_HUMAN 60S ribosomal protein L14 OS=Homo sapiens GN=RPL14 PE=1 SV=4 163,0 
RS11_HUMAN 40S ribosomal protein S11 OS=Homo sapiens GN=RPS11 PE=1 SV=3 162,0 
RL37A_HUMAN 60S ribosomal protein L37a OS=Homo sapiens GN=RPL37A PE=1 
SV=2 
161,0 
RS5_HUMAN 40S ribosomal protein S5 OS=Homo sapiens GN=RPS5 PE=1 SV=4 160,0 
RL23A_HUMAN 60S ribosomal protein L23a OS=Homo sapiens GN=RPL23A PE=1 
SV=1 
159,0 
RL38_HUMAN 60S ribosomal protein L38 OS=Homo sapiens GN=RPL38 PE=1 SV=2 157,0 
RS16_HUMAN 40S ribosomal protein S16 OS=Homo sapiens GN=RPS16 PE=1 SV=2 155,5 
DAZP1_HUMAN DAZ-associated protein 1 OS=Homo sapiens GN=DAZAP1 PE=1 SV=1 148,5 
FUS_HUMAN RNA-binding protein FUS OS=Homo sapiens GN=FUS PE=1 SV=1 147,5 
SF3B2_HUMAN Splicing factor 3B subunit 2 OS=Homo sapiens GN=SF3B2 PE=1 SV=2 147,5 
RL19_HUMAN 60S ribosomal protein L19 OS=Homo sapiens GN=RPL19 PE=1 SV=1 147,0 
ACACA_HUMAN Acetyl-CoA carboxylase 1 OS=Homo sapiens GN=ACACA PE=1 SV=2 142,5 
NOP2_HUMAN Putative ribosomal RNA methyltransferase NOP2 OS=Homo sapiens 
GN=NOP2 PE=1 SV=2 
141,0 
RL27A_HUMAN 60S ribosomal protein L27a OS=Homo sapiens GN=RPL27A PE=1 
SV=2 
140,0 
RL29_HUMAN 60S ribosomal protein L29 OS=Homo sapiens GN=RPL29 PE=1 SV=2 140,0 
DHX9_HUMAN ATP-dependent RNA helicase A OS=Homo sapiens GN=DHX9 PE=1 
SV=4 
137,5 
RL8_HUMAN 60S ribosomal protein L8 OS=Homo sapiens GN=RPL8 PE=1 SV=2 134,5 
RS4X_HUMAN 40S ribosomal protein S4, X isoform OS=Homo sapiens GN=RPS4X 
PE=1 SV=2 
134,0 
RL24_HUMAN 60S ribosomal protein L24 OS=Homo sapiens GN=RPL24 PE=1 SV=1 133,0 
KI67_HUMAN Antigen KI-67 OS=Homo sapiens GN=MKI67 PE=1 SV=2 131,0 
NOP58_HUMAN Nucleolar protein 58 OS=Homo sapiens GN=NOP58 PE=1 SV=1 129,5 
RL3_HUMAN 60S ribosomal protein L3 OS=Homo sapiens GN=RPL3 PE=1 SV=2 129,5 
ROA3_HUMAN Heterogeneous nuclear ribonucleoprotein A3 OS=Homo sapiens 
GN=HNRNPA3 PE=1 SV=2 
127,5 
RL18A_HUMAN 60S ribosomal protein L18a OS=Homo sapiens GN=RPL18A PE=1 
SV=2 
127,0 
PABP1_HUMAN Polyadenylate-binding protein 1 OS=Homo sapiens GN=PABPC1 PE=1 
SV=2 
124,5 
RS2_HUMAN 40S ribosomal protein S2 OS=Homo sapiens GN=RPS2 PE=1 SV=2 124,5 
RS3A_HUMAN 40S ribosomal protein S3a OS=Homo sapiens GN=RPS3A PE=1 SV=2 122,5 
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H15_HUMAN Histone H1.5 OS=Homo sapiens GN=HIST1H1B PE=1 SV=3 121,5 
RS10_HUMAN 40S ribosomal protein S10 OS=Homo sapiens GN=RPS10 PE=1 SV=1 121,5 
SMD1_HUMAN Small nuclear ribonucleoprotein Sm D1 OS=Homo sapiens GN=SNRPD1 
PE=1 SV=1 
120,5 
FBRL_HUMAN rRNA 2~-O-methyltransferase fibrillarin OS=Homo sapiens GN=FBL 
PE=1 SV=2 
119,0 
RS18_HUMAN 40S ribosomal protein S18 OS=Homo sapiens GN=RPS18 PE=1 SV=3 119,0 
RS7_HUMAN 40S ribosomal protein S7 OS=Homo sapiens GN=RPS7 PE=1 SV=1 117,0 
THOC4_HUMAN THO complex subunit 4 OS=Homo sapiens GN=THOC4 PE=1 SV=3 116,5 
NUFP2_HUMAN Nuclear fragile X mental retardation-interacting protein 2 OS=Homo 
sapiens GN=NUFIP2 PE=1 SV=1 
115,5 
XRCC5_HUMAN X-ray repair cross-complementing protein 5 OS=Homo sapiens 
GN=XRCC5 PE=1 SV=3 
112,0 
IF16_HUMAN Gamma-interferon-inducible protein 16 OS=Homo sapiens GN=IFI16 
PE=1 SV=3 
110,5 
RL13A_HUMAN 60S ribosomal protein L13a OS=Homo sapiens GN=RPL13A PE=1 
SV=2 
107,0 
RS24_HUMAN 40S ribosomal protein S24 OS=Homo sapiens GN=RPS24 PE=1 SV=1 106,5 
RL26_HUMAN 60S ribosomal protein L26 OS=Homo sapiens GN=RPL26 PE=1 SV=1 106,0 
RL10_HUMAN 60S ribosomal protein L10 OS=Homo sapiens GN=RPL10 PE=1 SV=4 103,5 
KHDR1_HUMAN KH domain-containing, RNA-binding, signal transduction-associated 
protein 1 OS=Homo sapiens GN=KHDRBS1 PE=1 SV=1 
103,0 
RL9_HUMAN 60S ribosomal protein L9 OS=Homo sapiens GN=RPL9 PE=1 SV=1 103,0 
RS6_HUMAN 40S ribosomal protein S6 OS=Homo sapiens GN=RPS6 PE=1 SV=1 100,0 
ROAA_HUMAN Heterogeneous nuclear ribonucleoprotein A/B OS=Homo sapiens 
GN=HNRNPAB PE=1 SV=2 
99,5 
RS29_HUMAN 40S ribosomal protein S29 OS=Homo sapiens GN=RPS29 PE=1 SV=2 99,5 
TOP1_HUMAN DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2 99,0 
PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 
SV=2 
97,0 
ILF3_HUMAN Interleukin enhancer-binding factor 3 OS=Homo sapiens GN=ILF3 PE=1 
SV=3 
95,5 
RL36A_HUMAN 60S ribosomal protein L36a OS=Homo sapiens GN=RPL36A PE=1 
SV=2 
94,0 
RL6_HUMAN 60S ribosomal protein L6 OS=Homo sapiens GN=RPL6 PE=1 SV=3 92,5 
SET_HUMAN Protein SET OS=Homo sapiens GN=SET PE=1 SV=3 90,0 
RL5_HUMAN 60S ribosomal protein L5 OS=Homo sapiens GN=RPL5 PE=1 SV=3 89,5 
RL35_HUMAN 60S ribosomal protein L35 OS=Homo sapiens GN=RPL35 PE=1 SV=2 88,5 
NAT10_HUMAN N-acetyltransferase 10 OS=Homo sapiens GN=NAT10 PE=1 SV=2 87,0 
SRSF3_HUMAN Serine/arginine-rich splicing factor 3 OS=Homo sapiens GN=SRSF3 
PE=1 SV=1 
85,5 
SF3B1_HUMAN Splicing factor 3B subunit 1 OS=Homo sapiens GN=SF3B1 PE=1 SV=3 85,0 
RS20_HUMAN 40S ribosomal protein S20 OS=Homo sapiens GN=RPS20 PE=1 SV=1 83,5 
RL11_HUMAN 60S ribosomal protein L11 OS=Homo sapiens GN=RPL11 PE=1 SV=2 81,5 
RS15A_HUMAN 40S ribosomal protein S15a OS=Homo sapiens GN=RPS15A PE=1 
SV=2 
81,5 
H13_HUMAN Histone H1.3 OS=Homo sapiens GN=HIST1H1D PE=1 SV=2 79,0 
RL10A_HUMAN 60S ribosomal protein L10a OS=Homo sapiens GN=RPL10A PE=1 
SV=2 
78,5 
RL34_HUMAN 60S ribosomal protein L34 OS=Homo sapiens GN=RPL34 PE=1 SV=3 76,5 
RL17_HUMAN 60S ribosomal protein L17 OS=Homo sapiens GN=RPL17 PE=1 SV=3 76,0 
RS23_HUMAN 40S ribosomal protein S23 OS=Homo sapiens GN=RPS23 PE=1 SV=3 75,0 
RBM14_HUMAN RNA-binding protein 14 OS=Homo sapiens GN=RBM14 PE=1 SV=2 74,0 
RS30_HUMAN 40S ribosomal protein S30 OS=Homo sapiens GN=FAU PE=1 SV=1 74,0 
GEMI4_HUMAN Component of gems 4 OS=Homo sapiens GN=GEMIN4 PE=1 SV=2 73,5 
RTTN_HUMAN Rotatin OS=Homo sapiens GN=RTTN PE=1 SV=3 73,5 
TRRAP_HUMAN Transformation/transcription domain-associated protein OS=Homo 
sapiens GN=TRRAP PE=1 SV=3 
73,5 
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RL7A_HUMAN 60S ribosomal protein L7a OS=Homo sapiens GN=RPL7A PE=1 SV=2 70,5 
RL18_HUMAN 60S ribosomal protein L18 OS=Homo sapiens GN=RPL18 PE=1 SV=2 68,5 
SF3A1_HUMAN Splicing factor 3A subunit 1 OS=Homo sapiens GN=SF3A1 PE=1 SV=1 67,5 
RS17_HUMAN 40S ribosomal protein S17 OS=Homo sapiens GN=RPS17 PE=1 SV=2 65,5 
RL30_HUMAN 60S ribosomal protein L30 OS=Homo sapiens GN=RPL30 PE=1 SV=2 65,0 
RS14_HUMAN 40S ribosomal protein S14 OS=Homo sapiens GN=RPS14 PE=1 SV=3 64,0 
RAN_HUMAN GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 
SV=3 
62,5 
RL27_HUMAN 60S ribosomal protein L27 OS=Homo sapiens GN=RPL27 PE=1 SV=2 62,5 
XRCC6_HUMAN X-ray repair cross-complementing protein 6 OS=Homo sapiens 
GN=XRCC6 PE=1 SV=2 
62,5 
HS74L_HUMAN Heat shock 70 kDa protein 4L OS=Homo sapiens GN=HSPA4L PE=1 
SV=3 
60,5 
HMGN2_HUMAN Non-histone chromosomal protein HMG-17 OS=Homo sapiens 
GN=HMGN2 PE=1 SV=3 
58,5 
HMGA1_HUMAN High mobility group protein HMG-I/HMG-Y OS=Homo sapiens 
GN=HMGA1 PE=1 SV=3 
58,0 
BUB3_HUMAN Mitotic checkpoint protein BUB3 OS=Homo sapiens GN=BUB3 PE=1 
SV=1 
56,0 
DDX6_HUMAN Probable ATP-dependent RNA helicase DDX6 OS=Homo sapiens 
GN=DDX6 PE=1 SV=2 
56,0 
CHD3_HUMAN Chromodomain-helicase-DNA-binding protein 3 OS=Homo sapiens 
GN=CHD3 PE=1 SV=3 
55,5 
HMGB2_HUMAN High mobility group protein B2 OS=Homo sapiens GN=HMGB2 PE=1 
SV=2 
54,5 
TERT_HUMAN Telomerase reverse transcriptase OS=Homo sapiens GN=TERT PE=1 
SV=1 
54,5 
HNRPQ_HUMAN Heterogeneous nuclear ribonucleoprotein Q OS=Homo sapiens 
GN=SYNCRIP PE=1 SV=2 
54,0 
MATR3_HUMAN Matrin-3 OS=Homo sapiens GN=MATR3 PE=1 SV=2 54,0 
MBB1A_HUMAN Myb-binding protein 1A OS=Homo sapiens GN=MYBBP1A PE=1 SV=2 52,5 
PSIP1_HUMAN PC4 and SFRS1-interacting protein OS=Homo sapiens GN=PSIP1 PE=1 
SV=1 
51,5 
EBP2_HUMAN Probable rRNA-processing protein EBP2 OS=Homo sapiens 
GN=EBNA1BP2 PE=1 SV=2 
49,5 
U2AF1_HUMAN Splicing factor U2AF 35 kDa subunit OS=Homo sapiens GN=U2AF1 
PE=1 SV=3 
48,0 
PRKDC_HUMAN DNA-dependent protein kinase catalytic subunit OS=Homo sapiens 
GN=PRKDC PE=1 SV=3 
45,0 
RL32_HUMAN 60S ribosomal protein L32 OS=Homo sapiens GN=RPL32 PE=1 SV=2 41,0 
RB6I2_HUMAN ELKS/Rab6-interacting/CAST family member 1 OS=Homo sapiens 
GN=ERC1 PE=1 SV=1 
40,0 
UCHL1_HUMAN Ubiquitin carboxyl-terminal hydrolase isozyme L1 OS=Homo sapiens 
GN=UCHL1 PE=1 SV=2 
39,0 
DHAK_HUMAN Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase 
(cyclizing) OS=Homo sapiens GN=DAK PE=1 SV=2 
38,0 
FREM3_HUMAN FRAS1-related extracellular matrix protein 3 OS=Homo sapiens 
GN=FREM3 PE=2 SV=1 
37,0 
MPIP1_HUMAN M-phase inducer phosphatase 1 OS=Homo sapiens GN=CDC25A PE=1 
SV=2 
33,5 
CAC1B_HUMAN Voltage-dependent N-type calcium channel subunit alpha-1B OS=Homo 
sapiens GN=CACNA1B PE=1 SV=1 
33,0 
PDK1_HUMAN [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial 
OS=Homo sapiens GN=PDK1 PE=1 SV=1 
33,0 
RADIL_HUMAN Ras-associating and dilute domain-containing protein OS=Homo sapiens 
GN=RADIL PE=1 SV=5 
33,0 
SEC63_HUMAN Translocation protein SEC63 homolog OS=Homo sapiens GN=SEC63 
PE=1 SV=2 
33,0 
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